

GenCore version 5.1.6
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model
 Run on: August 20, 2005, 00:10:37 ; Search time 168 Seconds
 (without alignments)
 1258.861 Million cell updates/sec

Title: US-10-649-852-32
 Perfect score: 2229
 Sequence: 1 MDSTIFFIIDEFDANCSSL.....SIPTSPTRISFSIKQTAAV 413

Scoring table: BLOSUM62
 Gapop 10.0 , Gapext 0.5

Searched: 1612378 seqs, 512079187 residues

Total number of hits satisfying chosen parameters: 1612378

Minimum DB seq length: 0
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing First 45 summaries

Database : UniProt_03;*
 1: uniprot_sprot;*
 2: uniprot_trembl;*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB	ID	Description
1	2229	100.0	413	1	CRF2_XENLA		042603 xenopus lae
2	2051	92.0	411	2	Q68Y60		Q68Y60 rana catesbe
3	1963.5	88.1	412	2	Q7ZZZ2		Q7ZZZ2 gallus galli
4	1904.5	85.4	414	2	Q8AWA1		Q8AWA1 oncorhynchus
5	1807	81.1	405	2	Q98UC1		Q98UC1 ameivurus ne
6	1804	80.9	411	1	CRF2_HUMAN		Q13324 homo sapien
7	1796.5	80.6	410	2	QBWM19		Q8Wm19 tupaia glis
8	1793	80.4	411	1	CRF2_RAT		P47866 rattus norvegicus
9	1792	80.4	437	2	QBWM18		Q8Wm18 tupaia glis
10	1770.5	79.4	431	1	CRF2_MOUSE		Q60748 mus musculus
11	1582.5	71.0	428	2	Q98UC0		Q98UC0 ameivurus nebulosus
12	1582	71.0	420	1	CRF1_CHICK		Q90812 gallus gallus
13	1578.5	70.8	445	2	Q98UC2		Q98UC2 ameivurus nebulosus
14	1566	70.3	415	2	Q76LL8		Q76LL8 macaca mulatta
15	1564.5	70.2	415	1	CRF1_XENLA		Q42602 xenopus laevis
16	1564.5	70.2	415	2	QBK3P2		Q8k3r2 mesocricetus auratus
17	1561.5	70.1	434	2	Q7T3S9		Q7t3s9 fugu rubripinnis
18	1559.5	70.0	430	2	QBAWA2		Q8awa2 oncorhynchus keta
19	1559	69.9	415	2	QBWM00		Q8wm0 tupaia glis
20	1556.5	69.8	415	1	CRF1_MOUSE		P35347 mus musculus
21	1553	69.7	415	2	Q9BGU4		Q9bgu4 bos taurus
22	1551.5	69.6	415	1	CRF1_RAT		P35353 rattus norvegicus
23	1541.5	69.2	444	1	CRF1_HUMAN		P34998 homo sapiens
24	1541.5	69.2	447	2	Q8NG71		Q8ng71 homo sapiens
25	1539.5	69.1	416	2	Q68Y61		Q68Y61 rana catesbeiana
26	1523	68.3	415	1	CRF1_SHEEP		Q62772 ovis aries
27	1409.5	63.2	329	2	Q70JV6		Q70jv6 cyprinus carpio
28	950	42.6	277	2	QBBDJ9		Q8bjd9 mus musculus
29	753	33.8	154	2	Q7TSA2		Q7tsa2 mesocricetus auratus
30	721.5	32.4	504	2	Q9V716		Q9v716 drosophila melanogaster
31	716.5	32.1	388	2	Q9V6C7		Q9v6c7 drosophila melanogaster

ALIGNMENTS

32	705	31.6	441	1	DIHR_ACHDO	Q16983 acheta dome
33	704	31.6	188	2	Q7TS1	Q7tsa1 mesocricetus auratus
34	649	29.1	465	2	Q7Q773	Q7q773 anopheles gambiae
35	641.5	28.8	641	2	Q65AS2	Q65as2 nilaparvata
36	636.5	28.6	631	2	Q8ML11	Q8ml11 drosophila melanogaster
37	619.5	27.8	350	2	P25107	P25107 didelphis virginiana
38	606	27.2	585	1	PTRR_PIG	P50133 sus scrofa
39	597	26.8	585	1	CALR_RAT	P32214 rattus norvegicus
40	596	26.7	516	1	CALR_CAVPO	Q08893 cavia porcellus
41	595.5	26.7	478	1	CALR_MOUSE	Q60755 mus musculus
42	593	26.6	515	1	Q924D7	Q924d7 mus musculus
43	593	26.6	532	2	P35464	P35464 manduca sexta
44	592.5	26.6	395	1	DIHR_MANSE	Q924d5 mus musculus
45	592.5	26.6	478	2	Q924D5	Q924d5 mus musculus

RESULT 1						
CRF2_XENLA		STANDARD;		PRT;		413 AA.
ID	CRF2_XENLA	AC	O42603;	DT	15-JUL-1998 (Rel. 36, Created)	SEQUENCE FROM N.A.
RA	"Identification of two corticotropin-releasing factor receptors from Xenopus laevis with high ligand selectivity: unusual pharmacology of the type 1 receptor."	RA	RX	RC	TISSUE=Brain, and Heart;	RP SEQUENCE FROM N.A.
RA	"Identification of two corticotropin-releasing factor receptors from Xenopus laevis with high ligand selectivity: unusual pharmacology of the type 1 receptor."	RA	RT	RT	RT	RC TISSUE=Brain, and Heart;
RA	J. Neurochem. 69:1640-1649 (1997).	RA	RT	RT	RT	RX MEDLINE=97465573; PubMed=9326293;
CC	-!- FUNCTION: This is a receptor for corticotropin releasing factor.	CC	CC	CC	CC	RA Dautzenberg F.M., Palchaudhuri M.R., Spiess J.;
CC	Shows high-affinity binding for urotensin I. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase (By similarity).	CC	CC	CC	CC	RA "Identification of two corticotropin-releasing factor receptors from Xenopus laevis with high ligand selectivity: unusual pharmacology of the type 1 receptor."
CC	-!- SUBCELLULAR LOCATION: Integral membrane protein.	CC	CC	CC	CC	RA "Identification of two corticotropin-releasing factor receptors from Xenopus laevis with high ligand selectivity: unusual pharmacology of the type 1 receptor."
CC	-!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.	CC	CC	CC	CC	RA "Identification of two corticotropin-releasing factor receptors from Xenopus laevis with high ligand selectivity: unusual pharmacology of the type 1 receptor."
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).	CC	CC	CC	CC	RA "Identification of two corticotropin-releasing factor receptors from Xenopus laevis with high ligand selectivity: unusual pharmacology of the type 1 receptor."
DR	EMBL; Y14037; CAA47364.1; -	DR	DR	DR	DR	DR SMART; SMO0008; HormR; PR00249; GPCRSECRETIN.
DR	InterPro; IPR000832; GPCR_secretin.	DR	DR	DR	DR	DR PROSITE; PS00649; G_PROTEIN_RECEP_F2_1; 1.
DR	InterPro; IPR001879; hormn_receptor.	DR	DR	DR	DR	DR PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR	PF000002; 7tm_2; 1.	DR	DR	DR	DR	DR PROSITE; PS02227; G_PROTEIN_RECEP_F2_3; 1.
DR	PFam; PF02793; HRM; 1.	DR	DR	DR	DR	DR PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
FT	FT SIGNAL 1	FT	FT	FT	FT	KW G-protein coupled receptor; Glycoprotein; Signal; Transmembrane.
FT	FT CHAIN 2	FT	FT	FT	FT	FT SIGNAL 2
FT	FT CHAIN 2	FT	FT	FT	FT	FT Corticotropin releasing factor receptor
FT	FT CHAIN 2	FT	FT	FT	FT	FT Corticotropin releasing factor receptor

FT DOMAIN	?	120	Extracellular (Potential).	DR EMBL; AB18B111; BAD36784.1; -.
FT TRANSMEM	121	141	1 (Potential).	DR GO; GO:0004872; F:receptor activity; IEA..
FT DOMAIN	142	150	Cytoplasmic (Potential).	DR InterPro; IPR003053; CRF2_receptor.
FT TRANSMEM	142	170	2 (Potential).	DR InterPro; IPR003051; CRF receptor.
FT DOMAIN	151	170	Extracellular (Potential).	DR InterPro; IPR003052; GPCR_secretin.
FT TRANSMEM	171	187	2 (Potential).	DR InterPro; IPR000832; GPCR receptor.
FT TRANSMEM	188	211	3 (Potential).	DR InterPro; IPR001879; hormn_receptor.
FT DOMAIN	212	225	Cytoplasmic (Potential).	DR Pfam; PF00002; 7tm_2; 1.
FT TRANSMEM	226	247	4 (Potential).	DR Pfam; PF02793; HRM; 1.
FT DOMAIN	248	266	Extracellular (Potential).	DR PRINTS; PR01279; CRFRECEPTOR.
FT TRANSMEM	267	289	5 (Potential).	DR PRINTS; PR01281; CRFRECEPTOR2.
FT DOMAIN	290	312	Cytoplasmic (Potential).	DR PRINTS; PR00249; GPCRSECRETIN.
FT TRANSMEM	313	332	6 (Potential).	DR SMART; SM00008; HormR; 1.
FT DOMAIN	333	347	Extracellular (Potential).	DR PROSITE; PS00649; G_PROTEIN_RECEP_F2_1;
FT TRANSMEM	348	367	7 (Potential).	DR PROSITE; PS00650; G_PROTEIN_RECEP_F2_2;
FT DOMAIN	368	413	Cytoplasmic (Potential).	DR PROSITE; PS50227; G_PROTEIN_RECEP_F2_3;
FT CARBOHYD	16	16	N-linked (G1cNAC. . .) (Potential).	DR PROSITE; PS50261; G_PROTEIN_RECEP_F2_4;
FT CARBOHYD	77	77	N-linked (G1cNAC. . .) (Potential).	KW Receptor.
FT CARBOHYD	89	89	N-linked (G1cNAC. . .) (Potential).	SQ SEQUENCE 411 AA; 48152 MW; 96D64ED8A24C179B CRC64;
FT CARBOHYD	97	97	N-linked (G1cNAC. . .) (Potential).	Query Match 92.0%; Score 2051; DB 2; Length 411;
SQ SEQUENCE	413 AA;	48458 MW;	DAD422P0A96C4626 CRC64;	Best Local Similarity 92.3%; Pred. No. 1.8e-144;
Query Match 100.0%; Score 2229; DB 1; Length 413;	Matches 413; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	Matches 381; Conservative 15; Mismatches 15; Indels 2; Gaps 2;	Query 1 MDSTIFELIIDEFDANCSLLDAFQDSFLHSESSSSFFGEGPYCSATIDQIGTCWPRSLAG 60	Query 1 MDSTIFELIIDEFDANCSLLDAFQDSFLHSESSSSFFGEGPYCSATIDQIGTCWPRSLAG 60
Best Local Similarity 100.0%; Pred. No. 1e-157; Matches 413; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	Db 1 MDSTIFELIIDEFDANCSLLDAFQDSFLHSESSSSFFGEGPYCSATIDQIGTCWPRSLAG 60	Db 1 MDSTIFELIIDEFDANCSLLDAYQDSFL-TINHTELPFDGPHCIAIDQIGTCWPRSLAG 59		
Query 1 MDSTIFELIIDEFDANCSLLDAFQDSFLHSESSSSFFGEGPYCSATIDQIGTCWPRSLAG 60	Db 1 ELVERPCPDSENGIYNTTRNVYRECFCNGT WASWMNYSQCVPLLDNKRKYALHYKIALI 120	Db 1 ELVERPCPDSENGIYNTTRNVYRECFCNGT WASWMNYSQCVPLLDNKRKYALHYKIALI 120		
Db 1 MDSTIFELIIDEFDANCSLLDAFQDSFLHSESSSSFFGEGPYCSATIDQIGTCWPRSLAG 60	Db 1 ELVERPCPDSENGIYNTTRNVYRECFCNGT WASWMNYSQCVPLLDNKRKYALHYKIALI 120	Db 60 ELVERPCPDSENGIYNTTRAVPRECFENGTVRECFCNGT WASWMNYSQCVPLLD-KRKHDLYHYKIALI 118		
Query 61 INYLGHCTISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHNTHE 120	Db 61 INYLGHCTISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHNTHE 120	Db 121 INYLGHCTISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHNTHE 120		
Db 61 INYLGHCTISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHNTHE 120	Db 61 SNEVWRCITTTIINYFVVTNFVWMFVEGCCYLHTAIWMTYSTDKLRKWVFLFIGWCIPSPI 240	Db 121 INYLGHCTISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHNTHE 120		
Query 121 INYLGHCTISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHNTHE 120	Db 121 SNEVWRCITTTIINYFVVTNFVWMFVEGCCYLHTAIWMTYSTDKLRKWVFLFIGWCIPSPI 240	Db 121 SNEVWRCITTTIINYFVVTNFVWMFVEGCCYLHTAIWMTYSTDKLRKWVFLFIGWCIPSPI 240		
Db 121 INYLGHCTISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHNTHE 120	Db 121 SNEVWRCITTTIINYFVVTNFVWMFVEGCCYLHTAIWMTYSTDKLRKWVFLFIGWCIPSPI 240	Db 121 SNEVWRCITTTIINYFVVTNFVWMFVEGCCYLHTAIWMTYSTDKLRKWVFLFIGWCIPSPI 240		
Query 121 INYLGHCTISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHNTHE 120	Db 121 SNEVWRCITTTIINYFVVTNFVWMFVEGCCYLHTAIWMTYSTDKLRKWVFLFIGWCIPSPI 240	Db 121 SNEVWRCITTTIINYFVVTNFVWMFVEGCCYLHTAIWMTYSTDKLRKWVFLFIGWCIPSPI 240		
Db 121 SNEVWRCITTTIINYFVVTNFVWMFVEGCCYLHTAIWMTYSTDKLRKWVFLFIGWCIPSPI 240	Db 121 SNEVWRCITTTIINYFVVTNFVWMFVEGCCYLHTAIWMTYSTDKLRKWVFLFIGWCIPSPI 240	Db 121 SNEVWRCITTTIINYFVVTNFVWMFVEGCCYLHTAIWMTYSTDKLRKWVFLFIGWCIPSPI 240		
Query 241 IVTWAICKLFYENEQCWIGKEPGKYIDYYQGRVLVLLINFVLNIVRLMTKLRAST 300	Db 241 IVTWAICKLFYENEQCWIGKEPGKYIDYYQGRVLVLLINFVLNIVRLMTKLRAST 300	Db 241 IVTWAICKLFYENEQCWIGKEPGKYIDYYQGRVLVLLINFVLNIVRLMTKLRAST 300		
Db 241 IVTWAICKLFYENEQCWIGKEPGKYIDYYQGRVLVLLINFVLNIVRLMTKLRAST 300	Db 241 IVTWAICKLFYENEQCWIGKEPGKYIDYYQGRVLVLLINFVLNIVRLMTKLRAST 300	Db 241 IVTWAICKLFYENEQCWIGKEPGKYIDYYQGRVLVLLINFVLNIVRLMTKLRAST 300		
Query 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSDQSIVFIVYFNNSFLQSFGFFFVSVF 360	Db 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSDQSIVFIVYFNNSFLQSFGFFFVSVF 360	Db 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSDQSIVFIVYFNNSFLQSFGFFFVSVF 360		
Db 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSDQSIVFIVYFNNSFLQSFGFFFVSVF 360	Db 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSDQSIVFIVYFNNSFLQSFGFFFVSVF 360	Db 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSDQSIVFIVYFNNSFLQSFGFFFVSVF 360		
Query 361 YCFLNGEVRSAARKRWHRQDHHSLSLRVARAMS IPTSPTRISFHSIKQTAAV 413	Db 361 YCFLNGEVRSAARKRWHRQDHHSLSLRVARAMS IPTSPTRISFHSIKQTAAV 413	Db 361 YCFLNGEVRSAARKRWHRQDHHSLSLRVARAMS IPTSPTRISFHSIKQTAAV 413		
Db 361 YCFLNGEVRSAARKRWHRQDHHSLSLRVARAMS IPTSPTRISFHSIKQTAAV 413	Db 361 YCFLNGEVRSAARKRWHRQDHHSLSLRVARAMS IPTSPTRISFHSIKQTAAV 413	Db 361 YCFLNGEVRSAARKRWHRQDHHSLSLRVARAMS IPTSPTRISFHSIKQTAAV 413		
RESULT 2 Q68Y60	RESULT 2 Q68Y60	RESULT 2 Q68Y60		
ID Q68Y60	ID Q68Y60	ID Q68Y60		
AC Q68Y60;	AC Q68Y60;	AC Q68Y60;		
DT 25-OCT-2004 (TREMBLrel. 28, Created)	DT 25-OCT-2004 (TREMBLrel. 28, Last sequence update)	DT 25-OCT-2004 (TREMBLrel. 28, Last annotation update)		
DT 25-OCT-2004 (TREMBLrel. 28, Last sequence update)	DT 25-OCT-2004 (TREMBLrel. 28, Last annotation update)	DT 25-OCT-2004 (TREMBLrel. 28, Last annotation update)		
DE Corticotropin releasing factor receptor type 2.	DE Corticotropin releasing factor receptor type 2.	DE Corticotropin releasing factor receptor type 2.		
GN Name=CRFR-2;	GN Name=CRFR-2;	GN Name=CRFR-2;		
OS Rana catesbeiana (Bull frog).	OS Rana catesbeiana (Bull frog).	OS Rana catesbeiana (Bull frog).		
OC Amphibia; Batrachia; Anura; Neobatrachia; Ranidae; Rana.	OC Amphibia; Batrachia; Anura; Neognathae; Galliformes; Phasianinae; Gallo-	OC Amphibia; Batrachia; Anura; Neognathae; Galliformes; Phasianinae; Gallo-		
OC NCBI_TaxID=8400;	OC NCBI_TaxID=8400;	OC NCBI_TaxID=8400;		
RN [1]	RN [1]	RN [1]		
RP SEQUENCE FROM N.A.	RP SEQUENCE FROM N.A.	RP SEQUENCE FROM N.A.		
RC TISSUE=Cerebellum;	RC TISSUE=Cerebellum;	RC TISSUE=Cerebellum;		
RA Ito Y., Ogata D., Hasunuma I., Kikuyama S.; "molecular cloning of two corticotropin releasing factor receptors from bullfrog."	RA Ito Y., Ogata D., Hasunuma I., Kuhn E.R., Darras V.M.; "Corticotropin-releasing hormone (CRH)-induced thyrotropin release is directly mediated through CRH receptor type 2 on thyrotropes."	RA Ito Y., Ogata D., Hasunuma I., Kuhn E.R., Darras V.M.; "Corticotropin-releasing hormone (CRH)-induced thyrotropin release is directly mediated through CRH receptor type 2 on thyrotropes."		
RT Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.	RT Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.	RT Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.		

RL	Endocrinology 144:5537-5544 (2003) .	DR	InterPro; IPR003053; CRF2_receptor.
DR	EMBL; AJ557031; CAD89534.2; -; C:membrane; IEA.	DR	InterPro; IPR003051; CRF_receptor.
DR	GO; GO:0016020; F:G-protein coupled receptor activity; IEA.	DR	InterPro; IPR000832; GPCR_secretin.
DR	GO; GO:0004930; F:receptor activity; IEA.	DR	InterPro; IPR001879; hormn_receptor.
DR	GO; GO:0004872; F:receptor activity; IEA.	DR	Pfam; PF00002; 7tm_2; 1.
DR	InterPro; IPR000832; GPCR_secretin.	DR	PRINTS; PRO1279; HRM; 1.
DR	InterPro; IPR001879; hormn_receptor.	DR	PRINTS; PRO1281; CRFRECEPTOR.
KW	Receptor; PR00002; 7tm_2; 1.	DR	PRINTS; PRO0249; GPCRSECRETIN.
SQ	SEQUENCE 412 AA; 48095 MW; 641B269460EC4041 CRC64;	DR	SMART; SM00008; HormR; 1.
	Query Match 88.1%; Score 1963.5; DB 2; Length 412;	DR	PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
	Best Local Similarity 87.7%; Pred. No. 5.7e-138;	DR	PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.
	Matches 362; Conservative 22; Mismatches 28; Indels 1; Gaps 1;	DR	PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
Qy	1 MDSTIFELIIDDEFDANCSSLDAFQDSFLHSESSSSPFPGECPYCSATIDQIGTCWPRSLAG 60	DR	Receptor.
Db	1 MDVTISQFILEEDANRSSL-LQETVLESFSISFLGFHGLYCNATTDOIGTCWPRASAG 59	DR	KW
Qy	61 ELVERPCPDSENGIRYNTTRNIVYRECENGNTWASWMNYSQCVPILDNKRKVALLYKIALI 120	DR	SEQUENCE 414 AA; 48329 MW; 11FB2E9E4481CCC2 CRC64;
Db	60 KLVERPCPEFFNGIKYNTTKNAYRECLNGNTWASKINYSQCEPILDDDRKRYAHHYKIALI 119	Qy	1 MDSTIFELIIDDEF-DANCSSLDAFQDSFLHSESSSSPFPGECPYCSATIDQIGTCWPRSLA 59
Qy	121 INVLGHCISILALVIAFLFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLLOMIDHNIIHE 180	Db	1 MDATIYQI1FGFDDNCVMDSFQDSFYENASFLMDFDGLYCNATTDBIGTCWPKSNT 60
Db	120 INVLGHCISVGALIVAFMLFLCLRSIRCLRNIVHWNLITTFILRNVMWFLLOMIDHNIIHE 179	Qy	60 GELVERPCPDSENGIRYNTTRNIVYRECENGNTWASWMNYSQCVPILDNKRKVALLYKIALI 119
Qy	181 SNEWWRCCRITTIVNYFVVTNFVFMMFVEGYCYLHTAIYMTYSTDKLRKWKVFLFIGWCIPSP 240	Db	61 GRMVERPCPEYINGVKYNTTRSARECIDNGTWALKSNYSSCCEPILEKRRKYPMHYKIALI 120
Db	180 SNEPWCRCLITTIYNYFVVTNFVFMMFVEGYCYLHTAIYMTYSTDKLRKWKVFLFIGWCIPCP 240	Qy	120 INVLGHCISILALVIAFLFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLLOMIDHNII 179
Qy	241 IVTWAICKLFYENEQCWIGKEPGKYIDYIYQGRVILVLLINFVFLNIVRILMTKLRAST 300	Db	121 INVLGHCISVGALVAFILFLCLRSIRCLRNIIHWNLITTFILRNVMWFLLOMIDHNII 180
Db	240 IVAWAIGKLYNENEQCWFGKEPGKYIDYIYQGPVILVLLINFVFLNIVRILMTKLRAST 299	Qy	180 ESNEWWRCCRITTIVNYFVVTNFVFMMFVEGYCYLHTAIYMTYSTDKLRKWKVFLFIGWCIPSP 239
Qy	301 TSETIQYRKAVKATLVLLPLLGITYMLFVNPNGEDDDVSQIVFIYFNNSFLQSFOGFFFVSV 360	Db	181 ESNEPWCRCLITTIYNYFVVTNFVFMMFVEGYCYLHTAIYMTYSTDKLRKWKVFLFIGWCIPCP 240
Db	300 TSETIQYRKAVKATLVLLPLLGITYMLFVNPNGEDDDISQIVFIYFNNSFLQSFOGFFFVSV 359	Qy	240 IVTWAICKLFYENEQCWIGKEPGKYIDYIYQGRVILVLLINFVFLNIVRILMTKLRAST 299
Qy	361 YCFLNGEVRSAARKRWHRWQDHSLRVRVARAMSIPSPTRISFHSIKQTAAV 413	Db	241 IVAWAIGKLYNENEQCWFGKEPGKYIDYIYQGPVILVLLINFVFLNIVRILMTKLRAST 300
Db	360 YCFLNGEVRSAARKRWHRWQDHSLRVRVARAMSIPSPTRISFHSIKQTAAV 414	Qy	300 TSETIQYRKAVKATLVLLPLLGITYMLFVNPNGEDDDVSQIVFIYFNNSFLQSFOGFFFVSV 359
		Db	360 YCFLNGEVRSAARKRWHRWQDHSLRVRVARAMSIPSPTRISFHSIKQTAAV 413
		Db	361 YCFLNGEVRSAARKRWHRWQDHSLRVRVARAMSIPSPTRISFHSIKQTAAV 414
		RESULT 5	RESULT 5
		Q98UC1	Q98UC1
		ID	ID
		Q98UC1	Q98UC1
		AC	AC
		Q98UC1;	Q98UC1;
		DT	DT
		01-JUN-2001 (TrEMBLrel. 17, Created)	01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
		DT	DT
		01-JUN-2003 (TrEMBLrel. 23, Last sequence update)	01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
		DT	DT
		01-OCT-2003 (TrEMBLrel. 25, Last annotation update)	Corticotropin releasing factor receptor 2.
		DE	DE
		Corticotropin-releasing factor receptor type 2.	Amelurus nebulosus.
		GN	OS
		Name=crfr2;	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; OC
		OS	Actinopterygii; Neopterygii; Teleostei; Osteostomi; Siluriformes; OC
		NCBI_TaxID=8018;	Ictaluridae; Ameiurus. OC
		RN	[1] NCBI_TaxID=27778; RN
		RP	SEQUENCE FROM N.A. RP
		RA	SEQUENCE FROM N.A. MEDLINE=21066341; PubMed=11145609; DOI=10.1210/en.142.1.446;
		RA	RA Ariai M., Abou-Samra A.B.;
		RT	"Characterization of three corticotropin-releasing factor receptors in catfish: a novel third receptor is predominantly expressed in pituitary and urophysis." RT
		RL	Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases. RL Endocrinology 142:446-454 (2001). EMBL; AF229360; AAK01069-1; DR GO; GO:0016020; C:membrane; IEA. DR GO; GO:0004930; F:G-protein coupled receptor activity; IEA. DR GO; GO:0004872; F:receptor activity; IEA. DR

DR GO:0004872; F:receptor activity; IEA.

DR InterPro; IPR003053; CRF2 receptor.

DR InterPro; IPR003051; CRF₂ receptor.

DR InterPro; IPR000832; GPCR₂ secretin.

DR InterPro; IPR001879; hormn_n receptor.

PFam; PF00002; 7tm₂; 1.

PFam; PF02793; HRM_n; 1.

PRINTS; PRO1279; CRFRECEPTOR.

PRINTS; PRO1281; CRFRECEPTOR2.

DR SMART; SM00008; HormR; 1.

DR PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.

DR PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.

DR PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.

Receptor.

SEQUENCE 405 AA; 46823 MW; E05E96BCFEAD5CC5 CRC64;

Query Match 81.1%; Score 1807; DB 2; Length 405;

Best Local Similarity 79.9%; Pred. No. 2.4e-126;

Matches 330; Conservative 33; Mismatches 42; Indels 8; Gaps 2;

QY 1 MDSTIFEIIIDEFDANCSLLDAFQDSFLHSESSSSFFEGPYCSATIDQIGTCWPRLAG 60

Db 1 MEVSLLELL--SVEVNCSLADAFGDPAYGNASDAL-----YCNAATADEIGTCWPRLSGAG 52

QY 61 ELVERPCPDPSFNGIRYNTTRNVTYRECENGTWASWMMYSQCVPILDNKRYALHYKIALI 120

Db 53 RVVARPCPDFINGKVYNSTRSAYPECLENGTWAFKINYSSCPEILEEKRYPVHYKIALI 112

QY 121 INYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMIDHNIHE 180

Db 113 INYLGHCISVGALVIAFVLFLCLRSIRCLRNVIHWNLITTFILRNIMWFLQLIDHNIHE 172

QY 181 SNEVWCRCITTTIYNYFVVTNFFWMFVEGCYLHTAIYMTYSTDKLRKWVFLFIGWCIPSPPI 240

Db 173 RNEPWCRLLTIVNYFVVTNFPETWMFVEGCYLHTAIYMTYSTDKLRKWVFLFIGWCIPCPV 232

QY 241 IVTWAICKLFYENEQCWIGKEPGKYIDYYQGRVILVILLNFVFLNIVRILMTKLRAST 300

Db 233 IIAWAVGKLYNENEQCWFGKEPGKYVDIYQGPVIVVLLINVFVFLNIVRILMTKLRAST 292

QY 301 TSETIQYRKAVKATLVLLPLLGITYMLFVNPGEDDVSOIYFVFLNIVRILMTKLRAST 360

Db 293 TSETIQYRKAVKATLVLLPLLGITYMLFVNPGDDDISQIVFYFNSFLQSFGFFFVSVF 352

QY 361 YCFLNGEVRSAARKRWHRQDHFHSLRVVARAMSPTSPTRISFHSIKQTAAV 413

Db 353 YCFLNGEVRSAVRKRWHRQDNHALRVVARAMSPTSPTRISFHSIKHTTAV 405

RESULT 6

ID CRF2_HUMAN STANDARD; PRT; 411 AA.

AC Q13324; O43461; Q99431; Name=CRHR2; Synonyms=CRF2R, CRH2R;

DT 01-NOV-1997 (Rel. 35, Created) Homo sapiens (Human).

DT 30-MAY-2000 (Rel. 39, Last sequence update)

DT 25-OCT-2004 (Rel. 45, Last annotation update)

DE Corticotropin releasing factor receptor 2 precursor (CRF-R 2) (CRF2)

DE (Corticotropin-releasing hormone receptor 2) (CRH-R 2).

GN Homo sapiens

OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OC NCBI_TaxID=9606;

OX RN [1] SEQUENCE FROM N.A. (ISOFORM CRF2-ALPHA).

RP MEDLINE=96107120; PubMed=8536644; DOI=10.1210/en.137.1.72; RX Liaw C.W., Lovenberg T.W., Barry G., Oltersdorf T., Grigoriadis D.E., RA de Souza E.B.; Name=InterPro; IPR000832; GPCR secretin.

RT "Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid." Endocrinology 137:72-77 (1996). [2]

RP SEQUENCE FROM N.A. (ISOFORM CRF2-GAMMA).

RC TISSUE=Amygda; RC TISSUE=amygdala; RX MEDLINE=98381934; PubMed=9717834; DOI=10.1210/me.12.8.1077; RA Kostich W.A., Chen A., Sperle K., Horlick R.A., Patterson J., Hyde T.M., Largent B.L.; RT "Molecular cloning of the human CRH2B receptor isoform: divergence from the rodent isoform in sequence and expression pattern." Submitted (JUN-1997) to the EMBL/GenBank/DDBJ databases. [3]

RN SEQUENCE FROM N.A. (ISOFORM CRF2-GAMMA).

RP TISSUE=Amygda; RC TISSUE=amygdala; RX MEDLINE=98381934; PubMed=9717834; DOI=10.1210/me.12.8.1077; RA Kostich W.A., Chen A., Sperle K., Largent B.L.; RT "Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor." Mol. Endocrinol. 12:1077-1085 (1998). [4]

RN SEQUENCE FROM N.A. (ISOFORMS CRF2-ALPHA AND CRF2-GAMMA).

RP Andrews S., Langston Y., Stoneking T., Maupin R.; RA Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases. [5]

RN SEQUENCE FROM N.A. (ISOFORM CRF2-ALPHA).

RP Suwa M., Sato T., Okouchi I., Arita M., Putami K., Matsumoto S., TSutsumi S., Aburatani H., Asai K., Akiyama Y.; RT "Genome-wide discovery and analysis of human seven transmembrane helix receptor genes." Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases. [6]

RN SEQUENCE OF 1-88 FROM N.A. (ISOFORM CRF2-BETA).

RC TISSUE=Skeletal muscle; RX MEDLINE=97342544; PubMed=9199241; DOI=10.1016/S0167-4781(97)00047-X; RA Valdenaire O., Giller T., Breu V., Gottowik J., Kilpatrick G.; RT "A new functional isoform of the human CRF2 receptor for corticotropin-releasing factor." Biochim. Biophys. Acta 1352:129-132 (1997).

RL -!- FUNCTION: This is a receptor for corticotropin releasing factor. Shows high-affinity CRF binding. Also binds to urocortin I, II and III. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.

CC -!- SUBCELLULAR LOCATION: Integral membrane protein.

CC -!- ALTERNATIVE PRODUCTS:

CC Name=CRF2-alpha; IsoID=Q13324-1; Sequence=Displayed;

CC Name=CRF2-beta; IsoID=Q13324-2; Sequence=VSP_001999;

CC Name=CRF2-gamma; IsoID=Q13324-3; Sequence=VSP_002000;

CC -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a licence agreement (see http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).

CC EMBL; U34587; AAA91320.1; DR EMBL; AF011406; AAB94503.1; DR EMBL; AF019381; AAB94562.1; DR EMBL; AC004976; AAC71653.1; DR EMBL; AC004976; AAC71654.1; DR EMBL; AB065699; BAC05922.1; DR EMBL; Y10151; CAA71235.1; DR Genew; HGNC:2358; CRHR2. DR MIM; 602034; DR GO; GO:0005887; C:integral to plasma membrane; TAS. DR GO; GO:0015056; F:corticotrophin-releasing factor receptor ac. . . ; TAS. DR GO; GO:0007188; P:G-protein signaling, coupled to CAMP nucleo. . . ; TAS. DR InterPro; IPR000832; GPCR secretin. DR InterPro; IPR001879; hormn_n receptor. DR PFam; PF00002; 7tm₂.1. DR PFam; PF02793; HRM_n; 1. DR PFam;

RESULT 7									
DR PRINTS; PR00249; GPCRSECRETIN.									
DR SMART; SM00008; HormR; 1.									
DR PROSITE; PS00649; G_PROTEIN_RECEP_F2_1; 1.									
DR PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.									
DR PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.									
DR PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.									
KW Alternative splicing; G-protein coupled receptor; Glycoprotein;									
KW Signal; Transmembrane.									
FT SIGNAL 1 17	Potential.	Corticotropin releasing factor receptor							
FT CHAIN 18 411	2.	Extracellular (Potential).							
FT DOMAIN 18 118	118	1 (Potential).							
FT TRANSMEM 119 139	139	Cytoplasmic (Potential).							
FT DOMAIN 140 148	148	2 (Potential).							
FT TRANSMEM 149 168	168	Extracellular (Potential).							
FT DOMAIN 169 185	185	3 (Potential).							
FT TRANSMEM 186 209	209	Cytoplasmic (Potential).							
FT DOMAIN 210 223	223	4 (Potential).							
FT TRANSMEM 224 245	245	Extracellular (Potential).							
FT DOMAIN 246 264	264	5 (Potential).							
FT TRANSMEM 265 287	287	Cytoplasmic (Potential).							
FT DOMAIN 288 310	310	6 (Potential).							
FT TRANSMEM 311 330	330	Extracellular (Potential).							
FT DOMAIN 331 345	345	7 (Potential).							
FT TRANSMEM 346 365	365	Cytoplasmic (Potential).							
FT DOMAIN 366 411	411	N-linked (GlcNAc . .) (Potential).							
FT CARBOHYD 41 41	41	N-linked (GlcNAc . .) (Potential).							
PT CARBOHYD 74 74	74	N-linked (GlcNAc . .) (Potential).							
PT CARBOHYD 86 86	86	N-linked (GlcNAc . .) (Potential).							
PT CARBOHYD 94 94	94	N-linked (GlcNAc . .) (Potential).							
PT VARSPLIC 1 34	34	MDAALLHSLLEANCSLALAEELLLDGWGPPLDPE -> MRG PSGGPGGLYLYVPHLLCLLCLLCLLPPPLQYAAAGQSQMPKQPLW ALLEQYCHTTIMTLTNTS (in isoform CRF2-beta).							
PT /FTId=VSP_001999.		R -> H (in Ref. 1).							
PT CONFFLICT 185 185	185	/FTId=VSP_002000.							
PT SEQUENCE 411 AA; 47687 MW;	47687 MW;	96B99A93594CF07F CRC64;							
VARSPLIC 1 34	34	EPPWEDRDLGFPQLFCQ (in isoform CRF2- gamma).							
FT QY 1 MDSTIFELIIDDEFDANCSSLDAFDQDSFLHSESSSSFFGFEQP--YCSATIDQIGTCWPRL 58	80.9%	Score 1804; DB 1; Length 411;	Query Match	80.6%	Score 1796.5; DB 2; Length 410;				
SO DB 1 MDAALLHSLL---EANCSL--ALAEELLLDGWGPPLDPEGPYSYCNTTLQDQIGTCWPRL 55	80.0%	Pred. No. 4.1e-126;	Best Local Similarity	79.0%	Pred. No. 1.5e-125;				
SO SEQUENCE 411 AA; 47687 MW;	47687 MW;	Mismatches 42; Indels 8; Gaps 4;	Mismatches	34;	Mismatches 46; Indels 7; Gaps 3;				
QY 1 MDSTIFELIIDDEFDANCSSLDAFDQDSFLHSESSSSFFGFEQP--YCSATIDQIGTCWPRL 58	80.9%	Score 1804; DB 1; Length 411;	Query Match	80.6%	Score 1796.5; DB 2; Length 410;				
DB QY 59 AGELVERPCPDSENGIRYNTTRNVRRECENGTWASWMNYSQCVPILDNNKRKYALHYKIA 117	80.0%	Pred. No. 4.1e-126;	Best Local Similarity	79.0%	Pred. No. 1.5e-125;				
DB QY 56 AGALVERPCPEYFGVKYNTTRNAYRECLENGTWASKINYSQCEPILDDKKQRKYDLHYRI 115	80.0%	Mismatches 42; Indels 8; Gaps 4;	Mismatches	328;	Conservative 34; Mismatches 46; Indels 7; Gaps 3;				
QY 118 ALIINYLGHCISIILALVTAFLFLCLRSIRCLRNNTIHWNLITTFILRNIMWFLQIDHN 177	80.0%	Score 1804; DB 1; Length 411;	Query Match	80.6%	Score 1796.5; DB 2; Length 410;				
DB QY 116 ALVVNLGHCVSAALVAAPFLFLALARSRICLERNVHWNLITTFILRNIMWFLQIDHEV 175	80.0%	Pred. No. 4.1e-126;	Best Local Similarity	79.0%	Pred. No. 1.5e-125;				
QY 178 IHESNWRCITTYNQYVTTNFWMFVEGGCYLHTAIIVMTYSTDKLRKWVFLFIGWCIP 237	80.0%	Mismatches 42; Indels 8; Gaps 4;	Mismatches	328;	Conservative 34; Mismatches 46; Indels 7; Gaps 3;				
DB QY 176 VHESNWRCITTYNQYVTTNFWMFVEGGCYLHTAIIVMTYSTERLRKWLFIGWCIP 235	80.0%	Score 1804; DB 1; Length 411;	Query Match	80.6%	Score 1796.5; DB 2; Length 410;				
QY 238 SPIIYTWAICKLFYENEQCWCIIYQYVTFVNPGEDDVSVIQVYFNSFLQSFGQPFV 357	80.0%	Pred. No. 4.1e-126;	Best Local Similarity	79.0%	Pred. No. 1.5e-125;				
DB QY 236 FPIIVAWAIGKLYENEQCWFGKEPGDVLVDIYQGPIILVLLINFVFLNIVRILMTKLR 295	80.0%	Mismatches 42; Indels 8; Gaps 4;	Mismatches	328;	Conservative 34; Mismatches 46; Indels 7; Gaps 3;				
QY 298 ASTTSETIQYRKAVAKATLVLLPLLGITYMLFVVNPGEDDVSVIQVYFNSFLQSFGQPFV 357	80.0%	Score 1804; DB 1; Length 411;	Query Match	80.6%	Score 1796.5; DB 2; Length 410;				
DB QY 296 ASTTSETIQYRKAVAKATLVLLPLLGITYMLFVVNPGEDDVSVIQVYFNSFLQSFGQPFV 355	80.0%	Pred. No. 4.1e-126;	Best Local Similarity	79.0%	Pred. No. 1.5e-125;				
QY 358 SVFYCFLNGEVRSAAKWRHRWDHSLRVPMARAMSIPTSPTISFHSIKQTAAV 413	80.0%	Mismatches 42; Indels 8; Gaps 4;	Mismatches	328;	Conservative 34; Mismatches 46; Indels 7; Gaps 3;				
DB QY 356 SVFYCFLNGEVRSAAKWRHRWDHSLRVPMARAMSIPTSPTISFHSIKQTAAV 413	80.0%	Score 1804; DB 1; Length 411;	Query Match	80.6%	Score 1796.5; DB 2; Length 410;				
QY 359 VFYCFLNGEVRSAAKWRHRWDHSLRVPMARAMSIPTSPTISFHSIKQTAAV 413	80.0%	Pred. No. 4.1e-126;	Best Local Similarity	79.0%	Pred. No. 1.5e-125;				

RN	[1]	SEQUENCE FROM N.A.	Mus musculus (Mouse).
RP		Euksaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
RX		OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.	
RA		NCBI_TaxID=10090;	
RT	"Isolation and pharmacological characterization of two functional	[1]	
RT	splice variants of corticotropin-releasing factor type 2 receptor from	SEQUENCE FROM N.A.	
RT	the tree shrew (Tupaia belangeri)."	TISSUE=Heart;	
RL	J. Neuroendocrinol. 11:419-428 (1999).	RC	
RN	[2]	RN	
RP	SEQUENCE FROM N.A.	RP	
RA	Dautzenberg F.M.;	RC	
RL	Submitted (DEC-2001) to the EMBL/GenBank/DDJBJ databases.	RC	
DR	EMBL; AJ422243; CAD19579.1; -.	RC	
DR	GO; GO:0016020; C:membrane; IEA.	RC	
DR	GO; GO:0004872; F:G-protein coupled receptor activity; IEA.	RC	
DR	Pfam; PF00002; 7tm_2; 1.	RC	
DR	PFam; PF02793; HRM_1.	RC	
DR	PRINTS; PR01279; CRFRECEPTOR.	RC	
DR	PRINTS; PR01281; CRFRECEPTOR2.	RC	
DR	PRINTS; PR00249; GPCRSECRETIN.	RC	
DR	SMART; SM00008; HormR; 1.	RC	
DR	PROSITE; PS00649; G_PROTEIN_RECEP_F2_1; UNKNOWN_1.	RC	
DR	PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.	RC	
DR	PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.	RC	
DR	PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.	RC	
RW	Receptor.	RC	
SQ	SEQUENCE	RC	
Query Match	40 GP--YCSATIDQIGTCWPRSLAGELVERPCPDSEFNCGIRYNTTRNVYRECFFENGTWASWMN 97	SEQUENCE FROM N.A.	
Best Local Similarity	80.4%; Score 1792; DB 2; Length 437;	STRAIN=BALB/C; TISSUE=Heart;	
Matches	85.1%; Pred. No. 3.4e-125;	STRAIN=95166778; PubMed=7755719;	
	29; Mismatches 25; Indels 2; Gaps 1;	MEDLINE=96015396; PubMed=7565810; DOI=10.1210/me.9.5.637;	
Db	62 GPySYCNTLDQIGTCWPRSAAGALLERPCPEYFNGVKYNATRAYRECLENGTWASRIN 121	Proc. Natl. Acad. Sci. U.S.A. 92:2969-2973 (1995).	
Qy	98 YSQCVPLLDNKRYKALHYKIALIINYLGHCISILALVIAFLLFLCLRSIRCLRNTHWNL 157	[2]	
Db	122 YSQCEPILDDKRYDLHYRALVNNYLGHCVSMAALVAAFFLFLALARSLIRCLRNTHWNL 181	SEQUENCE FROM N.A.	
Qy	158 ITTFILRNIMWFLQMDHNHESNEWCRCITIINYFVVTNFVWMFVEGCCYLHTAVM 217	SEQUENCE FROM N.A.	
Db	182 ITTFILRNVTWFLQLIDHEWTHESNEWVRCITIIFYFVVTNFVWMFVEGCCYLHTAVM 241	SEQUENCE FROM N.A.	
Qy	218 TYSTDKLRKWVFLFIGWCIPSPIITWAICKLFYENEQCWIGKEPGKYIDYYQGRVILV 277	[3]	
Db	242 TYSTERLRKWLFIGWCVPCCPIIAWAKLYENKOCWFGEKGDPDVYDYYQGPILV 301	SEQUENCE FROM N.A.	
Qy	278 LLINFVFLNIVRLMTKLRASTTSETIQRKAVKATVLPLLGITYMLFFVNPGEDDV 337	SEQUENCE FROM N.A.	
Db	302 LLINFVFLNIVRLMTKLRASTTSETIQRKAVKATVLPLLGITYMLFFVNPGEDDL 361	SEQUENCE FROM N.A.	
Qy	338 SQIVFVYFNNSFLQSFGFFFVSYFYCFLNGEVRSAAKRKRWHRWDHSLRVVARAMSIP 397	SEQUENCE FROM N.A.	
Db	362 SQIVFVYFNNSFLQSFGFFFVSYFYCFLNGEVRSALRKKRWHRWDHSLRVVARAMSIP 421	SEQUENCE FROM N.A.	
Qy	398 SPTRISFSIKQTAAV 413	[4]	
Db	422 SPTRISFSIKQTAAV 437	SEQUENCE FROM N.A.	
RESULT 10			
CRF2_MOUSE			
ID	CRF2_MOUSE STANDARD; PRT; 431 AA.		
AC	Q60748; Q60783; Q60808;		
DT	01-NOV-1997 (Rel. 35, Created)		
DT	01-NOV-1997 (Rel. 35, Last sequence update)		
DT	25-OCT-2004 (Rel. 45, Last annotation update)		
DE	Corticotropin releasing factor receptor 2 precursor (CRF-R 2) (CRF2)		
DE	(Corticotropin-releasing hormone receptor 2) (CRH-R 2) (CRF-RB) (CRH-R2).		
DE	Name=Cchr2; SyonymB=Crf2r;		

FT DOMAIN	160	168	Cytoplasmic (Potential).	RX MEDLINE=21066341; PubMed=11145609; DOI=10.1210/en.142.1.446;
FT TRANSMEM	169	188	2 (Potential).	RA Arai M., Assil I.Q., Abou-Samra A.B.;
FT DOMAIN	189	205	Extracellular (Potential).	RT "Characterization of three corticotropin-releasing factor receptors in catfish: a novel third receptor is predominantly expressed in pituitary and urophysis."
FT TRANSMEM	206	229	3 (Potential).	RT Endocrinology 142:446-454 (2001).
FT DOMAIN	230	243	Cytoplasmic (Potential).	RL EMBL; AF229361; AAC01070.1; -.
FT TRANSMEM	244	265	4 (Potential).	DR GO; GO:0016020; C:membrane; IEA.
FT DOMAIN	266	284	Extracellular (Potential).	DR GO; GO:0004930; F:G-protein coupled receptor activity; IEA.
FT TRANSMEM	285	307	5 (Potential).	DR GO; GO:0004872; F:receptor activity; IEA.
FT DOMAIN	308	330	Cytoplasmic (Potential).	DR InterPro; IPR003051; CRF receptor.
FT TRANSMEM	331	350	6 (Potential).	DR InterPro; IPR000832; GPCR secretin.
FT DOMAIN	351	365	Extracellular (Potential).	DR InterPro; IPR001879; hormn_receptor.
FT TRANSMEM	366	385	7 (Potential).	DR Pfam; PF00002; 7tm_2; 1.
FT DOMAIN	386	431	Cytoplasmic (Potential).	DR Pfam; PF02793; HRM; 1.
FT CARBOHYD	52	52	N-linked (G1cNAC. . .) (Potential).	DR PRINTS; PRO0249; GPCRSECRETIN.
FT CARBOHYD	61	61	N-linked (G1cNAC. . .) (Potential).	DR SMART; SM00008; HormR; 1.
FT CARBOHYD	94	94	N-linked (G1cNAC. . .) (Potential).	DR PROSITE; PS00649; G PROTEIN RECEP_F2_1; UNKNOWN_1.
FT CARBOHYD	106	106	N-linked (G1cNAC. . .) (Potential).	DR PROSITE; PS00650; G PROTEIN RECEP_F2_2; 1.
FT CARBOHYD	114	114	N-linked (G1cNAC. . .) (Potential).	DR PROSITE; PS50227; G PROTEIN RECEP_F2_3; 1.
FT CONFLICT	3	5	TPG -> QOI (in Ref. 2).	DR PROSITE; PS50261; G PROTEIN RECEP_F2_4; 1.
FT CONFLICT	126	126	Missing (in Ref. 3).	KW Receptor.
FT CONFLICT	392	393	KR -> NG (in Ref. 3).	SQ SEQUENCE 431 AA; 49923 MW; A6D9EDE575DB8061 CRC64;
FT CONFLICT	396	397	RW -> SG (in Ref. 2).	Query Match 79.4%; Score 1770.5; DB 1; Length 431;
FT CONFLICT	408	408	A -> R (in Ref. 2).	Best Local Similarity 84.7%; Pred. No. 1.3e-123; Indels 26; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	205	229	Indels 3; Gaps 2;	Query Match 73.1%; Best Local Similarity 73.1%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	230	243	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	244	265	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	266	284	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	285	307	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT DOMAIN	308	330	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	331	350	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT DOMAIN	351	365	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	366	385	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT DOMAIN	386	431	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	408	446	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	424	462	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	446	484	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	462	500	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	484	522	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	500	538	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	522	560	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	538	576	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	560	598	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	598	636	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	636	674	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	674	712	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	712	750	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	750	788	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	788	826	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	826	864	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	864	902	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	902	940	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	940	978	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	978	1016	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	1016	1054	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	1054	1092	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	1092	1130	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	1130	1168	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	1168	1206	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	1206	1244	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	1244	1282	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	1282	1320	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	1320	1358	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	1358	1396	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	1396	1434	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	1434	1472	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	1472	1510	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity 71.0%; Pred. No. 1.3e-109; Indels 5; Gaps 2;
FT TRANSMEM	1510	1548	Indels 29; Mismatches 26; Conservative Matches 321; Score 1582.5; Pred. No. 1.3e-109; Indels 5; Gaps 2;	Query Match 71.0%; Best Local Similarity

QY	SEQUENCE FROM N.A. MEDLINE=96107136; PubMed=8536612; DOI=10.1210/en.137.1.192; Yu J., Xie L.Y., Abou-Samra A.-B.; "Molecular cloning of a type A chicken corticotropin-releasing factor receptor with high affinity for urotensin I."; Endocrinology 137:192-197 (1996).	138 LLFLCLRSIRCLRNIIHNLITFIRNIMWFLLOM-IDHNTHESNEVWCRCITIINYF 196 RT Shows high-affinity binding for urotensin I. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
-!- SUBCELLULAR LOCATION: Integral membrane protein.		
-!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.		
This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).		
CC EMBL; L41563; AAA96656.1; -.		
DR InterPro; IPR000832; GPCR_secretin.		
DR PFam; PF00002; 7tm_2; 1.		
PRINTS: PR00249; GPCRSECRETIN.		
SMART: SM00008; HormR; 1.		
PROSITE; PS000649; G_PROTEIN_RECV_F2_1; 1.		
PROSITE; PS000650; G_PROTEIN_RECV_F2_2; 1.		
PROSITE; PS050227; G_PROTEIN_RECV_F2_3; 1.		
PROSITE; PS50261; G_PROTEIN_RECV_F2_4; 1.		
G-protein coupled receptor; Glycoprotein; Signal; Transmembrane.		
KW SIGNAL 1 28		
FT CHAIN 29 420		
FT DOMAIN 29 126		
FT TRANSMEM 127 147		1.Extracellular (Potential).
FT DOMAIN 148 156		1 (Potential).
FT TRANSMEM 157 176		Cytoplasmic (Potential).
FT DOMAIN 177 194		2 (Potential).
FT TRANSMEM 195 218		Extracellular (Potential).
FT DOMAIN 219 232		3 (Potential).
FT TRANSMEM 233 254		Cytoplasmic (Potential).
FT DOMAIN 255 273		4 (Potential).
FT TRANSMEM 274 296		F:G-protein coupled receptor activity: IEA.
FT DOMAIN 297 319		DR GO; GO:0004930; F:G-protein coupled receptor activity: IEA.
FT TRANSMEM 320 339		DR GO; GO:0004872; F:receptor activity; IEA.
FT DOMAIN 340 354		DR InterPro; IPR003052; CRF1 receptor.
FT TRANSMEM 355 374		DR InterPro; IPR003051; CRF receptor.
FT DOMAIN 375 420		DR InterPro; IPR00832; GPCR secretin.
FT DISULFID 35 59		DR InterPro; IPR001879; hormn_receptor.
FT DISULFID 49 92		DR Pfam; PF00002; 7tm_2; 1.
FT DISULFID 73 107		DR Pfam; PF02793; HormR; 1.
FT CARBOHYD 43 43		DR PRINTS; PR01279; CRFRECEPTOR.
FT CARBOHYD 50 50		DR PRINTS; PR01280; CRFRECEPTOR1.
FT CARBOHYD 83 83		DR SMART; SM00008; HormR; 1.
FT CARBOHYD 95 95		DR PROSITE; PS00649; G_PROTEIN_RECV_F2_1; UNKNOWN_1.
FT CARBOHYD 103 103		DR PROSITE; PS00650; G_PROTEIN_RECV_F2_2; 1.
SQ SEQUENCE 420 AA; 48600 MW;		DR PROSITE; PS50227; G_PROTEIN_RECV_F2_3; 1.
		DR PROSITE; PS50261; G_PROTEIN_RECV_F2_4; 1.
KW Receptor.		DR Receptor.
SQ SEQUENCE 445 AA; 51062 MW;		DR SEQUENCE 445 AA; 51062 MW; F17DA70BE22BB755 CRC64;
Query Match 70.8%; Score 1578.5; DB 2; Length 445;		
Best Local Similarity 76.5%; Pred. No. 2.6e-109;		
Matches 287; Conservative 49; Mismatches 55; Indels 6; Gaps 2;		
QY 18 SLLDAFQDSFLHSESSSSFFGPEGPYCSATIDQIGTCWPRSLAGELVERPCPDSSNGIRYN 77		
DB 29 SIQEYCSESLLPTTNHT----GPQCNAASVLDLIGTCWPRSAVGQLVARPCPEYYGVRYN 83		
QY 78 TTRNVYRECFENGTWASWMNSQCVPILDNKRKYALHYKIALIINYLGHCISILALVIAF 137		
DB 84 TTNNGYRECLANGSWAARVNYSQCOEILSEEKRSKLHYIAVINYLGVSLGGTLVAF 143		
QY 40 GPYCSATIDQIGTCWPRSLAGELVERPCPDSSNGIRYNTTTRNVYRECFENGTWASWMNS 99		
DB 71 GLFCNISIDGIGTCWPRSNAGEIVSRPCPETFLGVRYNTTNNVYRECLANGTWAKGNYS 130		
QY 100 QCVPILDNKRYALHYKIALIINYLGHCISILALVIAFLCLRSIRCLRNIIHWNLIT 159		

Db	131	QCQEILLEEKSKLHYHIAVINYLGHCISLGALLVAFILFMRMIRCLRNIIHWNLIM	190	
Qy	160	TFILRNIMWFLQQ-MIDHNTHESNEWWCRCITIINYFVVTFNFWFVEGCCYLHTATIVMT	218	QY
	161	: : : : : : : : : : : : :		Db
Db	191	APILRNATWFVQLTMNPVEHESNVIWCRLVTAAYNFHVTNFWMFEGGYLHTAIVLT	250	
Qy	219	YSTDKLRKWVFLFIGWCICPSPILLTWAICKL.FYENEQCWIGKEPGKYIDYIYQGRVILVL	278	QY
	220	: : : : : : : : : : : : :		Db
Db	251	YSTDKLRKWLFICIGWCICPSPILLTWAICKL.FYENEQCWIGKEPGKYIDYIYQGRVILVL	310	
Qy	279	LINFVFLNIVRILMTCRLRASSTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDS	338	QY
	280	: : : : : : : : : : : : :		Db
Db	311	LINFVFLNIVRILMTCRLRASSTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDS	370	
Qy	339	QIVFIYFNFSLQSRQGFFFVSVFYCFLNGEVRSAARKWRHQDHSLRVRVARAMSIPTS	398	QY
	340	: : : : : : : : : : : : :		Db
Db	371	QIVFIYFNFSLQSRQGFFFVSVFYCFLNSEVSAVRKRWRQRDKHSIRARVARAMSIPTS	430	
Qy	399	PTRISFHSIKQTAAV 413		QY
	400	: : : : : : : : : : : : :		Db
Db	431	PTRVSFHSIKQSSAV 445		
<hr/>				
RESULT 14				
	Q76LL8	PRELIMINARY;	PRT;	415 AA.
	ID	Q76LL8		
	AC	Q76LL8;		
	DT	05-JUL-2004 (TREMBLrel. 27, Created)		
	DT	05-JUL-2004 (TREMBLrel. 27, Last sequence update)		
	DT	05-JUL-2004 (TREMBLrel. 27, Last annotation update)		
	DE	Corticotropin releasing factor receptor type 1.		
	GN	Name=CRF1;		
	OS	Macaca mulatta (Rhesus macaque).		
	OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
	OC	Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae;		
	OC	Cercopithecinae; Macaca.		
	OX	NCBI_TaxID=9544;		
	RN	[1]		
	RP	SEQUENCE FROM N.A.		
	RA	Oshida Y., Ikeda Y., Chaki S., Okuyama S.;		
	RL	Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.		
	DR	EMBL; AB078141; BAD02831.1; -.		
	DR	GO; GO:0016020; C:membrane; IEA.		
	DR	GO; GO:0004930; F:G-protein coupled receptor activity; IEA.		
	DR	GO; GO:0004872; F:receptor activity; IEA.		
	DR	InterPro; IPR003052; CRF1 receptor.		
	DR	InterPro; IPR003051; CRF receptor.		
	DR	InterPro; IPR000832; GPCR secretin.		
	DR	InterPro; IPR001879; hormn_receptor.		
	DR	Pfam; PF00002; 7tm_2; 1.		
	DR	Pfam; PF02793; HRM; 1.		
	DR	PRINTS; PR01279; CRFRECEPTOR.		
	DR	PRINTS; PR01280; CRFRECEPTOR1.		
	DR	PRINTS; PR00249; GPCRSECRETIN.		
	DR	SMART; SM00008; HormR; 1.		
	DR	PROSITE; PS00649; G_PROTEIN_RECEP_F2_1; 1.		
	DR	PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.		
	DR	PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.		
	DR	PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.		
	KW	Receptor.		
	SQ	SEQUENCE. 415 AA; 47784 MW;		84C530DEC6DA97AD CRC64;
		Query Match 70.3%; Score 1566; DB 2; Length 415;		
		Best Local Similarity 72.8%; Pred. No. 2.1e-108;		
		Matches 287; Conservative 46; Mismatches 57; Indels 4; Gaps 3;		
Qy	22	AFQDSFLHSESSSF-EGFEGPYCSATIDQIGTCWPSLAGEVERPCPDSDNGIRYNTTR	80	DR
	23	: : : : : : : : : : : : : :		DR
Db	24	SLQDQ--HCESSLASNLISGLQCNASVDLIGTCWPSLSPAGQLVVRCPAFFYGVRYNTTN	81	SMART; SM00008; HormR; 1.
Qy	81	NVYRECENGTWASWNNYSQCVPILDNKRYALHYKIALINTLGHCISILALVIAFLLF	140	PROSITE; PS00649; G_PROTEIN_RECEP_F2_1;
	82	: : : : : : : : : : : : : :		PROSITE; PS00650; G_PROTEIN_RECEP_F2_2;
Db		NGYRECLANGSWAARVNYSECQELNEEKKSKVHYHVAVINYLGHCISLVALVAFVLF	141	PROSITE; PS50227; G_PROTEIN_RECEP_F2_3;
		.		PROSITE; PS50261; G_PROTEIN_RECEP_F2_4;
		.		G-protein coupled receptor; Glycoprotein; Signal; Transmembrane.

FT SIGNAL 1 24 Potential.
 FT CHAIN 25 415 Corticotropin releasing factor receptor
 FT DOMAIN 25 121 1.
 FT TRANSMEM 122 142 Extracellular (Potential).
 FT DOMAIN 143 151 1 (Potential).
 FT TRANSMEM 152 171 Cytoplasmic (Potential).
 FT DOMAIN 172 189 2 (Potential).
 FT TRANSMEM 190 213 Extracellular (Potential).
 FT DOMAIN 214 227 3 (Potential).
 FT TRANSMEM 228 249 Cytoplasmic (Potential).
 FT DOMAIN 250 268 4 (Potential).
 FT TRANSMEM 269 291 Extracellular (Potential).
 FT DOMAIN 292 314 Cytoplasmic (Potential).
 FT TRANSMEM 315 334 5 (Potential).
 FT DOMAIN 335 349 Extracellular (Potential).
 FT TRANSMEM 350 369 6 (Potential).
 FT DOMAIN 370 415 Cytoplasmic (Potential).
 FT DISULFID 30 54 By similarity.
 FT DISULFID 44 87 By similarity.
 FT DISULFID 68 102 By similarity.
 FT CARBOHYD 38 38 N-linked (GlcNAc. . .) (Potential).
 FT CARBOHYD 45 45 N-linked (GlcNAc. . .) (Potential).
 FT CARBOHYD 78 78 N-linked (GlcNAc. . .) (Potential).
 FT CARBOHYD 90 90 N-linked (GlcNAc. . .) (Potential).
 SQ SEQUENCE 415 AA; 47786 MW; 74ED24C17907B74D CRC64;

 Query Match 70.2%; Score 1564.5; DB 1; Length 415;
 Best Local Similarity 72.2%; Pred. No. 2.7e-108;
 Matches 285; Conservative 49; Mismatches 58; Indels 3; Gaps 2;

 Qy 20 LDAFDQDSFLHSESSSSFFGPEGPYCSATIDQIGTCWPRLPSLAGELVERPCPDSFNGIRYNTT 79
 Db 23 LTSLQDQCETLQHNS--NFTGLACNASIDMIGTCWPSTAAQMVARPCCPEYFHGVQYNTT 80

 Qy 80 RNVYRECFCFENGTVASWMNYSOCVPILDNKRYALKYKIALIINYLGHCISILALVIAFL 139
 Db 81 GNVYRECHLNGSWAGRGDYAQCQEILKQEKKTKVHYTHIAIVNFLGHSTISCALLVAFIL 140

 Qy 140 FLCLRSIRCLRNIIHWNLITFLRNIMWFLLOM-JIDHNTHESNEVWCRCTTTIINYFVV 198
 Db 141 FLRLRSIRCLRNIIHWNLITAPFLRNVTWFUMQLTLISHEADSNVWCRLVTIAHNYFVV 200

 Qy 199 TNFFWMFVEGGCYLHTAIYMTYSTDKLRKWWVFLFTGWCIPSPIIWTWAICKLYFENEQQWI 258
 Db 201 TNFFWMFGEGCYLHTAIVLTYSTDKLKRKMFICIGWCIPFPIIAWAIKGLYYDNEKCWF 260

 Qy 259 GKEPGKYIDYIYQGRVILVLLINFVLFNIVRLMTKLRASTTSETIQYRKAVKATLVL 318
 Db 261 GKKAGVYTDFIYQGPVILVLLINFVLFNIVRLMTKLRASTTSETIQYRKAVKATLVL 320

 Qy 319 PLLGITYMLFFVNPGEDDVSQIVFYFNSFLQSFGFFFVSYCPLNGEVRSAARKRWHR 378
 Db 321 PLLGITYMLFFFVTPGDEISRIVFVFSVYCFLNSEVRSAVRKRWHR 380

 Qy 379 WQDHHSLRVVARAMSIPSTRISFHSIKQTAAV 413
 Db 381 WQDKHSIRARVARAMSIPSTRISFHSIKQSSAI 415

This Page Blank (uspto)

GenCore version 5.1.6
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: August 20, 2005, 00:18:48 ; Search time 40 Seconds
 (without alignments)
 993.438 Million cell updates/sec

Title: US-10-649-852-32
 Perfect score: 2229
 Sequence: 1 MDSTIFIIIDEFDANCSSL.....SIPTSPTRISFHSIKQTAAV 413

Scoring table: BLOSUM62
 Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Database : PIR:79:
 1: pir1:
 2: pir2:
 3: pir3:
 4: pir4:
 <LOV>

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query %	Match	Length	DB ID	Description
1	1793	80.4	411	2	A55610	corticotropin-rele
2	1770.5	79.4	431	2	I49149	CRF receptor - mou
3	1769	79.4	430	2	A56726	corticoliberin rec
4	1746.5	78.4	431	2	I49279	sauvagine/corticot
5	1556.5	69.8	415	2	S39535	corticotropin-rele
6	1551.5	69.6	415	2	I58144	corticotropin-rele
7	1541.5	69.2	444	2	A48260	corticoliberin rec
8	1408.5	63.2	375	2	I38879	corticotropin rele
9	612	27.5	585	2	A39286	parathyroid hormon
10	595.5	26.7	479	2	S33746	calcitonin recepto
11	593	26.6	515	2	I49154	calcitonin recepto
12	590	26.5	515	2	I60800	calcitonin recepto
13	589.5	26.4	478	2	A37430	parathyroid hormon
14	587.5	26.4	593	2	A49191	calcitonin recepto
15	587	26.3	474	2	I37217	calcitonin recepto
16	569	25.5	490	2	S34486	parathyroid hormon
17	567	25.4	591	2	I54195	parathyroid hormon
18	565.5	25.4	591	2	S44203	calcitonin recepto
19	564	25.3	482	2	A39285	secretin receptor
20	553.5	24.8	449	2	S16319	calcitonin-like re
21	553.5	24.8	464	2	I60194	parathyroid hormon
22	553	24.8	440	2	JC2532	secretin receptor
23	548.5	24.6	461	2	JC2477	calcitonin recepto
24	546	24.5	498	2	I47130	parathyroid hormon
25	545	24.5	589	2	I59297	parathyroid hormon
26	535.5	24.0	550	2	A57519	vasoactive intesti
27	516.5	23.2	459	2	JH0594	vasoactive intesti
28	506	22.7	460	2	JC2194	vasoactive intesti
29	506	22.7	495	2	JC2195	vasoactive intesti

RESULT 1

A55610

corticotropin-releasing factor receptor subtype 2 - rat

C;Species: Rattus norvegicus (Norway rat)

C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004

C;Accession: A55610

R;Löwenberg, T.W.; Liaw, C.W.; Grigoriadis, D.E.; Clevenger, W.; Chalmers, D.T.; De Souz

Proc. Natl. Acad. Sci. U.S.A. 92, 836-840, 1995

A;Title: Cloning and characterization of a functionally distinct corticotropin-releasing

A;Reference number: A55610; MUID: 95148632; PMID: 7846062

A;Accession: A55610

A;Status: preliminary; translated from GB/EMBL/DDBJ

A;Residues: 1-411 <LOV>

A;Cross-references: UNIPROT:P47866; EMBL:U16253; NID:9644771; PIDN: AAC52159.1; PID:96447

C;Genetics:

A;Gene: CRF2R

C;Superfamily: glucagon receptor

Query	Match	80.4% ; Score 1793 ; DB 2 ; Length 411 ;	
Best	Local Similarity	80.0% ; Pred. No. 9.4e-143 ;	
Matches	3333 ; Conservative	30 ; Mismatches 45 ; Indels 8 ; Gaps 4 ;	
Qy	1	MDSTIFIIIDEFDANCSSLDAFQDSFLHSSSSSSFFGEGP--YCSATIDQIGTCWPRSL	58
Db	1	MDAA---LLSLEANCSSL--ALAAEELLDDGGEPPDPEGPSYCYNTTLDDQIGTCWPQSA	55
Qy	59	AGELVERCPDSDFNGIYNTTRNVYRECFCNGTWASWMMYSQCVPLDNNK-RKYALHYKI	117
Db	56	PGALVERCPPEYFNGIKYNTTRNAYRECLENGTWASRINYSHCCEPILDDQKRYDLHYRI	115
Qy	118	ALLINYLGHGCISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHN	177
Db	116	ALLINYLGHCVSVVALVAFAFLFLVLRSLRCLRNVIHWNLITTFILRNITWFLQLIDHE	175
Qy	178	IHSNEWWRCCITTTIYNFYVVTNFFWMFFEGCYLHTAIVNTYSTDKLRLKWVFLFIGWCIP	237
Db	176	VHEGNENVWRCCVTTIFFNYFVVTNFFWMFFEGCYLHTAIVMTYSTEHLRKWLFLFIGWCIP	235
Qy	238	SPIIVTWAICKLFYENEQCWIWKPEPKYIDIXYQGRVILVLLINFVFLNIVRILMTKL	297
Db	236	CPIIYAWAVGKLYYENEQCWFGEVRSAARKRWRQDHHSLRVRVARAMSIPSPTRISFSIKOTAAV	413
Qy	298	ASTTSETIQRKAVKATVLLPLLGITYMLFFVNPGEDDVSOIVFIFYNSFLQSFGFFFV	357
Db	296	ASTTSETIQRKAVKATVLLPLLGITYMLFFVNPGEDDSLQIVFIFYNSFLQSFGFFFV	355
Qy	358	SVFYCFNLGEVRSAARKRWRQDHHSLRVRVARAMSIPSPTRISFSIKOTAAV	413
Db	356	SVFYCFENGGEVRSAALKRWRQDHHSLRVRVARAMSIPSPTRISFSIKOTAAV	411

RESULT	2	149149	CRF receptor - mouse C;Species: Mus musculus (house mouse) C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004 C;Accession: I49149 R;Perrin, M.; Donaldson, C.; Chen, R.; Blount, A.; Berggren, T.; Bilezikjian, L.; Sawche Proc. Natl. Acad. Sci. U.S.A. 92, 2969-2973, 1995 A;Title: Identification of a second corticotropin-releasing factor receptor gene and cha A;Reference number: I49149; MUID:95224061; PMID:7708757 A;Accession: I49149 A;Status: preliminary; translated from GB/EMBL/DDJB A;Residues: 1-431 <RES> A;Cross-references: UNIPROT:Q60748; EMBL:U17858; NID:9727254; PIDN:AAA68026.1; PID:g7272 C;Superfamily: glucagon receptor				
Db	53	FSGPYTYCNTTLDQIGTCWPQSAPGALVERPCPEYFNGIKYNTTRNAYRECLENGTWASR	112				
Qy	96	MNYSQCVPILDNKHESNEWCRCITIINYFVVTNFWMFVEGCCYLHTA	155				
Db	113	VNYSHCEPILDKQRKYDLHYRIALIVNLGHCVSVVALVAFLFLVLRSRCLRNTH	154				
Qy	155	WNLITTFILRNIMWFLLQMDNKHESNEWCRCITIINYFVVTNFWMFVEGCCYLHTA	214				
Db	173	WNLITTFILRNIAWFLQLIDHEVHEGNEVRSACRPLSVERPCPEYFNGIKYNTTRNAYRECLENGTWASR	232				
Qy	215	IYMTYSTDKLRKWVFLFIGWCIPSIIIVTWAICKLFYENEQCWIGKEPGKYIDYYQGRV	274				
Db	233	IYMTYSTEHLRKWLFFIGWCIPCIIIAWVGKLYYENEQCWFGKEAGDVLVDYIYQGPV	292				
Qy	275	IYLLINFVFLNIVRILMTKLRASTTSETIQYRKAVKATVLLPLLGITYMLFFVNPG	334				
Db	293	IYLLINFVFLNIVRILMTKLRASTTSETIQYRKAVKATVLLPLLGITYMLFFVNPG	352				
Qy	335	DVSQIVFYFNSFLQSFGFVSVFYCFLNGEVRSAAARKRWHRWQDHSLRVRVARAMS	394				
Db	353	DLSQIVFYFNSFLQSFGFVSVFYCFFNGEVRAALRKWRWQDHSLRVRVARAMS	412				
RESULT 4							
Qy	149279	I49279 sauvagine/corticotropin-releasing factor receptor - mouse					
Db	173	C;Species: Mus musculus (house mouse)					
Qy	202	C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004					
Db	293	C;Accession: I49279 R;Kishimoto, T.; Pearse, R.V. Proc. Natl. Acad. Sci. U.S.A. 92, 1108-1112, 1995 A;Title: A sauvagine/corticotropin-releasing factor receptor expressed in heart A;Reference number: 149279; MUID:95166778; PMID:7755719 A;Accession: I49279 A;Status: preliminary; translated from GB/EMBL/DDJB A;Molecule type: mRNA A;Cross-references: UNIPROT:Q60748; EMBL:U21729; PIDN: AAC52174.1; C;Superfamily: glucagon receptor					
Qy	38	FEGP--YCSATIDQIGTCWPRLSLAGERPCPDSFNGIRYNTTRNAYRECENGTWASW	95				
Db	53	FSGPYTYCNTTLDQIGTCWPQSAPGALVERPCPEYFNGIKYNTTRNAYRECLENGTWASR	112				
Qy	96	MNYSQCVPILDNKHESNEWCRCITIINYFVVTNFWMFVEGCCYLHTA	155				
Db	113	VNYSHCEPILDKQRKYDLHYRIALIVNLGHCVSVVALVAFLFLVLRSRCLRNTH	172				
Qy	155	WNLITTFILRNIMWFLLQMDNKHESNEWCRCITIINYFVVTNFWMFVEGCCYLHTA	214				
Db	173	WNLITTFILRNIAWFLQLIDHEVHEGNEVRSACRPLSVERPCPEYFNGIKYNTTRNAYRECLENGTWASR	232				
Qy	215	IYMTYSTDKLRKWVFLFIGWCIPSIIIVTWAICKLFYENEQCWIGKEPGKYIDYYQGRV	274				
Db	233	IYMTYSTEHLRKWLFFIGWCIPCIIIAWVGKLYYENEQCWFGKEAGDVLVDYIYQGPV	292				
Qy	275	IYLLINFVFLNIVRILMTKLRASTTSETIQYRKAVKATVLLPLLGITYMLFFVNPG	334				
Db	293	IYLLINFVFLNIVRILMTKLRASTTSETIQYRKAVKATVLLPLLGITYMLFFVNPG	352				
Qy	335	DVSQIVFYFNSFLQSFGFVSVFYCFLNGEVRSAAARKRWHRWQDHSLRVRVARAMS	394				
Db	353	DLSQIVFYFNSFLQSFGFVSVFYCFFNGEVRAALRKWRWQDHSLRVRVARAMS	412				
Qy	395	IPTSPTRISFHSIKQTAAV 413					
Db	413	IPTSPTRISFHSIKQTAAV 431					
RESULT 3							
Qy	38	IYMTYSTDKLRKWVFLFIGWCIPSIIIVTWAICKLFYENEQCWIGKEPGKYIDYYQGRV	274				
Db	53	FSGPYTYCNTTLDQIGTCWPQSAPGALVERPCPEYFNGIKYNTTRNAYRECLENGTWASR	112				
Qy	96	MNYSQCVPILDNKHESNEWCRCITIINYFVVTNFWMFVEGCCYLHTA	155				
Db	113	VNYSHCEPILDKQRKYDLHYRIALIVNLGHCVSVVALVAFLFLVLRSRCLRNTH	172				
Qy	155	WNLITTFILRNIMWFLLQMDNKHESNEWCRCITIINYFVVTNFWMFVEGCCYLHTA	214				
Db	173	WNLITTFILRNIAWFLQLIDHEVHEGNEVRSACRPLSVERPCPEYFNGIKYNTTRNAYRECLENGTWASR	232				
Qy	215	IYMTYSTDKLRKWVFLFIGWCIPSIIIVTWAICKLFYENEQCWIGKEPGKYIDYYQGRV	274				
Db	233	IYMTYSTEHLRKWLFFIGWCIPCIIIAWVGKLYYENEQCWFGKEAGDVLVDYIYQGPV	292				
Qy	275	IYLLINFVFLNIVRILMTKLRASTTSETIQYRKAVKATVLLPLLGITYMLFFVNPG	334				
Db	293	MLVLLINFVFLNIVRILMTKLRASTTSETIQYRKAVKATVLLPLLGITYMLFFVNPG	352				
Qy	335	DDVSQIVFYFNSFLQSFGFVSVFYCFLNGEVRSAAARKRWHRWQDHSLRVRVARAMS	394				
Db	353	DDLSQIVFYFNSFLQSFGFVSVFYCFFNGEVRAALRKWRWQDHSLRVRVARAMS	412				
RESULT 2							
Qy	96	MNYSQCVPILDNKHESNEWCRCITIINYFVVTNFWMFVEGCCYLHTA	155				
Db	113	VNYSHCEPILDKQRKYDLHYRIALIVNLGHCVSVVALVAFLFLVLRSRCLRNTH	172				
Qy	156	NLTITTFILRNIMWFLLQMDNKHESNEWCRCITIINYFVVTNFWMFVEGCCYLHTA	215				
Db	173	NLTITTFILRNIAWFLQLIDHEVHEGNEVRSACRPLSVERPCPEYFNGIKYNTTRNAYRECLENGTWASR	232				
Qy	216	IYMTYSTDKLRKWVFLFIGWCIPSIIIVTWAICKLFYENEQCWIGKEPGKYIDYYQGRV	275				
Db	233	IYMTYSTEHLRKWLFFIGWCIPCIIIAWVGKLYYENEQCWFGKEAGDVLVDYIYQGPV	292				
Qy	275	IYLLINFVFLNIVRILMTKLRASTTSETIQYRKAVKATVLLPLLGITYMLFFVNPG	334				
Db	293	MLVLLINFVFLNIVRILMTKLRASTTSETIQYRKAVKATVLLPLLGITYMLFFVNPG	352				
Qy	335	DDVSQIVFYFNSFLQSFGFVSVFYCFLNGEVRSAAARKRWHRWQDHSLRVRVARAMS	394				
Db	353	DDLSQIVFYFNSFLQSFGFVSVFYCFFNGEVRAALRKWRWQDHSLRVRVARAMS	412				

Query Match 69.6%; Score 1551.5; DB 2; Length 415;
 Best Local Similarity 74.7%; Pred. No. 1.7e-122;
 Matches 280; Conservative 44; Mismatches 50; Indels 1; Gaps 1;

RESULT 5

Qy 395 IPTSPRISFHSIKQTAAV 413
 Db 413 IPTSPRISFHSIKQTAAV 431

corticotropin-releasing hormone receptor - mouse

C;Species: Mus musculus (house mouse)
 C;Date: 07-Oct-1994 #sequence_revision 10-Nov-1995 #text_change 09-Jul-2004
 C;Accession: S39535
 R;Vita, N.; Laurent, P.; Lefort, S.; Chalon, P.; Lelias, J.M.; Kaghad, M.; le Fur, G.; FEBS Lett. 335, 1-5, 1993
 A;Title: Primary structure and functional expression of mouse pituitary and human brain
 A;Reference number: S39534; MUID:94063063; PMID:8243652
 A;Accession: S39535
 A;Status: preliminary
 A;Molecule type: mRNA
 A;Residues: 1-415 <VIT>
 A;Cross-references: UNIPROT:P35347; EMBL:X72305; PIDN:CAA51053.1; PID:94361
 A;Note: the sequence from Fig. 1 is inconsistent with that from Fig. 3 in having an addi
 C;Superfamily: glucagon receptor
 C;Keywords: G protein-coupled receptor; transmembrane protein

Query Match 69.8%; Score 1556.5; DB 2; Length 415;
 Best Local Similarity 74.9%; Pred. No. 6.4e-123;
 Matches 281; Conservative 44; Mismatches 49; Indels 1; Gaps 1;

Qy 40 GPYCSATIDQIGTCWPRSLAGELVERPCPDSFNGIRYNTTRNVYRECFCNGTWASWMNYS 99
 Db 41 GLQCNASVDLIGTCWPRSPAGQLVVRCPAFFGYVRYNTTNNGRECLANGSWAARVNYS 100

Qy 100 QCVPILDNKRKYALHYKIALINYLGHCISILALVIAFLFLCLRSIRCLERNITHWNLT 159
 Db 101 ECQEILNEEKSKVHYHAVINYLGHCISLVALLVAFLVFLRSLIRCLERNITHWNLT 160

Qy 160 TPILRNIMMWFLQM-IDHNIHESNEWVWCRCITIINYFVVTNFFWMMFVEGCCYLHTAIYMT 218
 Db 161 AFILRNATWFLVQLTVSPEVHQSNVAVCRLVTAAYNYFHVNTNFFWMMFGECCYLHTAIYLT 220

Qy 219 YSTDKLKRKWVFLFIGWCIPSPIIVTWAICKLYFENEQCGWICPKYIDYYQGRVILVL 278
 Db 221 YSTDRLRKWMFVCIGWGVPPFPPIVVAIGKHYDNEKWCWFGKRPGVYTDYIYQGPMILVL 280

Qy 279 LINFVFLFNIVRILMTKLRASTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDV5 338
 Db 281 LINFIFLFNIVRILMTKLRASTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDEV5 340

Qy 339 QIVFIFYNSFLQSFGFFFVSYFYCFLNGEVRSAARKRWRWQDHHSLRVVARAMSIIPTS 398
 Db 341 RVVFIFYNSFLSFQGFFVSYFYCFLNSEVRSAIRKWRWRWQDKHSIRARVARAMSIIPTS 400

Qy 399 PTRISFHSIKQTAAV 413
 Db 401 PTRVSFHSIKQSTAV 415

RESULT 7

A48260 corticotropin receptor, long splice form - human
 N;Alternate names: corticoliberin binding protein; corticotropin releasing factor receptor
 C;Species: Homo sapiens (man)
 C;Date: 31-May-1996 #sequence_revision 11-Apr-1997 #text_change 09-Jul-2004
 C;Accession: I60975; A48260; S39534
 R;Chen, R.; Lewis, K.A.; Perrin, M.H.; Vale, W.W.
 Proc. Natl. Acad. Sci. U.S.A. 90, 8967-8971, 1993
 A;Title: Expression cloning of a human corticotropin-releasing factor (CRF) receptor.
 A;Reference number: A48260; PMID:7692441
 A;Accession: I60975
 A;Status: translated from GB/EMBL/DDBJ
 A;Molecule type: mRNA
 A;Residues: 1-444 <RES>
 A;Cross-references: UNIPROT:P34998; GB:L23333; PID:9408691; PID:AAA35719.1; PID:9408692
 A;Experimental source: Cushing corticotropic cell tumor
 A;Accession: A48260

Qy 339 QIVFIFYNSFLQSFGFFFVSYFYCFLNGEVRSAARKRWRWQDHHSLRVVARAMSIIPTS 398
 Db 341 RVVFIFYNSFLSFQGFFVSYFYCFLNSEVRSAIRKWRWRWQDKHSIRARVARAMSIIPTS 400

Qy 399 PTRISFHSIKQTAAV 413
 Db 401 PTRVSFHSIKQSTAV 415

RESULT 6

I58144 corticotropin-releasing factor receptor - rat
 C;Species: Rattus norvegicus (Norway rat)
 C;Date: 26-Jul-1996 #sequence_revision 26-Jul-1996 #text_change 09-Jul-2004
 C;Accession: I58144
 R;Chang, C.P.; Pearce, R.V.; O'Connell, S.; Rosenfeld, M.G.
 Neuron 11, 1187-1195, 1993
 A;Title: Identification of a seven transmembrane helix receptor for corticotropin-releas
 A;Reference number: I58144; PMID:94099969; PMID:8274282
 A;Accession: I58144
 A;Status: preliminary; translated from GB/EMBL/DDBJ
 A;Molecule type: mRNA
 A;Residues: 1-415 <RES>
 A;Cross-references: UNIPROT:P35353; GB:L25438; PID:9450298; PID:AAA16441.1; PID:9457615
 C;Superfamily: glucagon receptor
 C;Keywords: alternative splicing; transmembrane protein

A;Residues: 1-479 <ALB>
A;Cross-references: UNIPROT:P32214; GB:L14617; NID:9347429; PID:AAA65964.1; PMID:9347430
C;Superfamily: Glucagon receptor
C;Keywords: transmembrane protein

Query Match 26.7%; Score 595.5; DB 2; Length 479;
Best Local Similarity 33.8%; Pred. No. 2.8e-42;
Matches 138; Conservative 77; Mismatches 152; Indels 41; Gaps 14;

Db 19 LLDAFQDSFLHSESSSSFFGFFEGPYCSATIDQIGTCWPRSLAGELVERPCPDSFNGIRYNT 78
Db 48 LLDAQKYCYDRIQQLPPYEGEGPYCNRTWDG-WMCWDDTPAGVMSYQHCPCDFPD--FDP 104

Qy 79 TRNVYRECENGTw-----ASWMNYSQCVCPILDNK--RKYALHYKIALIINYLGHCIS 129
Db 105 TEKVSKYCDENGGEWRHPDSNRTWSNYTLCNAFTPDKLHNAYVLYY-LALV---GHSMS 159

Qy 130 ILALVIAFLLFLCLRSIRCLRNLIHWNLITTFILRNIMWFLQMD----NIHESNEWW 185
Db 160 IAALIASMGTFLFKNLSCQRVTLHKNMFLTYILNSII-IIIIHLVEVVVPNQDGLVRQDPI 218

Qy 186 CRCITIINYFVVTNFVMMFVEGCCYLHTAIW-TYSTDKLRKWVFLFIGWCIPSPIITW 244
Db 219 CKLHFHQYNNMACNYFWMLCEGIYLHTLIVMAVFTEDQRLRWYLY-LGWGFPPIVPTI 277

Qy 245 AICKLFYENEQCWIGKEPGKYYIDYIYQGRVILVLLINVFVLNIVRLMTKLRASTTSET 304
Db 278 AITRAVYYNDNCWLSTE--THLLYIHGPMVMAALVWNFFFLLNIVRLVTKMRQTHEAEA 335

Qy 305 IGYRKAVKATLVLPLLGITYMLFFFVNPNQEDDVSVQIVFIYFNSFLQSFOGGFFVSFYCFL 364
Db 336 YMYLKAVKATMVLVPLLGIQFVVFPPWRPSNKVLGKI-YDYLMSLIIHFQGFFFVATIYCF 394

Qy 365 NGEVRSAARKRW-----HRWQDHHSLSRVRVARAMSIPSTRISF 404
Db 395 NHEVQVTLKRQWAQFKIQWVSHRWGRRRPTNRVVA-----PRVAF 436

RESULT 11
I49154 calcitonin receptor 1b - mouse
C;Species: Mus musculus (house mouse)
C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 09-Jul-2004
C;Accession: I49154
R;Yamin, M.; Gorn, A.H.; Flannery, M.R.; Jenkins, N.A.; Gilbert, D.J.; Copeland, N.G.; Endocrinology 135, 2635-2643, 1994
A;Title: Cloning and characterization of a mouse brain calcitonin receptor complementary A;Reference number: I49154; PMID:95080136; PMID:7988453
A;Accession: I49154
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: mRNA
A;Residues: 1-515 <RES>
A;Cross-references: UNIPROT:P32214; GB:L113040; NID:g294532; PID:9294533
R;Albrandt, K.; Mull, E.; Brady, E.M.G.; Herich, J.; Moore, C.X.; Beaumont, K.
FEBS Lett. 325, 225-232, 1993
A;Title: Molecular cloning of two receptors from rat brain with high affinity for salmon A;Reference number: A37430; PMID:93368608; PMID:8395656
A;Accession: S33746
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: mRNA
A;Residues: 1-515 <ALB>
A;Cross-references: GB:L14618; NID:g347431; PID:AAA65965.1; PMID:9347432
C;Superfamily: glucagon receptor
C;Keywords: G protein-coupled receptor; transmembrane protein

Query Match 26.5%; Score 590; DB 2; Length 515;
Best Local Similarity 32.5%; Pred. No. 8.8e-42;
Matches 136; Conservative 71; Mismatches 143; Indels 68; Gaps 12;

Db 19 LLDAFQDSFLHSESSSSFFGFFEGPYCSATIDQIGTCWPRSLAGELVERPCPDSFNGIRYNT 78
Db 48 LLDAQKYCYDRIQQLPPYEGEGPYCNRTWDG-WMCWDDTPAGVMSYQHCPCDFPD--FDP 104

Qy 79 TRNVYRECENGTw-----ASWMNYSQCVCPILDNK--RKYALHYKIALIINYLGHCIS 130
Db 105 TEKVSKYCDENGGEWRHPDSNRTWSNYTLCNAFTPDKLHNAYVSYYLALV---GHSMS 160

Qy 131 LALVIAFLLFLCLRSIRCLRNLIHWNLITTFILRNIMWFL-----LQMI 174
Db 161 AALIASMGTFLFKNLSCQRVTLHKNMFLTYILNSII-IIIIHLVEVVVPNQDGLVRQDPI 220

Qy 175 DHNI-----HESENWVCRCCITIINYFVVTNFVMMFVEGGY 210
Db 221 HNNTYMWMTQWELSPPLPLSAHEGKMDPHDSEVISCKILHFFHQYMMACNYFWMLCEGIY 280

Qy 211 LHTAIVM-TYSTDKLRKWVFLFIGWCIPSPIITWAIKLFYENEQCWIGKEPGKYYIDYI 269
Db 281 LHTLIVMVAVFTEDQRLRWYLY-LGWGFPPIVPTIHAITRAVYYNDNCWLSTE--THLLYI 337

Qy 270 YQGRVILVLLINFVFLNIVRLMTKLRASTTSETIQRKAVKATLVLPLLGITYMLFF 329
Db 338 IHGPVMAAAYVNNFFFLLNIVRVLVTPKMRQTHEAEAMYLKAVKATMVLVPLLGIQFVVF 397

Qy 130 ILALVIAFLLFLCLRSIRCLRNLIHWNLITTFILRNIMWFLQMD-----H 176
Db 160 IAALVASMFLWFKNLSCQRVTLHKNMFLTYILNSII-IIIIHLVEVVVPNQDGLVRQDPMH 218
Qy 177 NIHESNEWW-----CRCITIINYFVVTNFVMMFVEG 208

Qy 330 VNPGEDDVSQIVFYFNSFLQSFGFFFVSVFYCFNLGEVRSAARKRW-----HRW 379
 Db 398 WRPSNKVLGKI-YDYLMLHSLIHFQFFFATIYCFCNHEVQVTLKRQWAQFKIQWSHRW 454

RESULT 13

A37430 calcitonin receptor - rat
 C;Species: *Rattus norvegicus* (Norway rat)
 C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 24-Nov-1999
 C;Accession: A37430
 R;Sexton, P.M.; Housami, S.; Hilton, J.M.; O'Keefe, L.M.; Center, R.J.; Gillespie, M.T.
 Mol. Endocrinol. 7, 815-821, 1993
 A;Title: Identification of brain isoforms of the rat calcitonin receptor.
 A;Reference number: A37430; MUID:93368608; PMID:8395656
 A;Accession: A37430
 A;Status: preliminary; translated from GB/EMBL/DDBJ
 A;Molecule type: mRNA
 A;Residues: 1-593 <RE2>
 A;Cross-references: EMBL:X688596; NID:9396812; PIDN:CAA48589.1; PID:q396813
 R;Levine, M.
 C;Superfamily: glucagon receptor
 C;Keywords: G protein-coupled receptor; transmembrane protein
 A;Submitted to the EMBL Data Library, November 1994
 A;Reference number: G07787
 A;Accession: G01562

Query Match 26.4%; Score 589.5; DB 2; Length 478;
 Best Local Similarity 34.6%; Pred. No. 9e-42;
 Matches 132; Conservative 75; Mismatches 142; Indels 33; Gaps 12;

Qy 19 LLDAFQDSFLHSESSSFFGGFEGGPYCSTATIDQIGTCWPRSLAGELVERPCPDSFNGTIRNT 78
 Db 48 LLDAQYKCYCDRIQQLPYEGEGPYCNRTWWDG-WMCWDDTPAGWMSYQHCYPDFYPD--FDP 104

Qy 79 TRNVYRECENGW-----ASWMNYSQCVPILDNKRKYA-LHYKIALIINYLGHCISI 130
 Db 105 TEKVKYCDENGWFRHPDSNRTWSNYTLCNNAFTPDKLHNAYVSYYLALV----GHSMSI 160

Qy 131 LALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMD---HNHESNEWWC 186
 Db 161 AALIASWGLIFLEFKNLSCORVTLHKNMFLTYILNSII-I-IIHLVEVVPNGDLVRRDPISC 219

Qy 187 RCITTIINYFVVTNFFWMFVEGCCYLHTAIYM-TYSTDKLRKWVFLFIGWCIPSPIIWTWA 245
 Db 220 KILHFFHQYMMACNYFWNLCEGIYLHTLIVMAVFTEDQRRLRWYLL-LGWGFPIVPTIIHA 278

Qy 246 ICKLFYNEQCWIGKEPGKYIDDIYQGRVILVLLINVFLENIVRILMTKLRASSTTSETI 305
 Db 279 ITRAVYYNDNCWLSTE--THLLYIHGPPMAALVVNNFFFLNIIVRVLVTKMRQTHEAEAY 336

Qy 306 QYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQIVFIFYFNSFLQSFGFFVSVFYCFLN 365
 Db 337 MYLKAVKATMVLVPLIGIQFVVFWRPSNPKVLGKI-YDYLMSLIHFQGFYVATIYCFCN 395

Qy 366 GEVRSAARKRW-----HRW 379
 Db 396 HEVQVTLKRQWAQFKIQWSHRW 417

RESULT 14

A49191 parathyroid hormone/PTH-related peptide receptor - human
 N;Alternate names: parathyroid hormone/parathyroid hormone related peptide receptor
 C;Species: *Homo sapiens* (man)
 C;Date: 19-Dec-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
 C;Accession: I38139; A49191; I38113; G01562; S29610
 R;Schipani, E.; Weinstein, L.S.; Bergwitz, C.; Iida-Klein, A.; Kong, X.F.; Stuhrmann, M.
 Kronenberg, H.M.; Abou-Samra, A.B.; Segre, G.V.; Jueppner, H.
 J. Clin. Endocrinol. Metab. 80, 1611-1621, 1995
 A;Title: Pseudohypoparathyroidism type Ib is not caused by mutations in the coding exone
 A;Reference number: I38139; MUID:95263723; PMID:7745008
 A;Accession: I38139
 A;Status: translated from GB/EMBL/DDBJ
 A;Molecule type: DNA
 A;Residues: 1-593 <RES>
 A;Cross-references: UNIPROT:Q03431; EMBL:U22409; NID:9897594; PIDN:AAB60657.1; PID:q8975
 R;Schipani, E.; Karga, H.; Karaplis, A.C.; Potts Jr., J.T.; Kronenberg, H.M.; Segre, G.J.

A;Title: Cloning and characterization of an abundant subtype of the human calcitonin receptor
A;Reference number: I37217; MUID:94359487; PMID:8078488
A;Accession: I37217
A;Status: preliminary; translated from GB/EMBL/DDBJ
A;Molecule type: mRNA
A;Residues: 1-474 <RES>
A;Cross-references: EMBL:X69920; NID:9474931; PID:CAA49541.1; PID:9474932
R;Prendo, J.L.; Pichaud, F.; DeLage Mourroux, R.; Bouizar, Z.; Segond, N.; Moukhtar, M.S.
PEBS Lett. 342, 214-216, 1994
A;Title: An isoform of the human calcitonin receptor is expressed in TT cells and in med
A;Reference number: S43673; MUID:94192834; PMID:8143880
A;Accession: S43673
A;Molecule type: mRNA
A;Residues: 121-168, 'X', 170-199, 'X', 201-216 <FRE>
C;Genetics:
A;Gene: GDB:CALCR
A;Cross-references: GDB:138127; OMIM:114131
A;Map position: 7q21.3-7q21.3
C;Superfamily: glucagon receptor
C;Keywords: transmembrane protein

Query Match 26.3%; Score 587; DB 2; Length 474;
Best Local Similarity 34.3%; Pred. No. 1.4e-41;
Matches 137; Conservative 73; Mismatches 151; Indels 38; Gaps 14;

Qy	19	LLDAFQDSFLHSESSFFGEGPYCSATIDQIGTCWPRSLAGELVERPCPDSFNGIRYNT 78
Db	48	MMDAQKYCYDRMQLQLPAYQGEPPYCNRWTWDG-WLCWDDTPAGVLSYQFCPDYFPD--FDP 104
Qy	79	TRNVYRECENGTV-----ASWMNYSQCVPILDNKRK--YALHYKTAIIINYLGHCIS 129
Db	105	SEKVTKYCDKEKGWFKHPENNRNTWSNYTMCNAFTPEKLKNAYVLYY-LAIV---GHSL 159
Qy	130	ILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMD----HNTHESNEVVW 185
Db	160	IPTLVIISLGIFVFRSLGCQRVTLHKNMFLTYIL-NSMIIIIHLVVEVPGELVRRDPS 218
Qy	186	RCRITTINYFVVTNFWMFVGGCYLHTAIUMTYSTDKLR-KWVFLFIGWCIPSPIITW 244
Db	219	CKILHFHQYMMACNYFWMLCSEGRLHTLIVVAVTEKORLRWYLY-LGWGFPLVPTTH 277
Qy	245	AICKLFYENEQCWIKGKEPGKVIDYIYQGRVILVLLINFVLFNIVRILMTKLRASTTSET 304
Db	278	AITRAVYFNNDNCWLSE--THILYIITHGPVMAALVYNFFFLLNIVRVLVTTKMRTHEAES 335
Qy	305	IQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSQLIVFIYFNSFLQSFGQFFFVSYCFL 364
Db	336	HMYLKAVKATMILVPLLGIQFVVFWRPSNKMGLKI-YDYVMHSLIHFGQFFFVATIYFC 394
Qy	365	NGEVRSAAARKRW-----HRW---QDHHSLRVVRVARA 392
Db	395	NNEVQTIVKROWAQFKIOWNQRWGRPSNRSARAARAAA 433

Search completed: August 20, 2005, 00:29:10
Job time : 41 secs

This Page Blank (uspto)

Appli	Sequence 4, Appli	GENERAL INFORMATION
12	1793 80.4	US-09-881-401-4
13	1793 80.4	US-09-818-009-12
14	1793 80.4	US-09-799-978-18
15	1793 80.4	US-10-649-852-18
16	1793 80.4	US-10-821-502-4
17	1787.5 80.2	US-09-799-978-14
18	1787.5 80.2	US-10-649-852-14
19	1786 80.1	US-09-799-978-12
20	1786 80.1	US-10-649-852-12
21	1786 80.1	US-10-482-029-178
22	1784.5 80.1	US-09-881-401-2
		GENERAL INFORMATION
		Sequence 2, Appli
		Sequence 10, Appli
		Sequence 20, Appli
		Sequence 20, Appli
		Sequence 10, Appli
		Sequence 24, Appli
		Sequence 140, Appli
		Sequence 26, Appli
		Sequence 26, Appli
		Sequence 36, Appli
		Sequence 36, Appli
		Sequence 129, Appli
		Sequence 42, Appli
		Sequence 2, Appli
		RESULT 1
		US-09-799-978-32
		; Sequence 32, Application US/09799978
		; Publication No. US20030165807A1
		; GENERAL INFORMATION:
		; APPLICANT: The Procter & Gamble Company
		; APPLICANT: Isfort, Robert
		; APPLICANT: Sheldon, Russell
		; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Function Using Corticotropin Releasing Factor Receptor
		; TITLE OF INVENTION: Function Using Corticotropin Releasing Factor Receptor
		; FILE REFERENCE: 8448
		; CURRENT APPLICATION NUMBER: US/09/799, 978
		; CURRENT FILING DATE: 2001-03-06
		; NUMBER OF SEQ ID NOS: 44
		; SOFTWARE: PatentIn version 3.0
		; SEQ ID NO: 32
		; LENGTH: 413
		; TYPE: PRT
		; ORGANISM: Xenopus laevis
		; US-09-799-978-32
		Query Match 100.0%; Score 2229; DB 10; Length 413;
		Best Local Similarity 100.0%; Pred. No. 5.3e-199;
		Matches 413; Conservative 0; Missmatches 0; Indels 0; Gaps 0
Qy	1 MDSTIFELIIDDEFDANCSILLDAFQDSFLHSESSSPFGFEGPYCSATIDQIGTCWPRSLAG	60
	2 MDSTIFELIIDDEFDANCSILLDAFQDSFLHSESSSPFGFEGPYCSATIDQIGTCWPRSLAG	60
	3 ELVERPCPDSFNGIRNTTRNVYRECENGTWASWMNYSQCVPILDNKRYALHYKIALI	120
	4 ELVERPCPDSFNGIRNTTRNVYRECENGTWASWMNYSQCVPILDNKRYALHYKIALI	120
	5 ELVERPCPDSFNGIRNTTRNVYRECENGTWASWMNYSQCVPILDNKRYALHYKIALI	120
	6 ELVERPCPDSFNGIRNTTRNVYRECENGTWASWMNYSQCVPILDNKRYALHYKIALI	120
	7 ELVERPCPDSFNGIRNTTRNVYRECENGTWASWMNYSQCVPILDNKRYALHYKIALI	120
	8 ELVERPCPDSFNGIRNTTRNVYRECENGTWASWMNYSQCVPILDNKRYALHYKIALI	120
	9 ELVERPCPDSFNGIRNTTRNVYRECENGTWASWMNYSQCVPILDNKRYALHYKIALI	120
	10 ELVERPCPDSFNGIRNTTRNVYRECENGTWASWMNYSQCVPILDNKRYALHYKIALI	120
	11 INYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMIDHNIE	120

Db 121 INYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLLITFILRNIMWLLQMDHNIE 180

Qy 181 SNEVWCRCITIINYFVVTNF FWMFVEGGCYLHTAIVMTYSTDKLRKWFLFIGWCIPSPI 240

Db 181 SNEVWCRCITIINYFVVTNF FWMFVEGGCYLHTAIVMTYSTDKLRKWFLFIGWCIPSPI 240

Qy 241 IVTWAICKLFYENEQCWIGKEPGKYIDYYQGRVILVLLINVFVLNIVRILMTKLRAST 300

Db 241 IVTWAICKLFYENEQCWIGKEPGKYIDYYQGRVILVLLINVFVLNIVRILMTKLRAST 300

Qy 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDSQIVFYNSFLQSFGQFFFVSVF 360

Db 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDSQIVFYNSFLQSFGQFFFVSVF 360

Qy 361 YCFLNGEVRSAARKRWRQDHHSLSLRVVARAMSIPSPTRISFHSIKQTAAV 413

Db 361 YCFLNGEVRSAARKRWRQDHHSLSLRVVARAMSIPSPTRISFHSIKQTAAV 413

Db 361 YCFLNGEVRSAARKRWRQDHHSLSLRVVARAMSIPSPTRISFHSIKQTAAV 413

RESULT 2
US-10-649-852-32
; Sequence 32, Application US/10649852
; Publication No. US20040101911A1
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; APPLICANT: Isfort, Robert
; APPLICANT: Sheldon, Russell
; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or Factor Receptors
; FILE REFERENCE: 8448

Query Match 81.1%; Score 1807; DB 10; Length 405;
Best Local Similarity 79.9%; Pred. No. 1.1e-159;
Matches 330; Conservative 33; Mismatches 42; Indels 8; Gaps 2;

Qy 1 MDSTIFELIIDDEFDANCSSLDAFQDSFLHSESSSSFFGEGPYCSATIDQIGTCWPRSLAG 60
Db 1 MEVSLLELL--SVEVNCSLADAFGDPAYGNASDAL----YCNAATADEIGTCWPRSGAG 52

Qy 61 ELVERPCPDSENGIRYNTTRNVYRECENGTWASWMNYSQCVPILDNKRKYALHYKIALI 120

Db 53 RVVARPCPDFFINGVKYNSTRSAYRECLENGTWAFKINYSCEPILEEKRYPVHYKIALI 112

Qy 121 INYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLLITFILRNIMWLLQMDHNIE 180

Db 113 INYLGHCISVGALVIAFLCLRSIRCLRNIVHWNLLITFILRNIMWLLQLIDHNIE 172

Qy 181 SNEVWCRCITIINYFVVTNF FWMFVEGGCYLHTAIVMTYSTDKLRKWFLFIGWCIPSPI 240

Db 173 RNEPWCRLLTTVNYFVVTNF FWMFVEGGCYLHTAIVMTYSTDKLRKWFLFIGWCIPCPV 232

Query Match 100.0%; Score 2229; DB 16; Length 413;
Best Local Similarity 100.0%; Pred. No. 5.3e-199;
Matches 413; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MDSTIFELIIDDEFDANCSSLDAFQDSFLHSESSSSFFGEGPYCSATIDQIGTCWPRSLAG 60
Db 1 MDSTIFELIIDDEFDANCSSLDAFQDSFLHSESSSSFFGEGPYCSATIDQIGTCWPRSLAG 60

Qy 61 ELVERPCPDSENGIRYNTTRNVYRECENGTWASWMNYSQCVPILDNKRKYALHYKIALI 120

Db 61 ELVERPCPDSENGIRYNTTRNVYRECENGTWASWMNYSQCVPILDNKRKYALHYKIALI 120

Qy 121 INYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLLITFILRNIMWLLQMDHNIE 180

Db 121 INYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLLITFILRNIMWLLQMDHNIE 180

Qy 181 SNEVWCRCITIINYFVVTNF FWMFVEGGCYLHTAIVMTYSTDKLRKWFLFIGWCIPSPI 240

Db 181 SNEVWCRCITIINYFVVTNF FWMFVEGGCYLHTAIVMTYSTDKLRKWFLFIGWCIPSPI 240

Qy 241 IVTWAICKLFYENEQCWIGKEPGKYIDYYQGRVILVLLINVFVLNIVRILMTKLRAST 300

Db 241 IVTWAICKLFYENEQCWIGKEPGKYIDYYQGRVILVLLINVFVLNIVRILMTKLRAST 300

Qy 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDSQIVFYNSFLQSFGQFFFVSVF 360

Db 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDSQIVFYNSFLQSFGQFFFVSVF 360

Qy 361 YCFLNGEVRSAARKRWRQDHHSLSLRVVARAMSIPSPTRISFHSIKQTAAV 413

Db 361 YCFLNGEVRSAARKRWRQDHHSLSLRVVARAMSIPSPTRISFHSIKQTAAV 405

Db 361 YCFLNGEVRSAARKRWRQDHHSLSLRVVARAMSIPSPTRISFHSIKQTAAV 413

RESULT 4
US-10-649-852-38
; Sequence 38, Application US/10649852
; Publication No. US20040101911A1
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; APPLICANT: Isfort, Robert
; APPLICANT: Sheldon, Russell
; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or Factor Receptors
; FILE REFERENCE: 8448

Query Match 81.1%; Score 1807; DB 10; Length 405;
Best Local Similarity 79.9%; Pred. No. 1.1e-159;
Matches 330; Conservative 33; Mismatches 42; Indels 8; Gaps 2;

Qy 1 MDSTIFELIIDDEFDANCSSLDAFQDSFLHSESSSSFFGEGPYCSATIDQIGTCWPRSLAG 60
Db 1 MEVSLLELL--SVEVNCSLADAFGDPAYGNASDAL----YCNAATADEIGTCWPRSGAG 52

Qy 61 ELVERPCPDSENGIRYNTTRNVYRECENGTWASWMNYSQCVPILDNKRKYALHYKIALI 120

Db 53 RVVARPCPDFFINGVKYNSTRSAYRECLENGTWAFKINYSCEPILEEKRYPVHYKIALI 112

Qy 121 INYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLLITFILRNIMWLLQMDHNIE 180

Db 113 INYLGHCISVGALVIAFLCLRSIRCLRNIVHWNLLITFILRNIMWLLQLIDHNIE 172

Qy 181 SNEVWCRCITIINYFVVTNF FWMFVEGGCYLHTAIVMTYSTDKLRKWFLFIGWCIPSPI 240

Db 173 RNEPWCRLLTTVNYFVVTNF FWMFVEGGCYLHTAIVMTYSTDKLRKWFLFIGWCIPCPV 232

Query Match 100.0%; Score 2229; DB 16; Length 413;
Best Local Similarity 100.0%; Pred. No. 5.3e-199;
Matches 413; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MDSTIFELIIDDEFDANCSSLDAFQDSFLHSESSSSFFGEGPYCSATIDQIGTCWPRSLAG 60
Db 1 MDSTIFELIIDDEFDANCSSLDAFQDSFLHSESSSSFFGEGPYCSATIDQIGTCWPRSLAG 60

Qy 61 ELVERPCPDSENGIRYNTTRNVYRECENGTWASWMNYSQCVPILDNKRKYALHYKIALI 120

Db 61 ELVERPCPDSENGIRYNTTRNVYRECENGTWASWMNYSQCVPILDNKRKYALHYKIALI 120

Qy 121 INYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLLITFILRNIMWLLQMDHNIE 180

Db 121 INYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLLITFILRNIMWLLQMDHNIE 180

Qy 181 SNEVWCRCITIINYFVVTNF FWMFVEGGCYLHTAIVMTYSTDKLRKWFLFIGWCIPSPI 240

Db 181 SNEVWCRCITIINYFVVTNF FWMFVEGGCYLHTAIVMTYSTDKLRKWFLFIGWCIPSPI 240

Qy 241 IVTWAICKLFYENEQCWIGKEPGKYIDYYQGRVILVLLINVFVLNIVRILMTKLRAST 300

Db 241 IVTWAICKLFYENEQCWIGKEPGKYIDYYQGRVILVLLINVFVLNIVRILMTKLRAST 300

Qy 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDSQIVFYNSFLQSFGQFFFVSVF 360

Db 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDSQIVFYNSFLQSFGQFFFVSVF 360

Qy 361 YCFLNGEVRSAARKRWRQDHHSLSLRVVARAMSIPSPTRISFHSIKQTAAV 413

Db 361 YCFLNGEVRSAARKRWRQDHHSLSLRVVARAMSIPSPTRISFHSIKQTAAV 405

Db 361 YCFLNGEVRSAARKRWRQDHHSLSLRVVARAMSIPSPTRISFHSIKQTAAV 413

Qy 361 YCFLNGEVRSAARKRWRQDHHSLSLRVVARAMSIPSPTRISFHSIKQTAAV 44

SOFTWARE: PatentIn version 3.0
; SEQ ID NO 38
; LENGTH: 405
; TYPE: PRT
; ORGANISM: *Ameiurus nebulosus*
US-10-649-852-38

Query Match 81.1%; Score 1807; DB 16; Length 405;
Best Local Similarity 79.9%; Pred. No. 1.1e-159;
Matches 330; Conservative 33; Mismatches 42; Indels 8; Gaps 2;

Qy 1 MDSTIFELIIDDEFDANCSSLDAFQDSFLHSESSSSFFGPEGPYCSATIDQIGTCWPRSLAG 60
Db 1 MEVSLLELL-SVEVNCSLADAFGDPAYGNASDAL-----YCNAATADEIGTCWPRSGAG 52

Qy 61 ELVERPCPDSFNGTRYNTTRNVYRECENGTWASWMNTSQCVPLDNKRYALHYKI 120
Db 53 RVARPCPDFINGTKINSTRSAYRECLENGTWAKFVINNYSCEPILEEKRYPVHYKALI 112

Qy 121 INVLGHCISILALVIAFLFLFLCLRSIRCLRNTHWNLTTFILRNIMWLLQMDHNIHE 180
Db 113 INVLGHCISVGALVIAFLVFLCLRSIRCLRNVIHWNLITTFILRNIMWLLQLIDHNIHE 172

Qy 181 SNEWWCRCITTINYFVVTNFFWMEVEGGCYLHTAIWMTYSTDKLRKWVFLFIGWCIPSPI 240
Db 173 RNEPWCRLLTtVNYFVVTNFFWMEVEGGCYLHTAIWMTYSTDKLRKWVFLFIGWCIPCPV 232

Qy 241 IVTWAICKLFYENEQCWIGKEPGKYIDYYQGRVILVLLINVFVFLNIVRILMTKLRAST 300
Db 233 IIAWAVGKLYNENBQCWFGEPKGVYDVIYQGPVIVVLLINVFVFLNIVRILMTKLRAST 292

Qy 301 TSETIQYRKAVKATLVLLPLLGITYMLFVNPNPGEDDVSOIVFVNSFLQSFOGFFFVSVF 360
Db 293 TSETIQYRKAVKATLVLLPLLGITYMLFVNPGDDDISQIVFVNSFLQSFOGFFFVSVF 352

Qy 361 YCFLNGEVRSAARKRWHRWQDHSLRVVRVARAMSIPTSPTRISFHSIKOTAAV 413
Db 353 YCFLNGEVRSAVRKRWHRWQDNHALRVVRVARAMSIPTSPTRISFHSIKHTTAV 405

RESULT 6
US-09-881-401-8
; Sequence 8, Application US/09881401
; Patent No. US2002007468A1
; GENERAL INFORMATION:
; APPLICANT: Lovenberg, Timothy W.
; Oltersdorf, Tilman
; Liaw, Chen
; Grigoriadis, Dimitri E.
; Chalmers, Derek T.
; Desouza, Errol B.
; TITLE OF INVENTION: CORTICOTROPIN RELEASING FACTOR 2
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed Intellectual Property Law Group
; STREET: 701 Fifth Avenue, Suite 6300
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/881,401
; FILING DATE: 13-Jun-2001
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Christiansen, William T.
; REGISTRATION NUMBER: 44,614
; REFERENCE/DOCKET NUMBER: 690068.401C4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 411 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
; US-09-881-401-8

RESULT 5
US-10-292-798-636
; Sequence 636, Application US/10292798
; Publication No. US20030235833A1
; GENERAL INFORMATION:
; APPLICANT: SUWA, MAKIKO
; APPLICANT: ASAII, KIYOSHI
; APPLICANT: AKIYAMA, YUTAKA
; APPLICANT: ABURATANI, HIROYUKI
; TITLE OF INVENTION: GUANOSINE TRIPHOSPHATE-BINDING PROTEIN COUPLED RECEPTORS
; FILE REFERENCE: 084335/166
; CURRENT APPLICATION NUMBER: US/10/292,798
; CURRENT FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: 10/017,161
; PRIOR FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: JP 2001-246789
; PRIOR FILING DATE: 2001-06-18
; NUMBER OF SEQ ID NOS: 2070
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 636
; LENGTH: 411
; TYPE: PRT
; ORGANISM: *Homo sapiens*
US-10-292-798-636

Query Match 80.9%; Score 1804; DB 15; Length 411;
Best Local Similarity 80.0%; Pred. No. 2.1e-159;
Matches 333; Conservative 33; Mismatches 42; Indels 8; Gaps 4;

Qy 1 MDSTIFELIIDDEFDANCSSLDAFQDSFLHSESSSSFFGPEGPYCSATIDQIGTCWPRSL 58
Db 1 MDAALLHSLL---EANCSL--ALAEELLDDGWGPPLDPEGPYSYCNNTLDQIGTCWPRSA 55

Query Match 80.7%; Score 1799; DB 9; Length 411;
Best Local Similarity 79.8%; Pred. No. 6.2e-159,

Matches 332; Conservative 33; Mismatches 43; Indels 8; Gaps 4; Db 236 FPIIVAWAIGKLYYENQCWFGKEPGLVVDIYQGPILLNIFVLNIRLMTKLR 295

Qy 1 MDSTIFELIIDFDAACSLLDAFQDSFLHSESSSSFFGFEGP--YCSATIDQIGTCWPRL 58
Db 1 MDAALLHSLL---EANCSL--ALAEELLIDGWGPPLDPEGPSYCNNTLDDQIGTCWPRL 55

Qy 59 AGELVERPCPDSENGIRNTTRNVYRECENGTWASWMNSQCVPILDNKRKYALHYKI 117
Db 56 AGALVERPCPEYFNGVKNTTRNAYRECLENGTWASKINYSQCEPILDDQKRYDLHYRI 115

Qy 118 ALIINYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHN 177
Db 116 ALVVNYLGHCVSVAVALVAAFLLFLALARSTRCLRNVIHWNLITTFILRNVMWFLQLVDHE 175

RESULT 8 US-10-225-567A-96

Qy 178 IHESNBVWCRCITTINYFVVTNFWMFVEGGCYLHTAIIVMITYSTDRLRKWVFLFIGWCIP 237
Db 176 VHESNBVWCCHCITTINYFVVTNFWMFVEGGCYLHTAIIVMITYSTERLRKCLFLFIGWCIP 235

Qy 238 SPIIVTWAICKLFYENEQCWIGKEPKYIDYIYQGRVILVLLINFVLNIVRILMTKLR 297
Db 236 SPIIVAWAIGKLYYENQCWFWGKKEPGLVWDIYQGPILVLLINFVLNIVRILMTKLR 295

Qy 298 ASTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDVSOIVFIYFNSFLQSFOGFFV 357
Db 296 ASTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDLSQIMFYFNSFLQSFOGFFV 355

Qy 358 SVFYCFNLGEVRSAARKRWHWRQDHSLRVRVARAMSIPTSPTRISFHSIKQTAAV 413
Db 356 SVFYCFNLGEVRSAVRKRWHRQDHSLRVRPMARAMSIPTSPTRISFHSIKQTAAV 411

RESULT 7 US-10-225-567A-96

Qy 1 MDSTIFELIIDFDAQDSFLHSESSSSFFGFEGP--YCSATIDQIGTCWPRL 58
Db 1 MDAALLHSLL---EANCSL--ALAEELLIDGWGPPLDPEGPSYCNNTLDDQIGTCWPRL 55

Qy 59 AGELVERPCPDSENGIRNTTRNAYRECENGTWASWMNSQCVPILDNKRKYALHYKI 117
Db 56 AGALVERPCPEYFNGVKNTTRNAYRECLENGTWASKINYSQCEPILDDQKRYDLHYRI 115

Qy 118 ALIINYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHN 177
Db 116 ALVVNYLGHCVSVAVALVAAFLLFLALARSTRCLRNVIHWNLITTFILRNVMWFLQLVDHE 175

Qy 178 IHESNBVWCRCITTINYFVVTNFWMFVEGGCYLHTAIIVMITYSTDRLRKWVFLFIGWCIP 237
Db 176 VHESNBVWCCHCITTINYFVVTNFWMFVEGGCYLHTAIIVMITYSTERLRKCLFLFIGWCIP 235

Qy 238 SPIIVTWAICKLFYENEQCWIGKEPKYIDYIYQGRVILVLLINFVLNIVRILMTKLR 297
Db 236 SPIIVAWAIGKLYYENQCWFWGKKEPGLVWDIYQGPILVLLINFVLNIVRILMTKLR 295

Qy 298 ASTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDVSOIVFIYFNSFLQSFOGFFV 357
Db 296 ASTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDLSQIMFYFNSFLQSFOGFFV 355

Qy 358 SVFYCFNLGEVRSAARKRWHWRQDHSLRVRVARAMSIPTSPTRISFHSIKQTAAV 413
Db 356 SVFYCFNLGEVRSAVRKRWHRQDHSLRVRPMARAMSIPTSPTRISFHSIKQTAAV 411

RESULT 9 US-10-649-852-10

Qy 178 IHESNBVWCRCITTINYFVVTNFWMFVEGGCYLHTAIIVMITYSTDRLRKWVFLFIGWCIP 237
Db 176 VHESNBVWCCHCITTINYFVVTNFWMFVEGGCYLHTAIIVMITYSTERLRKCLFLFIGWCIP 235

Qy 238 SPIIVTWAICKLFYENEQCWIGKEPKYIDYIYQGRVILVLLINFVLNIVRILMTKLR 295

APPLICANT: The Procter & Gamble Company
 APPLICANT: Isfort, Robert
 APPLICANT: Sheldon, Russell
 TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or Force
 FILE REFERENCE: 8448R
 CURRENT APPLICATION NUMBER: US/10/649,852
 PRIOR APPLICATION NUMBER: US/10/649,852
 PRIOR FILING DATE: 2003-08-27
 NUMBER OF SEQ ID NOS: 44
 SOFTWARE: PatentIn version 3.0
 SEQ ID NO 10
 LENGTH: 411
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-10-649-852-10

Query Match 80.7%; Score 1799; DB 16; Length 411;
 Best Local Similarity 79.8%; Pred. No. 6.2e-159;
 Matches 332; Conservative 33; Mismatches 43; Indels 8; Gaps 4;
 SEQUENCE DESCRIPTION: SEQ ID NO: 8:

US-10-821-502-8

```

Qy      1 MDSTIFELIIDDEFDANCSSLDAFQDSFLHSSESSSFFPGFEGP--YCSATIDQIGTCWPRSL 58
Db      1 MDAALLHSSL---EANCSL--ALAEELLDGWGPPLDPEGPYSCNTTLDQIGTCWPRSA 55
Qy      59 AGELVERPCPDSENGILRVNTTRNVYRECFCENGTWASWMNYSQCVPILDNNK-RKYALHYKI 117
Db      56 AGALVERPCPEYFNGVKYNTTRNAYRECLENGTWASKINYSQCEPILDDDKQRKYDLHYRI 115
Qy      118 ALIINYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQLMDHN 177
Db      116 ALVNVYLGHCVSAALVAFLRSLIRCLRNIVHWNLITTFILRNIVWFLQLVDHE 175
Qy      178 IHESENVWCRCTTINYFVUTNFWMVEGCCYLHTAIIVMTYSTDKLRKWWFLFIGWCIP 237
Db      176 VHESENVWCHCITTFNYFVUTNFWMVEGCCYLHTAIIVMTYSTERLRKCLFLFIGWCIP 235
Qy      238 SPIIIVTWAICKLFWENEQCWIIGKEPGKYIDYIYQGRVILVLLINFVFLNIVRLMTKLR 297
Db      236 FPIIIVAWAIGKLYENEQCWFGEKPGDLYQGPDLVYDIIYQGPILVLLINFVFLNIVRLMTKLR 295
Qy      298 ASTTSETIQYRKAVAKATVLPLLGITYMLFFFVNPGEDDVSIIVFIFYNSFLQSFGFFV 357
Db      296 ASTTSETIQYRKAVAKATVLPLLGITYMLFFFVNPGEDDLSQIMFIYFNFSFLQSFGFFV 355
Qy      358 SVFYCFNLGEVRSAARKRWHRWQDHSLRVARAMSIPSPTRISFHISIKQTAAV 413
Qy      356 SVFYCFNLGEVRSAVRKRWHRQDHSLRVPMARAMSIPSPTRISFHISIKQTAAV 411
Db      356 SVFYCFNLGEVRSAVRKRWHRQDHSLRVPMARAMSIPSPTRISFHISIKQTAAV 411

```

RESULT 10
 US-10-821-502-8
 Sequence 8, Application US/10821502
 Publication No. US20040185533A1
 GENERAL INFORMATION:
 APPLICANT: Lovenberg, Timothy W.
 Oltersdorf, Tilman
 Liaw, Chen Wang
 Grigoriadis, Dimitri E.
 Chalmers, Derek T.
 DeSouza, Errol B.
 TITLE OF INVENTION: CORTICOTROPIN RELEASING FACTOR 2
 NUMBER OF SEQUENCES: 8
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Seid Intellectual Property Law Group
 STREET: 701 Fifth Avenue, Suite 6300
 CITY: Seattle
 STATE: Washington
 COUNTRY: USA
 ZIP: 98104-7092
 COMPUTER READABLE FORM:

RESULT 11
 US-10-757-262-120
 Sequence 120, Application US/10757262
 Publication No. US20040197825A1
 GENERAL INFORMATION:
 APPLICANT: Karicheti, Venkateswarlu
 APPLICANT: Silos-Santiago, Inmaculada
 APPLICANT: Bliaosof, Scott D.
 APPLICANT: Title of Invention: METHODS AND COMPOSITIONS FOR TREATING UROLOGICAL DISORDERS USING 44390, 54181, 211, 5687, 884,
 TITLE OF INVENTION: 1405, 636, 4421, 5410, 30905, 2045, 18560, 2047,
 TITLE OF INVENTION: 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164,
 TITLE OF INVENTION: 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990,
 TITLE OF INVENTION: 18547, 115, 579, 15985, 15625, 760, 18603, 2395, 2554, 8675,
 TITLE OF INVENTION: 32720, 4809, 14303, 16816, 17827, 32620, 577, 619, 1423,
 TITLE OF INVENTION: 2158, 8263, 15402, 16209, 16386, 21165, 30911, 41897, 1643,

; TITLE OF INVENTION: 2543, 9626, 13231, 32409, 84260, 2882, 8203, 32678 OR
; TITLE OF INVENTION: 55053
; FILE REFERENCE: MPI03-007PRNOMNIM
; CURRENT APPLICATION NUMBER: US/10/757,262
; CURRENT FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 60/440,318
; PRIOR FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 60/444,783
; PRIOR FILING DATE: 2003-02-04
; PRIOR APPLICATION NUMBER: US 60/457,901
; PRIOR FILING DATE: 2003-03-27
; PRIOR APPLICATION NUMBER: US 60/468,775
; PRIOR FILING DATE: 2003-05-08
; PRIOR APPLICATION NUMBER: US 60/471,614
; PRIOR FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: US 60/478,742
; PRIOR FILING DATE: 2003-06-16
; PRIOR APPLICATION NUMBER: US 60/488,529
; PRIOR FILING DATE: 2003-07-18
; PRIOR APPLICATION NUMBER: US 60/491,156
; PRIOR FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US 60/499,594
; PRIOR FILING DATE: 2003-09-02
; PRIOR APPLICATION NUMBER: US 60/506,332
; PRIOR FILING DATE: 2003-09-26
; NUMBER OF SEQ ID NOS: 136
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO: 120
; LENGTH: 411
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-757-262-120

Query Match 80.7%; Score 1799; DB 16; Length 411;
Best Local Similarity 79.8%; Pred. No. 6.2e-159;
Matches 332; Conservative 33; Mismatches 43; Indels 8; Gaps 4;

Qy 1 MDSTIFFIIDEFDANCSLLDAFQDSFLHSESSSSFFGFFEGP--YCSATIDQIGTCWPRL 58
Db 1 MDAUJHSLL--EANCSL--ALAEELLJDGWGPPLDPEGPSYCNTTLDDQIGTCWPRL 55
Qy 59 AGELVERPCPDSENGIRYNTTRNVYRECENGTWASWMNYSQCVPILDNK-RKYALHYKI 117
Db 56 AGALVERPCPEYFNGVKNTTRNARECLENGTWASKINYSQCPEPILDQDKRQYDLHYRI 115
Qy 118 ALIINYLGHCISIALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHN 177
Db 116 ALVNYLGHCVSVAAVLAFLFLAIRSIRCLRNVIHWNLITTFILRNVMWFLQLVDHE 175
Qy 178 IHESNEWRCITTTIINYFVVTNFWMFVEGCCYLHTAIVMNTYSTDKLRKWVFLLFIGWCIP 237
Db 176 VHESNEWVWCHCITTENYFVVTNFWMFVEGCCYLHTAIVMNTYSTERLRKCLFLFIGWCIP 235
Qy 238 SPIIIVTWAICKLFYENEQCWIGKEPGKYIDTYQGRVILVLLINFVLNIVRILMTKL 297
Db 236 FPIIVAWAIGKLYYEQEQCWFGEKGFLDVLVDIYQGPILVLLINFVLNIVRILMTKL 295
Qy 298 ASTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDVSOIVFIVNSFLQSFGFFV 357
Db 296 ASTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDLSQIMFIYFNFLQSFGFFV 355
Qy 358 SVFYCFLNGEVRSAAKRKWRWQDHSLRVVARAMSPTSPTRISFSHIKQTAAV 413
Db 356 SVFYCFFNGEVRSALRKWRWQDHSLRVPMARAMSPTSPTRISFSHIKQTAAV 411
Qy 298 ASTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDLSQIVFIVNSFLQSFGFFV 357
Db 296 ASTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDLSQIVFIVNSFLQSFGFFV 355

RESULT 12
US-09-881-401-4
; Sequence 4, Application US/09881401
; Patent No. US20020077468A1
; GENERAL INFORMATION:
; APPLICANT: Lovenberg, Timothy W.
; Oltersdorf, Tilmann

RESULT 13

; Liaw, Chen
; Grigoriadis, Dimitri E.
; Chalmers, Derek T.
; DeSouza, Errol B.
; TITLE OF INVENTION: CORTICOTROPIN RELEASING FACTOR 2
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed Intellectual Property Law Group
; STREET: 701 Fifth Avenue, Suite 6300
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/881,401
; FILING DATE: 13-Jun-2001
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Christiansen, William T.
; REGISTRATION NUMBER: 44,614
; REFERENCE/DOCKET NUMBER: 690068.401C4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 411 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 4:
; US-09-881-401-4
; Query Match 80.4%; Score 1793; DB 9; Length 411;
; Best Local Similarity 80.0%; Pred. No. 2.3e-158;
; Matches 333; Conservative 30; Mismatches 45; Indels 8; Gaps 4;
; Qy 1 MDSTIFFIIDEFDANCSLLDAFQDSFLHSESSSSFFGFFEGP--YCSATIDQIGTCWPRL 58
; Db 1 MDAUJHSLL--EANCSL--ALAEELLJDGWGPPLDPEGPSYCNTTLDDQIGTCWPRL 55
; Qy 59 AGELVERPCPDSENGIRYNTTRNVYRECENGTWASWMNYSQCVPILDNK-RKYALHYKI 117
; Db 56 AGALVERPCPEYFNGVKNTTRNARECLENGTWASKINYSQCPEPILDQDKRQYDLHYRI 115
; Qy 118 ALIINYLGHCISIALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHN 177
; Db 116 ALVNYLGHCVSVAAVLAFLFLAIRSIRCLRNVIHWNLITTFILRNVMWFLQLVDHE 175
; Qy 178 IHESNEWRCITTTIINYFVVTNFWMFVEGCCYLHTAIVMNTYSTDKLRKWVFLLFIGWCIP 237
; Db 176 VHESNEWVWCHCITTENYFVVTNFWMFVEGCCYLHTAIVMNTYSTERLRKCLFLFIGWCIP 235
; Qy 238 SPIIIVTWAICKLFYENEQCWIGKEPGKYIDTYQGRVILVLLINFVLNIVRILMTKL 297
; Db 236 FPIIVAWAIGKLYYEQEQCWFGEKGFLDVLVDIYQGPILVLLINFVLNIVRILMTKL 295
; Qy 298 ASTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDVSOIVFIVNSFLQSFGFFV 357
; Db 296 ASTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDLSQIMFIYFNFLQSFGFFV 355
; Qy 358 SVFYCFLNGEVRSAAKRKWRWQDHSLRVVARAMSPTSPTRISFSHIKQTAAV 413
; Db 356 SVFYCFFNGEVRSALRKWRWQDHSLRVPMARAMSPTSPTRISFSHIKQTAAV 411
; RESULT 12
; Sequence 4, Application US/09881401
; Patent No. US20020077468A1
; GENERAL INFORMATION:

US-09-818-009-12
; GENERAL INFORMATION:
; APPLICANT: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
; TITLE OF INVENTION: UROCORTIN PEPTIDES
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FITCH, EVEN, TABIN & FLANNERY
; STREET: 120 S. Lasalle Street, Suite 1600
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60603
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.3.0

CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/818,009
; FILING DATE: 26-Mar-2001
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: US 08/981,189
; FILING DATE: 10-DEC-1997
; APPLICATION NUMBER: US 60/028,144
; FILING DATE: 13-JUN-1995
; APPLICATION NUMBER: US 60/002,223
; FILING DATE: 11-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Schumann, James J.
; REGISTRATION NUMBER: 20,856
; REFERENCE/DOCKET NUMBER: 57611
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 858-552-1311
; TELEFAX: 858-552-0095
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
; US-09-818-009-12

Query Match 80.4%; Score 1793; DB 10; Length 411;
Best Local Similarity 80.0%; Pred. No. 2.3e-158;
Matches 333; Conservative 30; Mismatches 45; Indels 8; Gaps 4;

Qy 1 MDSTIFELIIDEDFANCSSLLDAFQDSFLHSESSSSFFGFEFGP--YCSATIDQIGTCWPRSL 58
Db 1 MDAA--LILSLEANCSL--ALAEELLDDGWEPPDPPEGPSYCNTTLDQIGTCWQPSA 55

Qy 59 AGELVERPCPDSENGIRNTTRNAYRECENGTWASWMNYSQCVPILDNK-RKYALHYKI 117
Db 56 PGALVERPCPEYNGIKYNTTRNAYRECLENGTWASRINYSHCEPILDSDKQRKYDLHYRI 115

Qy 118 ALIINYLGHCISILALVIAFLFLCLRSIRCLRNTHWNLLITFILRNIMWFLQMDHN 177
Db 116 ALIINYLGCVSVVALVAFLFLVLRSLRNRVHWNLLITFILRNITWFLQLIDHE 175

Qy 178 IHESENEWRCRITTINYFVVTNFFWMEVEGCCYLHTAIYMTYSTDKLRKWKVFLFIGWCIP 237
Db 176 VHEGNEWRCRVTTFINYFVVTNFFWMEVEGCCYLHTAIYMTYSTEHLRKWLFLFIGWCIP 235

Qy 238 SPIIVTWAICKLKYENEQCWIGKEPGKYIDYYQGRVILVLLINFVLNFNIVRLMTKLR 297
Db 236 CPIIVAWAVGKLYYENEOCWFGKEPGDLYVDIYQGPILVNLINFLNFNIVRLMTKLR 295

Qy 298 ASTTSETIQYRKAVKATVLLPLLGITYMFLFVNPGEDDVSOIVFIFYPNFSLQSFGFFV 357
Db 296 ASTTSETIQYRKAVKATVLLPLLGITYMFLFVNPGEDDLSQIVFIFYFNFSLQSFGFFV 355

Qy 358 SVFYCFNLGEVRSAARKRWRQDHHSLRVVRVARAMSIPSPTRISFHSIKQTAAV 413
Db 356 SVFYCFNLGEVRSAALKRWRQDHHALRVPVVARAMSIPSPTRISFHSIKQTAAV 411

RESULT 15
US-10-649-852-18
; Sequence 18, Application US/10649852
; Publication No. US20040101911A1
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; APPLECTANT: Isfort, Robert
; CURRENT APPLICATION NUMBER: US/10/649, 852
; CURRENT FILING DATE: 2003-08-27
; PRIOR APPLICATION NUMBER: US 09/799, 978
; PRIOR FILING DATE: 2001-03-06
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 18
; LENGTH: 411
; TYPE: PRT
; ORGANISM: Rattus norvegicus
; US-10-649-852-18

RESULT 14
US-09-799-978-18
; Sequence 18, Application US/09799978

; Publication No. US20030165807A1
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; APPLECTANT: Sheldon, Russell
; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or Function Using Corticotropin Releasing Factor Receptors
; FILE REFERENCE: 8448
; CURRENT APPLICATION NUMBER: US/09/799, 978
; CURRENT FILING DATE: 2001-03-06
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 18
; LENGTH: 411
; TYPE: PRT
; ORGANISM: Rattus norvegicus
; US-09-799-978-18

Query Match 80.4%; Score 1793; DB 10; Length 411;
Best Local Similarity 80.0%; Pred. No. 2.3e-158;
Matches 333; Conservative 30; Mismatches 45; Indels 8; Gaps 4;

Qy 1 MDSTIFELIIDEDFANCSSLLDAFQDSFLHSESSSSFFGFEFGP--YCSATIDQIGTCWPRSL 58
Db 1 MDAA--LILSLEANCSL--ALAEELLDDGWEPPDPPEGPSYCNTTLDQIGTCWQPSA 55

Qy 59 AGELVERPCPDSENGIRNTTRNAYRECENGTWASWMNYSQCVPILDNK-RKYALHYKI 117
Db 56 PGALVERPCPEYNGIKYNTTRNAYRECLENGTWASRINYSHCEPILDSDKQRKYDLHYRI 115

Qy 118 ALIINYLGHCISILALVIAFLFLCLRSIRCLRNTHWNLLITFILRNIMWFLQMDHN 177
Db 116 ALIINYLGCVSVVALVAFLFLVLRSLRNRVHWNLLITFILRNITWFLQLIDHE 175

Qy 178 IHESENEWRCRITTINYFVVTNFFWMEVEGCCYLHTAIYMTYSTDKLRKWKVFLFIGWCIP 237
Db 176 VHEGNEWRCRVTTFINYFVVTNFFWMEVEGCCYLHTAIYMTYSTEHLRKWLFLFIGWCIP 235

Qy 238 SPIIVTWAICKLKYENEQCWIGKEPGKYIDYYQGRVILVLLINFVLNFNIVRLMTKLR 297
Db 236 CPIIVAWAVGKLYYENEOCWFGKEPGDLYVDIYQGPILVNLINFLNFNIVRLMTKLR 295

Qy 298 ASTTSETIQYRKAVKATVLLPLLGITYMFLFVNPGEDDVSOIVFIFYPNFSLQSFGFFV 357
Db 296 ASTTSETIQYRKAVKATVLLPLLGITYMFLFVNPGEDDLSQIVFIFYFNFSLQSFGFFV 355

Qy 358 SVFYCFNLGEVRSAARKRWRQDHHSLRVVRVARAMSIPSPTRISFHSIKQTAAV 413
Db 356 SVFYCFNLGEVRSAALKRWRQDHHALRVPVVARAMSIPSPTRISFHSIKQTAAV 411

RESULT 15
US-10-649-852-18
; Sequence 18, Application US/10649852
; Publication No. US20040101911A1
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; APPLECTANT: Isfort, Robert
; CURRENT APPLICATION NUMBER: US/10/649, 852
; CURRENT FILING DATE: 2003-08-27
; PRIOR APPLICATION NUMBER: US 09/799, 978
; PRIOR FILING DATE: 2001-03-06
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 18
; LENGTH: 411
; TYPE: PRT
; ORGANISM: Rattus norvegicus
; US-10-649-852-18

```

Query Match 80.4%; Score 1793; DB 16; Length 411;
Best Local Similarity 80.0%; Pred. No. 2.3e-158;
Matches 333; Conservative 30; Mismatches 45; Indels 8; Gaps 4;

Qy      1 MDSTIFFIIDEFDANCSSLDAFQDSFLHSESSSSFFGFEGP--YCSATIDQIGTCWPRLS 58
Db      1 MDAA---LILSLBANCSL--ALAEELL.DGWEEPDPPEGPSYCNTLDQIGTCWPQSA 55

Qy      59 AGELEYVERPCPDSFNGIRYNTTRNVYRECENGTWASWMNYSQCVPILDNK-RKYALHYKI 117
Db      56 PGALVERPCPEYFNGIKYNTTRNAVRECLENGTWASRINYSHCEPILDKQRKYDLHYRI 115

Qy      118 ALIINYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWLLQMIIDHN 177
Db      116 ALIINYLGHCVSVAVALVAAFLLFLVLRSLIRCLRNVIHWNLITTFILRNITWFLQLIDHE 175

Qy      178 IHESENEWCRCITTINYFVVTNF FWMFVEGCYLHTAIVMTYSTDKLRKWVFFIGWCIP 237
Db      176 VHEGNEWRCRCTTINYFVVTNF FWMFVEGCYLHTAIVMTYSTEHLRKWLFFIGWCIP 235

Qy      238 SPIIVTWAICKLYENEQCWIGKEPGKYIDYIYQGRVILVLLINFEVLNIVRILMTKL R 297
Db      236 CPIIVAWAVGKLYENEQCWFFGKEPGDLWDIYQGPILVLLINFEVLNIVRILMTKL R 295

Qy      298 ASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDVSOIVFIFYNSFLQSFGFFV 357
Db      296 ASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDLSQIVFIFYNSFLQSFGFFV 355

Qy      358 SVFYCFLNGEVRSAAARKRWHRQDHSLRVVARAMSIPTSPTRISFHSIKQTAAV 413
Db      356 SVFYCFLNGEVRSAAARKRWHRQDHSLRVVARAMSIPTSPTRISFHSIKQTAAV 411

```

Search completed: August 20, 2005, 00:42:16
 Job time : 165 secs

GenCore version 5.1.6
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model
 Run on: August 20, 2005, 00:23:03 ; Search time 43 Seconds
 (without alignments)
 716.978 Million cell updates/sec

Title: US-10-649-852-32
 Perfect score: 2229
 Sequence: 1 MDSTIFELIIDDEFDANCSSIL.....SIPTSPTRISFSIKQTAAV 413
 Scoring table: BLOSUM62
 Gapop 10.0 , Gapext 0.5

Searched: 513545 seqs, 74649064 residues

Total number of hits satisfying chosen parameters: 513545

Minimum DB seq length: 0
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
 Maximum Match 100%
 Listing first 45 summaries

Database : Issued_Patents_AA:
 1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep:
 2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep:
 3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep:
 4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep:
 5: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep:
 6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:
 7: 1793 80.4 411 1 US-08-381-433A-4

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2229	100.0	413	4 US-09-799-978-32	Sequence 32, Appl
2	1807	81.1	405	4 US-09-799-978-38	Sequence 38, Appl
3	1804	80.9	411	4 US-09-631-603-12	Sequence 12, Appl
4	1799	80.7	411	1 US-08-381-433A-8	Sequence 8, Appl
5	1799	80.7	411	4 US-09-799-978-10	Sequence 10, Appl
6	1799	80.7	411	4 US-09-881-401-8	Sequence 8, Appl
7	1793	80.4	411	1 US-08-381-433A-4	Sequence 4, Appl
8	1793	80.4	411	3 US-08-981-189B-12	Sequence 12, Appl
9	1793	80.4	411	4 US-09-799-978-18	Sequence 18, Appl
10	1793	80.4	411	4 US-09-881-401-4	Sequence 4, Appl
11	1787.5	80.2	397	4 US-09-799-978-14	Sequence 14, Appl
12	1786	80.1	438	4 US-09-799-978-12	Sequence 12, Appl
13	1784.5	80.1	431	3 US-08-981-189B-13	Sequence 13, Appl
14	1784.5	80.1	431	4 US-09-881-401-2	Sequence 2, Appl
15	1778.5	79.8	431	1 US-08-381-433A-2	Sequence 2, Appl
16	1776.5	79.7	431	4 US-09-799-978-20	Sequence 20, Appl
17	1770.5	79.4	431	3 US-08-981-189B-11	Sequence 11, Appl
18	1770.5	79.4	431	3 US-08-482-746-10	Sequence 10, Appl
19	1770.5	79.4	431	4 US-09-580-734-10	Sequence 10, Appl
20	1770.5	79.4	431	4 US-08-374-009-10	Sequence 10, Appl
21	1770.5	79.4	431	4 US-09-191-724-10	Sequence 10, Appl
22	1770.5	79.4	431	4 US-09-799-978-24	Sequence 24, Appl
23	1769	79.4	430	4 US-09-799-978-26	Sequence 26, Appl
24	1582.5	71.0	428	4 US-09-799-978-36	Sequence 36, Appl
25	1582	71.0	420	4 US-09-799-978-42	Sequence 42, Appl
26	1578.5	70.8	445	4 US-09-799-978-34	Sequence 34, Appl
27	1566	70.3	415	1 US-08-110-286A-2	Sequence 2, Appl

ALIGNMENTS

RESULT 1						
;	Sequence 32, Application US/09799978	;	Patent No. 6670140	;	GENERAL INFORMATION:	
;	;	;	;	;	APPLICANT: The Procter & Gamble Company	
;	;	;	;	;	APPLICANT: Isfort, Robert Sheldon, Russell	
;	;	;	;	;	TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass Or Function Using Corticotropin Releasing Factor Receptors	
;	;	;	;	;	TITLE OF INVENTION: Function Using Corticotropin Releasing Factor Receptors	
;	;	;	;	;	FILE REFERENCE: 8448	
;	;	;	;	;	CURRENT APPLICATION NUMBER: US/09/799,978	
;	;	;	;	;	CURRENT FILING DATE: 2001-03-06	
;	;	;	;	;	NUMBER OF SEQ ID NOS: 44	
;	;	;	;	;	SOFTWARE: PatentIn version 3.0	
;	;	;	;	;	SEQ ID NO 32	
;	;	;	;	;	LENGTH: 413	
;	;	;	;	;	TYPE: PRT	
;	;	;	;	;	ORGANISM: Xenopus laevis	
;	;	;	;	;	US-09-799-978-32	

Query Match						
Best Local Similarity	100.0%	Score 2229;	DB 4;	Length 413;		
Matches	413;	Conservative	0;	Mismatches	0;	Pred. No. 1.2e-200;
Qy	1 MDSTIFELIIDDEFDANCSSILDAFQDSFLHSESSSSFFGPEGPYCSATIDQIGTCWPRSLAG 60	Db	1 MDSTIFELIIDDEFDANCSSILDAFQDSFLHSESSSSFFGPEGPYCSATIDQIGTCWPRSLAG 60	Qy	1 MDSTIFELIIDDEFDANCSSILDAFQDSFLHSESSSSFFGPEGPYCSATIDQIGTCWPRSLAG 60	Db
Qy	61 ELVERPCPDSDENGIRNTTRNVYRECENGTWASWMNTSQCVPLILDNKRKYALHYKIALI 120	Qy	61 ELVERPCPDSDENGIRNTTRNVYRECENGTWASWMNTSQCVPLILDNKRKYALHYKIALI 120	Qy	61 ELVERPCPDSDENGIRNTTRNVYRECENGTWASWMNTSQCVPLILDNKRKYALHYKIALI 120	Qy
Db	61 SNEWLCRCCISLALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHNIHE 180	Db	61 SNEWLCRCCISLALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHNIHE 180	Db	61 SNEWLCRCCITIINYFVVTFNFWMFVEGGYLHTAIIVMTYSTDKLRKWVFLFIGWCIPSPI 240	Qy
Qy	181 SNEWLCRCCITIINYFVVTFNFWMFVEGGYLHTAIIVMTYSTDKLRKWVFLFIGWCIPSPI 240	Qy	181 SNEWLCRCCITIINYFVVTFNFWMFVEGGYLHTAIIVMTYSTDKLRKWVFLFIGWCIPSPI 240	Qy	181 TSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDSQIVFNSFLQSFGFFVSVF 360	Qy
Qy	241 IVTWAICKLFYNEOCWIGKEPKYIDYIYGGRVLYLINFVFLNIVRLMTKLRAST 300	Qy	241 IVTWAICKLFYNEOCWIGKEPKYIDYIYGGRVLYLINFVFLNIVRLMTKLRAST 300	Qy	241 TSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDSQIVFNSFLQSFGFFVSVF 360	Qy
Db	241 IVTWAICKLFYNEOCWIGKEPKYIDYIYGGRVLYLINFVFLNIVRLMTKLRAST 300	Db	241 IVTWAICKLFYNEOCWIGKEPKYIDYIYGGRVLYLINFVFLNIVRLMTKLRAST 300	Db	241 IVTWAICKLFYNEOCWIGKEPKYIDYIYGGRVLYLINFVFLNIVRLMTKLRAST 300	Qy

Db 361 YCFLNGEVRSAARKRWHRWQDDHSLRVRVARAMSINTSPTRISSFSIKOTAAV 413

RESULT 2
US-09-799-978-38
; Sequence 38, Application US/09799978
; Patent No. 6670140
; GENERAL INFORMATION:
; APPLICANT: Isfort, Robert
; APPLICANT: Sheldon, Russell
; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or Function Using Corticotropin Releasing Factor Receptors
; FILE REFERENCE: 8448
; CURRENT APPLICATION NUMBER: US/09/799, 978
; NUMBER OF SEQ ID NOS: 44
; CURRENT FILING DATE: 2001-03-06
; SOFTWARE: Patentin version 3.0
; SEQ ID NO: 38
; LENGTH: 405
; TYPE: PRT
; ORGANISM: Ameiurus nebulosus
; US-09-799-978-38

Query Match 81.1%; Score 1807; DB 4; Length 405;
Best Local Similarity 79.9%; Pred. No. 4e-161;
Matches 330; Conservative 33; Mismatches 42; Indels 8; Gaps 2;

Db 1 MDSTIFELIIDEFDANCSLLDAFQDSFLHSSESSSSFFGFFEGP-YCSATIDQIGTCWPRSL 60

Qy 1 MEVSLLELL--SVEVNCSLADAFGDPAYGNASDAL-----YCNATADEIGTCWPRSGAG 52

Db 61 ELVERCPDSDFNGIPTYNTTRNVYRECOPENGTWASWMNYSQCVPILDNKRYKALHYKIALI 120

Qy 53 RVVARCPPDFINGWKYNSTRSAVRECLENGTWAKFKINYSSCEPILEEKRKYPVPHYKIALI 112

Db 121 INYLGHCISILALVIAFLFLCLRSIRCLRNTHWNLLITFILRNIMWLLQMDHNIE 180

Qy 113 INYLGHCISVGALVIAFLFLCLRSIRCLRNVIHWNLITFILRNIMWLLQLIDHNIE 172

Db 181 SNEVWCRCTTINYFVVTNFFWMFVEGCCYLHTAIVMTYSTDKLRKWVFLFIGWCIPSPI 240

Qy 173 RNEPWCRLLTTVNYFVVTNFFWMFVEGCCYLHTAIVMTYSTDKLRKWVFLFIGWCIPCPV 232

Db 241 IVTWAICKLIFYENEQCWIGKEPGKYIDYIYQGRVILVLLINVFVLNIVRLMTKLRAST 300

Qy 233 IIAWAVGKLYNENEQCWFGKEPGKYVDIYQGPVIVVLLINVFVLNIVRLMTKLRAST 292

Db 301 TSETIQYRKAVKATLVLLPLLGITYMLFPVNPGEDDVSDQIVFIFYNSFLQSFGQFFFVSVF 360

Qy 293 TSETIQYRKAVKATLVLLPLLGITYMLFPVNPGDDDISQIVFIFYNSFLQSFGQFFFVSVF 352

Db 361 YCFLNGEVRSAARKRWHRWQDDHSLRVRVARAMSINTSPTRISSFSIKOTAAV 413

Db 353 YCFLNGEVRSAVRKRWQDDNHALRVRVARAMSINTSPTRISSFSIKHTTAV 405

RESULT 4
US-09-381-433A-8
; Sequence 8, Application US/08381433A
; Patent No. 5786203
; GENERAL INFORMATION:
; APPLICANT: Lovenberg, Timothy W.
; APPLICANT: Oltersdorf, Tilman
; APPLICANT: Liaw, Chen
; APPLICANT: Grigoriadis, Dimitri E.
; APPLICANT: DeSouza, Errol B.
; TITLE OF INVENTION: CORTICOTROPIN RELEASING FACTOR 2
; TITLE OF INVENTION: RECEPTORS
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/381, 433A
; FILING DATE: 31-JAN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:

RESULT 3
US-09-631-603-12
; Sequence 12, Application US/09631603
; Patent No. 6733990
; GENERAL INFORMATION:
; APPLICANT: Hodge, Martin R.
; APPLICANT: Lloyd, Clare
; APPLICANT: Weich, Nadine
; TITLE OF INVENTION: A No. 6733990el GPCR-like Molecule of the Secretin-Like Family and Uses Thereof
; FILE REFERENCE: 5800-48A
; CURRENT APPLICATION NUMBER: US/09/631, 603
; CURRENT FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: 09/515, 781
; PRIOR FILING DATE: 2000-02-29

NAME: McMasters, David D.
 REGISTRATION NUMBER: 33, 963
 REFERENCE/DOCKET NUMBER: 690068.401C1
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (206) 622-4900
 TELEX: 3723836 SEEDANDBERRY
 INFORMATION FOR SEQ ID NO: 8:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 411 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-381-433A-8

Query Match 80.7%; Score 1799; DB 1; Length 411;
 Best Local Similarity 79.8%; Pred. No. 2.3e-160;
 Matches 332; Conservative 33; Mismatches 43; Indels 8; Gaps 4;

Qy 1 MDSTIFELIIDEFDANCSLLDAFQDSFLHSESSSSFFGEGP--YCSATIDQIGTCWPRSL 58
 Db 1 MDAALLHSLL--EANCSL--ALAEELLGDGWPPPLDPEGPSYCNTLDOIQTCWPRSA 55

Qy 59 AGELVERPCPDSENGIRNTTRNRYRECENGTWASWMNYSQCVPIIDNK-RKYALHYKI 117
 Db 56 AGALVERPCPEYFNGKVNTTRNAYRECLENGTWASKINYSQCEPIIDDKQRKYDLHYRI 115

Qy 118 ALINYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMIIDHN 177
 Db 116 ALVNVNLGHCVSVAALVAAFFLFLALRSIRCLRNIVHWNLITTFILRNIMWFLQLVDHE 175

RESULT 6
 US-09-881-401-8 ; Sequence 8, Application US/09881401
 ; Patent No. 6723841 ;
 ; GENERAL INFORMATION:
 ; APPLICANT: Lovenberg, Timothy W.
 ; Oltendorff, Tilman
 ; Liaw, Chen
 ; Grigoriadis, Dimitri E.
 ; Chalmers, Derek T.
 ; DeSouza, Errol B.
 ; TITLE OF INVENTION: CORTICOTROPIN RELEASING FACTOR 2
 ; NUMBER OF SEQUENCES: 8
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Seed Intellectual Property Law Group
 ; STREET: 701 Fifth Avenue, Suite 6300
 ; CITY: Seattle
 ; STATE: Washington
 ; COUNTRY: USA
 ; ZIP: 98104-7092
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/881,401
 ; FILING DATE: 13-Jun-2001
 ; CLASSIFICATION: <Unknown>
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Christiansen, William T.
 ; REGISTRATION NUMBER: 44,614
 ; REFERENCE/DOCKET NUMBER: 690068.401C4
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (206) 622-4900
 ; TELEFAX: (206) 682-6031
 ; INFORMATION FOR SEQ ID NO: 8:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 411 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: protein
 ; SEQUENCE DESCRIPTION: SEQ ID NO: 8:

RESULT 5
 US-09-799-978-10 ; Sequence 10, Application US/09799978
 ; Patent No. 6670140 ;
 ; GENERAL INFORMATION:
 ; APPLICANT: The Procter & Gamble Company
 ; APPLICANT: Isfort, Robert
 ; APPLICANT: Sheldon, Russell
 ; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or Title of Invention: Function Using Corticotropin Releasing Factor Receptors
 ; FILE REFERENCE: 8448
 ; CURRENT APPLICATION NUMBER: US/09/799,978
 ; CURRENT FILING DATE: 2001-03-06
 ; NUMBER OF SEQ ID NOS: 44
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO: 10
 ; LENGTH: 411
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; US-09-799-978-10

Query Match 80.7%; Score 1799; DB 4; Length 411;
 Best Local Similarity 79.8%; Pred. No. 2.3e-160;
 Matches 33; Mismatches 43; Indels 8; Gaps 4;

US-09-881-401-8

Query Match Score 1799; DB 4; Length 411;
Best Local Similarity 79.8%; Pred. No. 2.3e-160;
Matches 332; Conservative 33; Mismatches 43; Indels 8; Gaps 4;

US-08-381-433A-4

SEQUENCE CHARACTERISTICS:
LENGTH: 411 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein

	Query	Match	Score 1793; DB 1; Length 411;
Qy	1 MDSTIFELIIDEFDANSCLDAFQDSFLHSESSSSFFGFEGP--YCSATIDQIGTCWPRLS 58	80.4%; Best Local Similarity 80.0%; Pred. No. 8.3e-160;	Indels 8; Gaps 4;
Db	1 MDAALLHSLL---EANCSL--ALAELLGNGPPPLDPEGPSYCNNTLDQIGTCWPRSA 55	30; Mismatches 45;	Matches 333; Conservative 333;
Qy	59 AGELVERPCPDSFNGIRYNTTRNVYRECENGTwASWmNYSQCVPILDNk-RKYALHYK 117	1 MDSTIFELIIDEFDANSCLDAFQDSFLHSESSSSFFGFEGP--YCSATIDQIGTCWPRLS 58	1 MDAA---LLSLLEANCSL--ALAELLGNGPPPLDPEGPSYCNNTLDQIGTCWPQSA 55
Db	56 AGALVERPCPEYFGVKNTRNAYRECLENGTwASKINySQCEPILDKQRKYDLHYR 115	1 MDAA---LLSLLEANCSL--ALAELLGNGPPPLDPEGPSYCNNTLDQIGTCWPQSA 55	
Qy	118 ALIINYLGHCISILALVIAFLFLCLRSIRCLRNtIHWNLITTFILRNIMWFLQMDHN 177	59 AGELVERPCPDSFNGIRYNTTRNVYRECENGTwASWmNYSQCVPILDNk-RKYALHYK 117	
Db	116 ALVVNLYLGHCVSVAALVAAFLLFLALARSTRCLRNtIHWNLITTFILRNIMWFLQLVDE 175	56 PGALVERPCPEYFGIKYNTTRNAYRECLENGTwASRINySHCEPILDKQRKYDLHYR 115	
Qy	178 IHEsNEWvRCRITTtIYNFVVTNFWMFVEFGCYLHTAIvMTYSTDKLRKwVFLFIGWCIP 237	118 ALIINYLGHCISILALVIAFLFLCLRSIRCLRNtIHWNLITTFILRNIMWFLQMDHN 177	
Db	176 VHEsNEWvWCHCITtIYNFVVTNFWMFVEFGCYLHTAIvMTYSTERLRKCLFLFIGWCIP 235	116 ALIINYLGHCVSVAALVAAFLLFLALARSTRCLRNtIHWNLITTFILRNIMWFLQLVDE 175	
Qy	238 SPIIVTWAICKLIFYENEQCWIGKEPGKYIDYIYQGRVILVLLINFVFLFNIVRILMTKL 297	178 IHEsNEWvRCRITTtIYNFVVTNFWMFVEFGCYLHTAIvMTYSTDKLRKwVFLFIGWCIP 237	
Db	236 FPIIVAWAIGKLYYENEQCWFQGKPEPGLDVYIYQGPiIvLLINFVFLFNIVRILMTKL 295	176 VHEgNEWvRCRVTtIYNFVVTNFWMFVEFGCYLHTAIvMTYSTERLRKwVFLFIGWCIP 235	
Qy	298 ASTTSETIQRKAVKATLVLPLLGITYMLFFVNPGEDDVSOIVFIFNSFLQSFOQGPFFV 357	238 SPIIVTWAICKLIFYENEQCWIGKEPGKYIDYIYQGRVILVLLINFVFLFNIVRILMTKL 297	
Db	296 ASTTSETIQRKAVKATLVLPLLGITYMLFFVNPGEDDLSQIMFIYFNSFLQSFOQGPFFV 355	236 CPIIVAWAIGKLYYENEQCWFQGKPEPGLDVYIYQGPiIvLLINFVFLFNIVRILMTKL 295	
Qy	358 SVFYCFNLGEVRSAARKRWHRWQDHHSLRVYVARAMSIPSPTRISFHsIKQTAAV 413	298 ASTTSETIQRKAVKATLVLPLLGITYMLFFVNPGEDDVSOIVFIFNSFLQSFOQGPFFV 357	
Db	356 SVFYCFNLGEVRSAVRKRWHRWQDHHSLRVPMARAMSIPSPTRISFHsIKQTAAV 411	296 ASTTSETIQRKAVKATLVLPLLGITYMLFFVNPGEDDLSQIVFIFNSFLQSFOQGPFFV 355	

RESULT 7

US-08-381-433A-4

Sequence 4, Application US/08381433A

Patent No. 5786203

GENERAL INFORMATION:

APPLICANT: Lovenberg, Timothy W.
APPLICANT: Oltersdorf, Tilman
APPLICANT: Liaw, Chen
APPLICANT: Grigoriadis, Dimitri E.
APPLICANT: DeSouza, Errol B.

TITLE OF INVENTION: CORTICOTROPIN RELEASING FACTOR 2

NUMBER OF SEQUENCES: 8

CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/381,433A
FILING DATE: 31-JAN-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: McMasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 690068.401C1
TELECOMMUNICATION INFORMATION:
.TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
TELEX: 3723836 SEEDANDBERRY
INFORMATION FOR SEQ ID NO: 4:

RESULT 8

US-08-981-189B-12

Sequence 12, Application US/08981189B

Patent No. 6214797

GENERAL INFORMATION:

APPLICANT:
TITLE OF INVENTION: UROCORTIN PEPTIDES
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: FITCH, EVEN, TABIN & FLANNERY
STREET: 120 S. LaSalle Street, Suite 1600
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60603

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/981,189B
FILING DATE: 10-DEC-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/002,223
FILING DATE: 11-AUG-1995
ATTORNEY/AGENT INFORMATION:
NAME: Schumann, James J.
REGISTRATION NUMBER: 20,856
REFERENCE/DOCKET NUMBER: 57611

TELECOMMUNICATION INFORMATION:
 TELEPHONE: 858-552-1311
 TELEXFAX: 858-552-0095
 INFORMATION FOR SEQ ID NO: 12:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 411 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 FEATURE:
 NAME/KEY: Protein
 LOCATION: 1..411 /note= "Rat CRF-R2 Short Form"
 PUBLICATION INFORMATION:
 AUTHORS: Lovenberg, Timothy W
 AUTHORS: Liaw, Chen W
 AUTHORS: Grigoriadis, Dimitri E
 AUTHORS: Clevermers, Derek T
 AUTHORS: Chalmers, Dereck T
 AUTHORS: Desouza, Errol B
 AUTHORS: Oltersdorf, Tilman
 TITLE: Cloning and characterization of a
 TITLE: functionally distinct corticotropin-releasing
 TITLE: factor receptor subtype from rat brain
 JOURNAL: Proc. Natl. Acad. Sci. U.S.A.
 VOLUME: 92
 PAGES: 836-840
 DATE: January-1995
 US-08-981-189B-12

Query Match 80.4%; Score 1793; DB 3; Length 411;
 Best Local Similarity 80.0%; Pred. No. 8.3e-160;
 Matches 333; Conservative 30; Mismatches 45; Indels 8; Gaps 4;

Qy 1 MDSTIFELIIDEFFDANCSLLDAFQDSFLHSESSSSFFGFEFP--YCSATIDQIGTCWPRSL 58
 Db 1 MDAA--LILSLEANCSL--ALAEELLDDGNGEPPDPPEGPSYCNTTLQDQIGTCWPRSA 55

Qy 59 AGELVERPCPDNSFGIRYNTTRNYRECENGTWASWMNYSQCVPILDNK-RKYALHYKI 117
 Db 56 PGALVERPCPEYFNGIKYNTTRNAYRECLENGTWASRINYSHCEPILDDKQRKYDLHYRI 115

Qy 118 ALIINYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHN 177
 Db 116 ALIINYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHN 175

Qy 178 IHESENEWWCRCTTINYFVVTNFWMFVEGCCYLHTAIVMTYSTDKLRLKWNFLFIGWCIP 237
 Db 176 VHEGNEWWCRCTTINYFVVTNFWMFVEGCCYLHTAIVMTYSTDKLRLKWNFLFIGWCIP 235

Qy 238 SPIIVTWAICKLYENEQCWIGKEPGKYIDYYQGRVILVLLINFFVLNIVRLMTKLR 297
 Db 236 CPIIVAWAVGKLYYENEQCWFGKEPGDLYDYYQGPILVLLINFFVLNIVRLMTKLR 295

Qy 298 ASTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDVSOIVFYFNSFQGFFV 357
 Db 296 ASTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDLSQIVFYFNSFQGFFV 355

Qy 358 SVFYCFLNGEVRSAARKRWHWRQDHSLRVVARAMSIPSPTRISFHSIKQTAAY 413
 Db 356 SVFYCFFNGEVRSALARKRWHWRQDHSLRVVARAMSIPSPTRISFHSIKQTAAY 411

RESULT 10
 US-09-881-401-4
 ; Sequence 4, Application US/09881401
 ; Patent No. 6723841
 ; GENERAL INFORMATION:
 ; APPLICANT: Lovenberg, Timothy W.
 ; Oltersdorf, Tilman
 ; Liaw, Chen
 ; Grigoriadis, Dimitri E.
 ; Chalmers, Dereck T.
 ; Desouza, Errol B.
 ; TITLE OF INVENTION: CORTICOTROPIN RELEASING FACTOR 2
 ; NUMBER OF SEQUENCES: 8
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Seed Intellectual Property Law Group
 ; STREET: 701 Fifth Avenue, Suite 6300
 ; CITY: Seattle
 ; STATE: Washington
 ; COUNTRY: USA
 ; ZIP: 98104-7092
 ; COMPUTER READABLE FORM:
 ; MEDIUM, TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/881,401
 ; FILING DATE: 13-Jun-2001

RESULT 9
 US-09-799-978-18
 ; Sequence 18, Application US/09799978
 ; Patent No. 6670140
 ; GENERAL INFORMATION:
 ; APPLICANT: The Procter & Gamble Company
 ; APPLICANT: Isfort, Robert
 ; APPLICANT: Sheldon, Russell
 ; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or Function Using Corticotropin Releasing Factor Receptors

CLASSIFICATION: <Unknown>

ATTORNEY/AGENT INFORMATION:

NAME: Christiansen, William T.

REGISTRATION NUMBER: 44,614

REFERENCE/DOCKET NUMBER: 690068.401C4

TELECOMMUNICATION INFORMATION:

TELEPHONE: (206) 622-4900

TELEFAX: (206) 682-6031

INFORMATION FOR SEQ ID NO: 4:

SEQUENCE CHARACTERISTICS:

LENGTH: 411 amino acids

TYPE: amino acid

TOPOLGY: linear

MOLECULE TYPE: protein

SEQUENCE DESCRIPTION: SEQ ID NO: 4 :

US-09-881-401-4

Query Match 80.4%; Score 1793; DB 4; Length 411;
Best Local Similarity 80.0%; Pred. No. 8.3e-160;
Matches 333; Conservative 30; Mismatches 45; Indels 8; Gaps 4;

Db 1 MDSTIFFELIIDEFDANCSSLDAFQDSFLHSESSSSFFFEGP--YCSATIDQIGTCWPRL 58
1 MDAA--LRLSLLEANCSL--ALAEELLIDGWGEPPDPEGPSYCNTTLDDQIGTCWPQSA 55

Qy 59 AGEIVVERPCPDSEFNGLRNYNTTRNVRCEFENGTWASWMNYSQCVPILDNK-RKYALHYKI 117
56 PGALVERPCPEYFNGIKXNTTRNAYRECLENGTWASRINYSHCEPILDQKRYDLHYRI 115

Qy 118 ALIINYLGHCISILALVIAFLFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHN 177
Db 116 ALIINYLGHCVSVALVALVAEFLFLVLRSTRCLRNTHWNLTFLQLDHE 175

RESULT 12 US-09-799-978-12
; Sequence 12, Application US/09799978
; Patent No. 6670140
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; ISFORT, Robert
; APPLICANT: Sheldon, Russell
; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or Function Using Corticotropin Releasing Factor Receptors
; FILE REFERENCE: 8448
; CURRENT APPLICATION NUMBER: US/09/799,978
; CURRENT FILING DATE: 2001-03-06
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 12
; LENGTH: 438
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-799-978-12

Query Match 80.1%; Score 1786; DB 4; Length 438;
Best Local Similarity 82.3%; Pred. No. 4.1e-159;
Matches 325; Conservative 31; Mismatches 35; Indels 4; Gaps 3;

Qy 22 AFQDSFLHSESSSSFFFEGP--YCSATIDQIGTCWPRLSLAGELVERPCPDSFGNGIRYNTT 79
45 ALLEQYCHT-IMTLTNLSGPYSYCNTTLDDQIGTCWPRLSAGALVERPCPEYFGVKINTT 103

Db 238 SPIIVTWAICKLFYENEQCGWIGKEPGRYIDTYQGRVILVLLINFTLKR 297
236 CPIIVAWAVGKLYYENEQCGWIGKEPGRDLYDYYQGPVILVLLINFTLKR 295

Qy 298 ASTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDVSOIVFVFLNIVRLMTLKR 357
296 ASTTSETIQYRKAVKATLVLPLLGITYMLFFVNPGEDDLSQIVFVFLNIVRLMTLKR 355

Qy 358 SVFYCFNLGEVRSAAKRWHRWQDHHSRLRVARAMSIPTSPTRISFSIKQTAAV 413
Db 356 SVFYCFNLGEVRSALRKWRWQDHHALRVARAMSIPTSPTRISFSIKQTAAV 411

RESULT 11 US-09-799-978-14
; Sequence 14, Application US/09799978
; Patent No. 6670140
; GENERAL INFORMATION:
; APPLICANT: The Procter & Gamble Company
; ISFORT, Robert
; APPLICANT: Sheldon, Russell
; TITLE OF INVENTION: Methods for Identifying Compounds for Regulating Muscle Mass or Function Using Corticotropin Releasing Factor Receptors
; FILE REFERENCE: 8448
; CURRENT APPLICATION NUMBER: US/09/799,978
; CURRENT FILING DATE: 2001-03-06
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14
; LENGTH: 397
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-799-978-14

Query Match 80.2%; Score 1787.5; DB 4; Length 397;
Best Local Similarity 85.4%; Pred. No. 2.6e-159;

Qy 139 LFLCLRSIRCLRNIIHWNLITTFILRNIMWFLQMDHNTHESNEWWCRCITTYNYFVV 198
164 LFLAIRSIRCLRNTHWNLTFLRNVMWFLQLVDHEVESNEWWCRCITTFNYFVV 223

Db 104 RNAYRECLENGTWASKINYSQCVPILDNK-RKYALHYKIALIINYLGHCISILALVIAFL 163

Qy 199 TNFFWMFVEGGCYLHTAIVMTYSTDQLRKWVFLFIGWCIPSIIVTWAIKLFYENEQCW 258
224 TNFFWMFVEGGCYLHTAIVMTYSTERLRKCLFLFIGWCIPFPIIAWAIKGKLYENEQCW 283

Qy 259 GREPKYIDYIYQGRVILVILLNFVFLNIVRILMTKLRASTTSETIQRKAVKATLVLL 318

SEQUENCE CHARACTERISTICS:
 LENGTH: 431 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 SEQUENCE DESCRIPTION: SEQ ID NO: 2:
 US-09-881-401-2

Query Match 80.1%; Score 1784.5; DB 4; Length 431;
 Best Local Similarity 85.5%; Pred. No. 5.5e-159;
 Matches 324; Conservative 24; Mismatches 28; Indels 3; Gaps 2;

QY 38 FEGP--YCSATIDQIGTCWPRSLAGELVERPCPDSSFNGIRNTTRNVYRECENGTWASW 95
 Db 53 FSGPPSYCNCNTLDQIGTCWPOSAPGALVERCPPEYFNGIKYNTTRNAYRECLENGTWASR 112
 QY 96 MNYSOCVPILDNK-RKYALHYKIALIINTLGHCISILALVIAFLFLCLRSIRCLRNIIH 154
 Db 113 INYSHCEPILDQDKQRKYDLHYRIALIINYLGHCVSVALVAAPLLFLVLRSIRCLRNVIH 172
 QY 155 WNLITTFILRNIMWFLLQMDHNTHESNEWNCRCITIINYFVVTNFFWMFVEGCCYLHTA 214
 Db 173 WNLITTFILRNITWFLLQLIDHEVHEGNEWNCRVTTIFNYFVVTNFFWMFVEGCCYLHTA 232
 QY 215 IVMYSTDKLRKWVPLFIGWCIPSPIIYTWAICKLYENEQCWIGKEPGKYIDYIYQGRV 274
 Db 233 IVMYSTEHLRKWVPLFIGWCIPCPIIVAWVGKLYENEQCWIGKEPGKYIDYIYQGRV 292
 QY 275 ILLVLLINFVFLNIVRLMTKLRASTTSETIQRKAVKATLVLLPLLGITYMLFFVNPG 334
 Db 293 ILLVLLINFVFLNIVRLMTKLRASTTSETIQRKAVKATLVLLPLLGITYMLFFVNPG 352
 QY 335 DDVSQIVFYFNNSFLQSFGQFFVSVFYCFNLGEVRSAARKRWHRWQDHHSLRVVARAMS 394
 Db 353 DDLSQIVFYFNNSFLQSFGQFFVSVFYCFNLGEVRSAALKRWHRWQDHHALRVVARAMS 412
 QY 395 IPTSPTRISFHSIKOTAAV 413
 Db 413 IPTSPTRISFHSIKOTAAV 431

RESULT 15
 US-08-381-433A-2
 ; Sequence 2, Application US/08381433A
 ; Patent No. 5786203
 ; GENERAL INFORMATION:
 / APPLICANT: Lovenberg, Timothy W.
 / APPLICANT: Oltersdorf, Filman
 / APPLICANT: Liaw, Chen
 / APPLICANT: Grigoriadis, Dimitri E.
 / APPLICANT: DeSouza, Errol B.
 ; TITLE OF INVENTION: CORTICOTROPIN RELEASING FACTOR 2
 ; TITLE OF INVENTION: RECEPTORS
 ; NUMBER OF SEQUENCES: 8
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: SEED and BERRY
 ; STREET: 6300 Columbia Center, 701 Fifth Avenue
 ; CITY: Seattle
 ; STATE: Washington
 ; COUNTRY: USA
 ; ZIP: 98104-7092
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent In Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/381,433A
 ; FILING DATE: 31-JAN-1995
 ; CLASSIFICATION: 435
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: McMasters, David D.
 ; REGISTRATION NUMBER: 33,963

Query Match 79.8%; Score 1778.5; DB 1; Length 431;
 Best Local Similarity 85.2%; Pred. No. 2e-158;
 Matches 323; Conservative 24; Mismatches 29; Indels 3; Gaps 2;

QY 38 FEGP--YCSATIDQIGTCWPRSLAGELVERPCPDSSFNGIRNTTRNVYRECENGTWASW 95
 Db 53 FSGPPSYCNCNTLDQIGTCWPOSAPGALVERCPPEYFNGIKYNTTRNAYRECLENGTWASR 112
 QY 96 MNYSOCVPILDNK-RKYALHYKIALIINTLGHCISILALVIAFLFLCLRSIRCLRNIIH 154
 Db 113 INYSHCEPILDQDKQRKYDLHYRIALIINYLGHCVSVALVAAPLLFLVLRSIRCLRNVIH 172
 QY 155 WNLITTFILRNIMWFLLQMDHNTHESNEWNCRCITIINYFVVTNFFWMFVEGCCYLHTA 214
 Db 173 WNLITTFILRNITWFLLQLIDHEVHEGNEWNCRVTTIFNYFVVTNFFWMFVEGCCYLHTA 232
 QY 155 WNLITTFILRNIMWFLLQMDHNTHESNEWNCRCITIINYFVVTNFFWMFVEGCCYLHTA 214
 Db 173 WNLITTFILRNITWFLLQLIDHEVHEGNEWNCRVTTIFNYFVVTNFFWMFVEGCCYLHTA 232
 QY 215 IVMYSTDKLRKWVPLFIGWCIPSPIIYTWAICKLYENEQCWIGKEPGKYIDYIYQGRV 274
 Db 233 IVMYSTEHLRKWVPLFIGWCIPCPIIVAWVGKLYENEQCWIGKEPGKYIDYIYQGRV 292
 QY 275 ILLVLLINFVFLNIVRLMTKLRASTTSETIQRKAVKATLVLLPLLGITYMLFFVNPG 334
 Db 293 ILLVLLINFVFLNIVRLMTKLRASTTSETIQRKAVKATLVLLPLLGITYMLFFVNPG 352
 QY 335 DDVSQIVFYFNNSFLQSFGQFFVSVFYCFNLGEVRSAARKRWHRWQDHHSLRVVARAMS 394
 Db 353 DDLSQIVFYFNNSFLQSFGQFFVSVFYCFNLGEVRSAALKRWHRWQDHHALRVVARAMS 412
 QY 395 IPTSPTRISFHSIKOTAAV 413
 Db 413 IPTSPTRISFHSIKOTAAV 431

Search completed: August 20, 2005, 00:38:08
 Job time : 45 secs

GenCore version 5.1.6
(c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: August 20, 2005, 00:09:52 ; Search time 166 Seconds
962.241 Million cell updates/sec (without alignments)

Title: US-10-649-852-32
Perfect score: 2229
Sequence: 1 MDSTIFBIIIDEFDANCSSL.....SIPTSPTRISFHSIKQTAAV 413

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2105692 seqs, 386760381 residues

Total number of hits satisfying chosen parameters: 2105692

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_16Dec04:
1: geneseqp1990s:
2: geneseqp1990s:
3: geneseqp2000s:
4: geneseqp2001s:
5: geneseqp2002s:
6: geneseqp2003as:
7: geneseqp2003bs:
8: geneseqp2004s:
8:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB	ID	Description
1	2229	100.0	413	5	AAO19435		Aao19435 Xenopus C
2	2229	100.0	413	8	AD050813		Ado50813 Frog cort
3	1807	81.1	405	5	AAO19438		Aao19438 Fish cort
4	1807	81.1	405	8	AD050819		Ado50819 Brown bul
5	1804	80.9	411	2	AAW16481		Aaw16481 Human cor
6	1804	80.9	411	4	AAB71867		Aab71867 Human CRF
7	1804	80.9	411	7	ADC86183		Adc86183 Human GPC
8	1804	80.9	411	8	ADO29267		Ado29267 Human GPC
9	1799	80.7	411	2	AAR90576		Aar90576 Human CRF
10	1799	80.7	411	5	AAO19424		Aao19424 Human cor
11	1799	80.7	411	6	ABP81806		Abp81806 Human cor
12	1799	80.7	411	8	ADO50791		Ado50791 Human cor
13	1799	80.7	411	8	ADQ89168		Adq89168 Human uro
14	1793	80.4	411	2	ABU62363		Abu62363 Rat corti
15	1793	80.4	411	5	AAO19428		Aao19428 Rat corti
16	1793	80.4	411	8	AD050799		Ado50799 Rat corti
17	1790	80.3	411	2	AAR90574		Aar90574 Rat CRF2-
18	1787.5	80.2	397	5	AAO19426		Aao19426 Human cor
19	1787.5	80.2	397	8	AD050795		Ado50795 Human cor
20	1786	80.1	438	5	AAO19425		Aao19425 Human cor
21	1786	80.1	438	8	AD050793		Ado50793 Human cor
22	1784.5	80.1	431	2	ABU62364		Abu62364 Rat corti
23	1776.5	79.7	431	2	AAR90575		Aar90575 Rat CRF2-
24	1776.5	79.7	431	5	AAO19429		Aao19429 Rat corti
25	1776.5	79.7	431	8	AD050801		Ado50801 Rat corti

ALIGNMENTS

RESULT 1
ID AAO19435 standard; protein; 413 AA.
XX
AC AAO19435;
XX DT 10-DEC-2002 (first entry)
XX DE Xenopus corticotrophin releasing factor receptor CRF2R.
XX KW Human; rat; mouse; sheep; cow; chicken; CRF1R; CRF2R;
KW skeletal muscle atrophy; corticotrophin releasing factor-2 receptor;
KW muscular dystrophy; corticotrophin releasing factor-1 receptor;
KW gene therapy.

Xenopus laevis.

OS Xenopus laevis.
XX PN WO200269908-A2.
XX PD 12-SEP-2002.
XX XX PR 06-MAR-2002; 20002WO-US007476.
XX PR 06-MAR-2001; 2001US-00799978.

(PROC) PROCTER & GAMBLE CO.
XX PA
XX XX PI Isfort RJ, Sheldon RJ;
XX PD WPI; 2002-713413/77.
DR DR N-PSDB; AAL49986.
XX PT Identifying candidate compounds for regulating skeletal muscle mass or treating skeletal muscle atrophy by identifying test compounds that bind to, or activate, the corticotropin releasing factor-2 receptor.
XX XX PT Claim 7; Page 142-143; 167pp; English.
CC The present invention relates to a method of identifying candidate compounds for regulating skeletal muscle mass or function, and comprises contacting a test compound with a corticotropin releasing factor-2 receptor (CRF2R) or with a cell expressing a functional CRF2R, determining whether the test compound binds to, or activates, the CRF2R and identifying the test compounds that bind to, or activates, the CRF2R as candidate compounds for regulating skeletal muscle mass or function. The method is useful for preparing a medicament for treating skeletal muscle atrophy or for prophylactic treatment of muscular dystrophies. The present sequence is a corticotrophin releasing factor receptor.

XX SQ sequence 413 AA;
 Query Match 100.0%; Score 2229; DB 5; Length 413;
 Best Local Similarity 100.0%; Pred. No. 6.9e-217;
 Matches 413; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 MDSTIFFIIDEFDANCSLLDAFQDSFLHSESSSFFGEGPYCSATIDQIGTCWPRSLAG 60
 Db 1 MDSTIFFIIDEFDANCSLLDAFQDSFLHSESSSFFGEGPYCSATIDQIGTCWPRSLAG 60
 Qy 61 ELVERPCPDSFNGIRYNTTRNVYRECENGTwASWMMYSQCVPILDNKRYALHYKTLI 120
 Db 61 ELVERPCPDSFNGIRYNTTRNVYRECENGTwASWMMYSQCVPILDNKRYALHYKTLI 120
 Qy 121 INYLGHCISILALVIAFPLFLCLRSIRCLRNIIHWNLITTPILRNIMWFLQMIDHNIE 180
 Db 121 INYLGHCISILALVIAFPLFLCLRSIRCLRNIIHWNLITTPILRNIMWFLQMIDHNIE 180
 Qy 181 SNEVWCRCTTINYFVVTNFVMMFVEGCCYLHTAIWMTYSTDKLRKWVFLFIGWCIPSPI 240
 Db 181 SNEVWCRCTTINYFVVTNFVMMFVEGCCYLHTAIWMTYSTDKLRKWVFLFIGWCIPSPI 240
 Qy 241 IVTWAICKLFYNEQCWIGKEPGKYIDYYQGRVLVILLINFVLNIVRLMTKLRAST 300
 Db 241 IVTWAICKLFYNEQCWIGKEPGKYIDYYQGRVLVILLINFVLNIVRLMTKLRAST 300
 Qy 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDVSQIVFIYFNSFLQSFGFFFVSVF 360
 Db 301 TSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDVSQIVFIYFNSFLQSFGFFFVSVF 360
 Qy 361 YCFLNGEVRSAARKRWRWQDHHSLRVVRVARAMSIPSPTRISFHSIKQTAAV 413
 Db 361 YCFLNGEVRSAARKRWRWQDHHSLRVVRVARAMSIPSPTRISFHSIKQTAAV 413

RESULT 2
 ADO50813 ID ADO50813 Standard; protein: 413 AA.
 XX AC ADO50813;
 XX DT 12-AUG-2004 (First entry)

DE Frog corticotropin releasing factor receptor 2, CRF2R.
 XX Frog; receptor; corticotropin releasing factor receptor; CRF1R; CRF2R;
 KW Skeletal muscle; hypertrophy; surgery; skeletal muscle dystrophy;
 KW skeletal muscle; atrophy; broken bone; broken bone;
 KW infectious disease; AIDS; cachexia.
 XX OS Xenopus laevis.
 XX PN US2004101911-A1.
 XX PD 27-MAY-2004.
 XX PP 27-AUG-2003; 2003US-00649852.
 XX PR 06-MAR-2001; 2001US-00799978.
 XX PA (PROC) PROCTER & GAMBLE CO.
 XX PI Isfort RJ, Sheldon RJ;
 XX DR WPI; 2004-459890/43.
 DR N-PSDB; AD050812.

XX PT Identifying compounds for regulating skeletal muscle mass or function, by
 PT Contacting test compound with vertebrate corticotropin releasing factor 2
 PT receptors (CRF2R), selecting compounds that bind or activate CRF2R.
 XX PS Claim 3; SEQ ID NO 32; 100pp; English.
 XX DR 10-DEC-2002 (first entry)

RESULT 3
 AAO19438 ID AAO19438 standard; protein; 405 AA.
 XX AC AAO19438;
 XX DT 10-DEC-2002

XX Fish corticotrophin releasing factor receptor CRF2R.
 DE XX Human; rat; mouse; sheep; cow; chicken; CRF1R; CRF2R;
 KW skeletal muscle atrophy; corticotrophin releasing factor-2 receptor;
 KW muscular dystrophy; corticotrophin releasing factor-1 receptor;
 KW gene therapy.
 XX OS Ameiurus nebulosus.
 XX WO200269908-A2.
 PD XX 12-SEP-2002.
 XX PP 06-MAR-2002; 2002WO-US007476.
 XX PR 06-MAR-2001; 2001US-00799978.
 PA (PROC) PROCTER & GAMBLE CO.
 PI XX Isfort RJ, Sheldon RJ;
 XX DR WPI; 2002-713413/77.
 DR N-PSDB; AAL49989.
 PT XX Identifying candidate compounds for regulating skeletal muscle mass or
 PT treating skeletal muscle atrophy by identifying test compounds that bind
 PT to, or activate, the corticotropin releasing factor-2 receptor.
 PS XX Claim 7; Page 154-156; 167pp; English.
 XX The present invention relates to a method of identifying candidate
 CC compounds for regulating skeletal muscle mass or function, and comprises
 CC contacting a test compound with a corticotropin releasing factor-2
 CC receptor (CRF2R) or with a cell expressing a functional CRF2R,
 CC determining whether the test compound binds to, or activates, the CRF2R,
 CC and identifying the test compounds that bind to, or activates, the CRF2R
 CC as candidate compounds for regulating skeletal muscle mass or function.
 CC The method is useful for preparing a medicament for treating skeletal
 CC muscle atrophy or for prophylactic treatment of muscular dystrophies. The
 CC present sequence is a corticotrophin releasing factor receptor
 XX SQ Sequence 405 AA.
 Query Match 81.1%; Score 1807; DB 5; Length 405;
 Best Local Similarity 79.9%; Pred. No. 4e-174;
 Matches 330; Conservative 33; Mismatches 42; Indels 8; Gaps 2;
 QY 1 MDSTIFELIIDDEFDANCSLLDAFODSFLHSESSSSFFGFEQPYCSATIDQIGTCWPRSLAG 60
 DB 1 MEVSLLELL--SVEVNCSLADAFGDPAYGNASDAL-----YONATADEIGTCWPRSGAG 52
 QY 61 ELVERPCPDSENGIRYNTTRNYRECFCENGTWASWMNSQCVPILDNKRKYALHYKIALI 120
 DB 53 RVVARPCPDFINGVKYNSTRSAYRECLENGTWAFKINYSSCEPILEBKRYKPVHYKIALI 112
 QY 121 INYLGHCISILALVIAFLFLPLRSIRCLRNIIHWNLTITFLRNIMWFLQMIDHNIHE 180
 DB 113 INYLGHCISVGALVIAFVLFLPLRSIRCLRNIVHWNLTITFLRNIMWLLQLIDHNIHE 172
 QY 181 SNEVWCRCITIINYFVVTNFWMFVEGCYLHTAIUMTYSTDKLRKWVFLFIGWCIPSPI 240
 DB 173 RNEPWCRLLTYYNYFVVTNFFWMFVEGCYLHTAIUMTYSTDKLRKWVFLFIGWCIPCPV 232
 QY 241 IVTWAICKLFYNEQCWIGKEPGKYIDYYQGRVILVLLINFVFLENIVRLMTKLRAST 300
 DB 233 IIAWAVGKLNNEQCWFGEKGPKYVDYYQGPVIVVLLINFVFLENIVRLMTKLRAST 292
 QY 301 TSETIQYRKAVKATLVLLPLLGITYMLFVNPGEDVSQIVFYFNSFLQSFGFFVSVF 360
 DB 293 TSETIQYRKAVKATLVLLPLLGITYMLFVNPGDDDISQIVFYFNSFLQSFGFFVSVF 352
 QY 361 YCFLNGEVRSAAKRKRWHDHSLRVRVARAMSIPSPTRISFHSIKQTAAV 413

Db 353 YCFLNGEVRSAVRKWRQDNHALRVVARAMSIPSPTRISFHSIKHTTAV 405

RESULT 4
 ID AD050819
 ID AD050819 standard; protein; 405 AA.

XX AC AD050819;
 XX AC
 DE XX Brown bullhead catfish corticotropin releasing factor receptor 2, CRF2R.
 XX Brown bullhead catfish; receptor;
 KW corticotropin releasing factor receptor; CRF1R; CRF2R; skeletal muscle;
 KW muscle atrophy; skeletal muscle dystrophy; skeletal muscle hypertrophy;
 KW surgery; bed rest; broken bone; infectious disease; AIDS cachexia.
 XX OS Ameiurus nebulosus.
 XX PN US2004101911-A1.
 XX PD 27-MAY-2004.
 XX PP 27-AUG-2003; 2003US-00649852.
 XX PR 06-MAR-2001; 2001US-00799978.
 XX PA (PROC) PROCTER & GAMBLE CO.
 XX PI Isfort RJ, Sheldon RJ;
 XX DR WPI; 2004-459890/43.
 DR N-PSDB; AD050818.
 XX PT XX Identifying compounds for regulating skeletal muscle mass or function, by
 PT contacting test compound with vertebrate corticotropin releasing factor-2
 PT receptors (CRF2R), selecting compounds that bind or activate CRF2R.
 XX PS SEQ ID NO 38; 100pp; English.
 XX The invention relates to identifying candidate compounds for regulating
 CC skeletal muscle mass or function, comprising contacting a test compound
 CC with vertebrate corticotropin releasing factor-2 receptors (CRF 2 R),
 CC determining if the compound binds to or activates CRF2R, selecting
 CC compounds that bind or activate CRF 2 R, and determining if compound
 CC increases muscle mass or function in muscle atrophy model. Also included
 CC are identifying candidate therapeutic compounds from a group of one or
 CC more candidate compounds which have been previously determined to bind to
 CC or activate a vertebrate CRF 2 R (comprising administering the candidate
 CC compound to a non-human animal and determining whether the candidate
 CC compound regulates skeletal muscle mass or function in the treated
 CC animal), increasing skeletal muscle mass or function in a subject in
 CC which such an increase is desirable (comprising identifying a subject in
 CC which an increase in muscle mass or function is desirable and
 CC administering to the subject a safe and effective amount of a CRF 2 R
 CC agonist), a purified antibody specific for a CRF2R (where the antibody is
 CC a chimaeric or human antibody), and a pharmaceutical composition
 CC comprising a safe and effective amount of a CRF2R agonist and carrier.
 CC The methods are useful for identifying candidate compounds for regulating
 CC skeletal muscle mass or function, for increasing skeletal muscle mass or
 CC function (in a subject in which an increase is desirable), for
 CC identifying candidate compounds that are potentially useful in the
 CC treatment of skeletal muscle dystrophy and for identifying compounds that
 CC prolong or augment the agonist-induced activation of CRF2R or of a CRF2R
 CC signal transduction pathway. The compound is useful for treating skeletal
 CC muscle hypertrophy and for modulating skeletal muscle atrophy induced by
 CC e.g. surgery, bed rest, broken bones, infectious disease or AIDS
 CC cachexia. The present sequence represents a corticotropin releasing
 CC factor receptor.
 XX SQ Sequence 405 AA;

(CRF2) receptor protein, which can be used to screen for an agonist or antagonist which activates the receptor, or competitively inhibits the binding of the receptor to CRF. The agonist can be used to prevent or treat dementia and obesity, or accelerate stress adaptation. The antagonist can be used to prevent or treat melancholia, anxiety, stress headaches, AIDS, Alzheimer's disease or gastrointestinal disorders.

Query Match Score 1807; DB 8; Length 405;
 Best Local Similarity 79.9%; Pred. No. 4e-174;
 Matches 330; Conservative 33; Mismatches 42; Indels 8; Gaps 2;

Qy 1 MDSTIPEIIIDEFDANCSLLDAFQDSFLHSESSSSFFGPEGPYCSATIDQIGTCWPRSLAG 60
 Db 1 MEVSLLELL--SVEVNCSLADAFGDPAYGNASDAL-----YCNATADEIGTCWPRSGAG 52

Query Match Score 1804; DB 2; Length 411;
 Best Local Similarity 80.0%; Pred. No. 8.3e-174;
 Matches 333; Conservative 33; Mismatches 42; Indels 8; Gaps 4;

Qy 1 MDSTIPEIIIDEFDANCSLLDAFQDSFLHSESSSSFFGPEGP--YCSATIDQIGTCWPRSL 58
 Db 1 MDAALLHSLL---EANCSL- -ALAEEELLGDGWGPPLDPEGPSYCNCNTLDDQIGTCWPRSA 55

Qy 121 INYLGHCISILALVIAFLLFCLRSIRCLRNTHWNLLITTFILRNIMWFLLOMIDHNIHE 180
 Db 113 INYLGHCISVGALVIAFLFLCLRSIRCLRNVIHWNLITTFILRNIMWLLQLIDHNIHE 172

Qy 181 SNEVWCRCTTIIYNFVVNTNFWMFVEGCCYLHTAIVMTYSTDKLRKWVFLFIGWCIPSPI 240
 Db 173 RNEPWCRLLTTVNVYFVVTNFWMFVEGCCYLHTAIVMTYSTDKLRKWVFLFIGWCIPCPV 232

Qy 241 IWTWAICKLFYENEQCwigKEPGKYIDYYQGRVILVLLINVFELNIVRILMTKLRAST 300
 Db 233 IIAWAVGKLYNNEQCWFGKEPGKYVDYIYQGPVIVVLLINVFPLNIVRILMTKLRAST 292

Qy 301 TSETIQYRKAVKATLVLPPLGGITYMLFFVNPGEDDVSQIVFIYFNNSFLQSFGGFFVSYF 360
 Db 293 TSETIQYRKAVKATLVLPPLGGITYMLFFVNPGEDDISQIVFIYFNNSFLQSFGGFFVSYF 352

Qy 361 YCFLNGEVRSAARKRWHRWQDHSLRVRVARAMSINTSPTRISFHSIKOTAAV 413
 Db 353 YCFLNGEVRSAVRKRWHRWQDNNHALRVRVARMSINTSPTRISFHSIKHTTAAV 405

RESULT 5
 AAW16481 ID AAW16481 standard; protein; 411 AA.
 AC AAW16481;
 XX DT 20-JUN-1997 (First entry)

DE Human corticotrophin releasing factor 2 receptor protein.

XX Human; corticotrophin: corticotropin; releasing factor 2: CRF2; receptor; screen; agonist; antagonist; activation; inhibition; prevention; treatment; dementia; obesity; acceleration; stress adaptation; melancholia; anxiety; stress headache; AIDS; acquired immunodeficiency syndrome; Alzheimer's disease; gastrointestinal disorder.

XX Homo sapiens.

XX JP09070289-A.
 XX PD 18-MAR-1997.
 XX PF 14-SEP-1995; 95JP-00237081.
 XX PR 27-JUN-1995; 95JP-00161213.
 XX PA (TAKE) TAKEDA CHEM IND LTD.

XX WPI: 1997-230023/21.
 DR DR N-PSDB; AAT66508.

XX PCR primer for G protein conjugate type receptor protein DNA - and human corticotrophin releasing factor 2 receptor protein, useful to screen for agonists and antagonists to treat dementia and anxiety.

XX *PS Claim 8; Page 39-40; 46pp; Japanese.

CC The present sequence is the human corticotrophin releasing factor 2 sequence.

CC (CRF2) receptor protein, which can be used to screen for an agonist or antagonist which activates the receptor, or competitively inhibits the binding of the receptor to CRF. The agonist can be used to prevent or treat dementia and obesity, or accelerate stress adaptation. The antagonist can be used to prevent or treat melancholia, anxiety, stress headaches, AIDS, Alzheimer's disease or gastrointestinal disorders.

Query Match Score 1804; DB 2; Length 411;
 Best Local Similarity 80.0%; Pred. No. 8.3e-174;
 Matches 333; Conservative 33; Mismatches 42; Indels 8; Gaps 4;

Qy 1 MDSTIPEIIIDEFDANCSLLDAFQDSFLHSESSSSFFGPEGP--YCSATIDQIGTCWPRSL 58
 Db 1 MDAALLHSLL---EANCSL- -ALAEEELLGDGWGPPLDPEGPSYCNCNTLDDQIGTCWPRSA 55

Qy 59 AGELVERPCPDSSFNGIIRYNTTRNVTRECFCENGTVASWMMNYSQCVPILDNK-RKYALHYKI 117
 Db 56 AGALVERPCPEYFNGVKYNTTRNAYRECLENGTWASKINYSQCEPILDDQKRYDLHYRI 115

Qy 118 ALIINYLGHCISILALVIAFLFLFLCLRSIRCLRNTHWNLLITTFILRNIMWFLLOMIDHNIHE 177
 Db 116 ALVNVNLGHCVSAALVAFAFLFLPLALARSLIRCLRNVIHWNLITTFILRNIMWFLQLVDHE 175

Qy 178 IHESENWWRCCITTTIINYFVVNTNFWMFVEGCCYLHTAIVMTYSTDKLRKWVFLFIGWCIP 237
 Db 176 VHESENWWRCCITTTIINYFVVNTNFWMFVEGCCYLHTAIVMTYSTERLKRKCLFLFIGWCIP 235

Qy 238 SPIIIVTWAICKLFYENEQCwigKEPGKYIDYYQGRVILVLLINVFELNIVRILMTKLRAST 297
 Db 236 FPIIIVAWAIGKLYYENEQCWFGKEPGDVLVDDYIYQGPILVLLINVFELNIVRILMTKLRAST 295

Qy 298 ASTTSETIQYRKAVKATLVLPPLGGITYMLFFVNPGEEDVSQIVFIYFNNSFLQSFGGFFV 357
 Db 296 ASTTSETIQYRKAVKATLVLPPLGGITYMLFFVNPGEEDDSQIMFIYFNNSFLQSFGGFFV 355

Qy 358 SVFYCFLNGEVRSAARKRWHRWQDHSLRVRVARAMSINTSPTRISFHSIKOTAAV 413
 Db 356 SVFYCFFNGEVRSAVRKRWHRWQDNNHALRVRVARMSINTSPTRISFHSIKOTAAV 411

RESULT 6
 AAB71867 ID AAB71867 standard; protein; 411 AA.
 AC AAB71867;
 XX DT 03-MAY-2001 (First entry)

DE Human CRF2 seven transmembrane domain.

XX Human; CRF2; corticotropin releasing factor receptor 2; h15571;
 KW immunomodulatory; vascular; hepatic; antiasthma; anitmicrobial;
 KW antiinflammatory; immunosuppressive; gene therapy; vaccine;
 KW G-protein coupled receptor; GPCR; liver fibrosis; respiratory disorder;
 KW infection; chronic inflammatory disease; organ-specific autoimmunity;
 KW graft rejection; cystic fibrosis.

XX OS Homo sapiens.

XX PN WO200109328-A1.
 XX PD 08-FEB-2001.

XX PP 03-AUG-2000; 2000WO-US021278.

XX PR 03-AUG-1999; 99US-0146916P.
 PR 29-FEB-2000; 2000US-00515781.

XX PA (MILL-) MILLENNIUM PHARM INC.

XX PI Hodge MR, Lloyd C, Weich NS;

CC invention. Note: The full sequence data for this patent did not form part
 CC of the printed specification; those sequences not shown were obtained in
 CC electronic format directly from WIPO at
 CC ftp://wipo.int/pub/published_pct_sequences.

XX SQ Sequence 411 AA;

	Query	Match	Score 1804;	DB 8;	Length 411;
	Best Local Similarity	80.0%;	Pred. No. 8	3e-174;	
	Matches	33;	Mismatches	42;	Indels 8; Gaps 4;
QY	1 MDSTIFELIIDFEDANCSLLDAFQDSFLHSESSSFEGFP--YCSATIDQIGTCWPRLS 58				
Db	1 MDAALLHSLL---EANCSL--ALAEELLGDGWGPPLDPEGPSYCNTTLDQIGTCWPRLS 55				
QY	59 AGELVERPCPDSENGIYNTNTVYRECFCNGTWASWMNSQCVPILDNK-RKYALHYKI 117				
Db	56 AGALVERPCPEYFNGVKYNTTRNAYRECLENGTWASKINYSQCEPILLDDKQRKYDLHYRI 115				
QY	118 ALIINYLGHCISILALVIAFLFLCLRSIRCLRNIIHMNLITTFILRNIMWFLQLMIDHN 177				
Db	116 ALIVVNLYLGCVSAALVAFLLEALRSIRCLRNIVHWNLTTFILRNIMWFLQLVDHE 175				
QY	178 IHSNEWCRCCITTINYYFVVTNFFMMFVEGYCYLHTAIUMTYSTDKLRKWVFLFIGWCIP 237				
Db	176 VHSNEWCRCCITTINYYFVVTNFFMMFVEGYCYLHTAIVMTYSTERLKCLFLFIGWCIP 235				
QY	238 SPIIVTWAIICKLFYENEQCWIGKEPKYIDYIYQGRVILVLLINFVFLFNIVRILMTKLR 297				
Db	236 FPIIVAWAIGKLYYENEQCWFGKEPGDLDVYIYQGPILVLLINFVFLFNIVRILMTKLR 295				
QY	298 ASTTSETIQYRKAVKATLVLLPLLGITYMLFVNPGEDVSQIVFIYFNSFLQSFGQFFFV 357				
Db	296 ASTTSETIQYRKAVKATLVLLPLLGITYMLFVNPGEDLSQIMFYFNSFLQSFGQFFFV 355				
QY	358 SVFYCFLNGEVRSAARKRWHRWQDHSHSLRVVARAMSIPSPTRISFHSIKQTAAV 413				
Db	356 SVFYCFFENGEVRSAVRKRWQDHSHSLRVPMARAMSIPSPTRISFHSIKQTAAV 411				

RESULT 9
 AAR90576

ID AAR90576 standard; protein; 411 AA.

XX AC AAR90576;

XX DT 08-APR-1996 (first entry)

XX DE Human CRF2 receptor.

XX KW CRF2 receptor; corticotropin-releasing factor-2 receptor; cerebrovascular disorder; memory disorder; Alzheimer disease.

XX OS Homo sapiens.

XX PD 21-DEC-1995.

XX PN WO9534651-A2.

XX PR 14-JUN-1995; 95WO-US007757.

XX PR 14-JUN-1995; 94US-00259959.

XX PR 31-JAN-1995; 95US-00381433.

XX PR 07-JUN-1995; 95US-00485984.

XX PA (NEUR-) NEUROCRINE BIOSCIENCES INC.

XX PI Chalmers D, Lovenberg TW, Oltersdorf T, Liaw CW, Grigoriadis DE;

XX PI De Souza EB;

XX DR WPI; 1996-049680/05.

XX DR N-PSDB; AAT12247.

XX DR

XX PS Claim 151; SEQ ID NO 368; 542pp; English.

XX The invention relates to human and mouse G protein-coupled receptors (GPCRs) and nucleic acids encoding them. The invention also relates to sequences at least 90% identical to the GPCR proteins and nucleic acids of the invention; methods of treating, preventing or diagnosing diseases associated with GPCRs of the invention; methods of screening for compounds useful in the treatment of GPCR-related diseases; a transgenic mouse comprising a GPCR gene of the invention; a mouse comprising a mutation in a GPCR transgene or in an endogenous GPCR gene; cells derived from the transgenic mice; kits comprising several mice, each of which has a mutation in a different GPCR gene of the invention; and kits comprising probes which hybridise to GPCR polynucleotides of the invention. The invention further discloses variants of the GPCR polypeptides and vectors comprising a GPCR nucleic acid. The GPCR nucleic acids and proteins may be used in the diagnosis, treatment or prevention of a wide variety of diseases including neurological disorders (e.g., Alzheimer's disease, depression, diabetic neuropathy, Parkinson's disease or schizophrenia); disorders of the adrenal gland; disorders of the colon or intestine (e.g., Crohn's disease, diarrhoea, food poisoning or irritable bowel syndrome); cardiovascular disorders (e.g., angina, cardiac arrhythmia or myocardial infarction); muscular disorders; blood disorders (e.g., anaemia or leukaemia); immune disorders (e.g., autoimmune disorders or AIDS); bone and joint disorders (e.g., osteoarthritis, rheumatoid arthritis, gout or osteoporosis); metabolic or nutritive disorders (e.g., obesity, enzyme deficiency-related diseases or vitamin deficiency-related diseases); and disorders of the kidney, liver, lung, breast, ovary, uterus, prostate, testis, skin, stomach, pancreas, spleen, thymus and thyroid (e.g., cancers). The present sequence represents a GPCR of the

PT Corticotropin-releasing factor-2 receptor, and DNA encoding it - used to
 PT isolate CRF-2 receptor antagonists for the treatment of cerebrovascular
 PT disorders, memory disorders and Alzheimer's disease.
 XX Disclosure; Page 80-82; 109pp; English.

XX (PROC) PROCTER & GAMBLE CO.
 XX PA
 XX PI Isfort RJ, Sheldon RJ;
 XX DR WPI; 2002-713413/77.
 N-PSDB; AAL49975.

CC Human corticotropin-releasing factor-2 (CRF2) receptor (AAR90576) is a
 CC membrane-bound G-coupled protein receptor involved in signal
 CC transduction. It can be produced by expression of encoding cDNA
 CC (AAT12247) in prokaryotic or eucaryotic host cells. Recombinant CRF2R
 CC receptor is used to screen CRF2 receptor agonists and antagonists of
 CC therapeutic appln., and to prepare antibodies which specifically bind to
 CC CRF2 receptors.

SQ Sequence 411 AA;

Query Match	80.7%;	Score 1799;	DB 2;	Length 411;
Best Local Similarity	79.8%;	Pred. No. 2.7e-173;		
Matches	332;	Mismatches	43;	Indels 8; Gaps 4;
Qy	1 MDSTIFEEIIIDEPDANCSLLDAFQDSFLHSESSSSFFGEGP--YCSATIDQIGTCWPRLS 58			
Db	1 MDAALLHSLL--EANCSL--ALAEELLLDGWGPPLDPEGPSYCNTTLQDQIGTCWPRLS 55			
Qy	59 AGELVERPCPDSPNGIRYNTTRNRYRECENGTWASWMMNYSOCPVILDDNK-RKYALHYKI 117			
Db	56 AGALVERPCPEYFNGVKNTTRNAYRECLENGTWASKINYSQECPILDDKQRKYDLHYRI 115			
Qy	118 ALIINYLGHCISIALVIAFLFLCLRSIRCLRNTIHWNLITTFILRNIMWFLQMDHN 177			
Db	116 ALVNNYLGHCVSAALVAFLFLALARNSIRCLRNVHLWNLITTFILRNIMWFLQLVDHE 175			
Qy	178 IHESENEWWCRCITIINYFVVTNFFWMFVEGCYLHTAIWMTYSTDKLRKWVFLFIGWCIP 237			
Db	176 VHESENEWWCRCITIINYFVVTNFFWMFVEGCYLHTAIWMTYSTERLRKCLFLFIGWCIP 235			
Qy	238 SPIIVTWAICKLFYENEQCWIGKEPGKYIDYYQGRVLVILLINFLNIVRLMTKLR 297			
Db	236 FPIIVAWAIGKLYYENEQCWIGKEPGDLYDYYQGPILVILLINFLNIVRLMTKLR 295			
Qy	298 ASTTSETIQYRKAVAKATLVLLPLLGITYMLFFVNPGEDDSQIVFIFYNSFLQSFGFFV 357			
Db	296 ASTTSETIQYRKAVAKATLVLLPLLGITYMLFFVNPGEDDLSQIMFIYFNStLQSFGFFV 355			
Qy	358 SVFYCFNLGEVRSAARKRWHRWODHHSLRVARAMSIPTSPTRISFHSIKQTAAV 413			
Db	356 SVFYCFNLGEVRSAVRKRWHRWODHHSLRVPMARAMSIPTSPTRISFHSIKQTAAV 411			
RESULT 10				
ID AAO19424	standard; protein; 411 AA.			
XX AC AAO19424;				
XX DT 10-DEC-2002 (first entry)				
XX DE Human corticotropin releasing factor receptor CRF2Ralpha.				
XX KW Human; rat; mouse; sheep; cow; chicken; CRF1R; CRF2R;				RESULT 11
KW skeletal muscle atrophy; corticotropin releasing factor-2 receptor;				ABP81806
KW muscular dystrophy; corticotropin releasing factor-1 receptor;				ID ABP81806 standard; protein; 411 AA.
KW gene therapy.				XX AC ABP81806;
XX OS Homo sapiens.				XX DT 04-MAR-2003 (first entry)
XX PN WO200269908-A2.				XX DE Human corticotropin releasing factor receptor 2 protein SEQ ID NO:96.
XX PD 12-SEP-2002.				XX KW G protein-coupled receptor; GPCR; antigenic peptide; Gene therapy;
XX PF 06-MAR-2002; 2002WO-US007476.				KW G protein-coupled receptor modulator; antibody; immune-related disease;
XX PR 06-MAR-2001; 2001US-00799978.				KW growth-related disease; cell regeneration-related disease; AIDS; cancer;

QY	immunological-related cell proliferative disease; autoimmune disease; Alzheimer's disease; atherosclerosis; infection; osteoarthritis; allergy; osteoporosis; cardiomopathy; inflammation; Crohn's disease; diabetes; graft versus host disease; Parkinson's disease; multiple sclerosis; pain; psoriasis; anxiety; depression; schizophrenia; dementia; memory loss; mental retardation; epilepsy; asthma; tuberculosis; obesity; nausea; hypertension; hypotension; renal disorder; rheumatoid arthritis; trauma; ulcer.
QY	Homo sapiens.
QY	WO200261087-A2.
QY	08-AUG-2002.
XX	19-DEC-2001; 2001WO-US050107.
XX	19-DEC-2000; 2000US-0257144P.
PA	(LIFE-) LIFESPAN BIOSCIENCES INC.
PI	Burmer GC, Roush CL, Brown JP;
XX	WPI; 2003-046718/04.
DR	N-PSDB; ABZ42652.
PT	New isolated antigenic peptides e.g., for G protein-coupled receptors (GPCR), useful for diagnosing and designing drugs for treating conditions in which GPCRs are involved, e.g. AIDS, Alzheimer's disease, cancer or autoimmune diseases.
PT	Disclosure; Fig 1; 523pp; English.
CC	The present invention describes antigenic peptides (I) comprising: (a) any one of 1601 sequences (see ABP82019 to ABP83619) of 12-24 amino acids. Also described: (1) an assay for the detection of a particular G protein-coupled receptor (GPCR) or a candidate polypeptide in a sample; and (2) an isolated antibody having high specificity and high affinity or avidity for a particular GPCR. (I) can be used as GPCR modulators and in gene therapy. The antigenic peptides for GPCRs are useful in detecting an antibody against a particular GPCR, and in the production of specific antibodies. The peptides and antibodies are also useful for detecting the presence or absence of corresponding GPCRs. The antigenic peptides for GPCRs and antibodies are useful for diagnosing and designing drugs for treating immune-related diseases, growth-related diseases, cell regeneration-related disease, immunological-related cell proliferative diseases, or autoimmune diseases, e.g. AIDS, Alzheimer's disease, atherosclerosis, bacterial, fungal, protozoan or viral infections, osteoarthritis, osteoporosis, cancer, cardiomyopathy, chronic and acute inflammation, allergies, Crohn's disease, diabetes, graft versus host disease, Parkinson's disease, multiple sclerosis, pain, psoriasis, anxiety, depression, schizophrenia, dementia, mental retardation, memory loss, epilepsy, asthma, tuberculosis, obesity, nausea, hypertension, hypotension, renal disorders, rheumatoid arthritis, trauma, ulcers, or any other disorder in which GPCRs are involved. The antibodies may be used in immunoassays and immunodiagnosis. ABZ42523 to ABZ42869 encode GPCR proteins given in ABP81675 to ABP82018, which are used in the exemplification of the present invention
PS	Sequence 411 AA;
Query Match	80.7%; Score 1799; DB 6; Length 411;
Best Local Similarity	79.8%; Pred. No. 2.7e-173;
Matches	332; Conservative 43; Mismatches 43; Indels 8; Gaps 4;
QY	1 MDSTIFELIIDEFDANCSLLDAFQDSFLHSESSSSFFGFFEGP--YCSATIDQIGTCWPRSL 58 1 MDAALLHSLL--EANCSL--ALAEELLIDGWGPPLDPEGPYSYCNTTLDQIGTCWPRSA 55
QY	59 AGELVERPCPDSDFNGIRYNTTRNVYRECENGTWASWMNYSOCVPILDNK-RKYALHYKI 117 1 AGALVERPCPEYFNGKVNTTRNAYRECLENGTWASKINYSQCEPILDQDKQRKYDLHYRI 115
Db	178 THESENWCRCITIINYFVVTNFFWMFVEGGYLHTAIWMTYSTDKLRLKWWFLFIGWCIP 237 176 VHESENWCCHCITTIFNYFVVTNFFWMFVEGGYLHTAIWMTYSTERLRKCLFLFIGWCIP 235
QY	238 SPIIVTWAICKLYENEQCWIGKEPGKYIDYIYQGRVLVILLINFVFLNIVRILMTKL 297 236 FPIIVAWAIGKLYENEQCWIGKEPGDVLVDYIYQGPIILVLLINFVFLNIVRILMTKL 295
QY	298 ASTTSETIQYRKAVKATLVILLPLLGITYMLFFVNPGEDDVQSIVFIYFNNSFLQSFGQFFV 357 296 ASTTSETIQYRKAVKATLVILLPLLGITYMLFFVNPGEDDLSQIMFIYFNNSFLQSFGQFFV 355
QY	358 SVFYCFNLGEVRSAARKRWRWQDHISLRLRVRAAMSIFTSPTRISFHSIKQTAAV 413 356 SVFYCFNNGEVRSAVRKWRWQDHISLRLVPMARAMSIFTSPTRISFHSIKQTAAV 411
Db	RESULT 12 ADO50791 ID ADO50791 standard; protein; 411 AA. XX AC ADO50791; XX DT 12-AUG-2004 (first entry) XX Human corticotropin releasing factor receptor 2 alpha. XX KW Human; receptor; corticotropin releasing factor receptor; CRF1R; CRF2R; KW skeletal muscle; muscle atrophy; skeletal muscle dystrophy; KW skeletal muscle hypertrophy; surgery; bed rest; broken bone; KW infectious disease; AIDS cachexia. XX DE Homo sapiens. XX OS US2004101911-A1. XX PN US2004101911-A1. XX PD 27-MAY-2004. XX PR 27-AUG-2003; 2003US-00649852. XX PR 06-MAR-2001; 2001US-00799978. XX PA (PROC) PROCTER & GAMBLE CO. XX PI Isfort RJ, Sheldon RJ; XX DR WPI; 2004-459890/43. XX DR N-PSDB; ADO50790. XX PT Identifying compounds for regulating skeletal muscle mass or function, by contacting test compound with vertebrate corticotropin releasing factor 2 receptors (CRF2R), selecting compounds that bind or activate CRF2R. XX PS Claim 3; SEQ ID NO 10; 100pp; English. XX CC The invention relates to identifying candidate compounds for regulating skeletal muscle mass or function, comprising contacting a test compound with vertebrate corticotropin releasing factor 2 receptors (CRF 2 R), determining if the compound binds to or activates CRF2R, selecting compounds that bind or activate CRF 2 R, and determining if compound increases muscle mass or function in muscle atrophy model. Also included are identifying candidate therapeutic compounds from a group of one or more candidate compounds which have been previously determined to bind to or activate a vertebrate CRF 2 R (comprising administering the candidate compound to a non-human animal and determining whether the candidate compound regulates skeletal muscle mass or function in the treated animal), increasing skeletal muscle mass or function in a subject in which such an increase is desirable (comprising identifying a subject in which an increase in muscle mass or function is desirable and

CC administering to the subject a safe and effective amount of a CRF 2 R
 CC agonist), a purified antibody specific for a CRF2R (where the antibody is
 CC a chimaeric or human antibody), and a pharmaceutical composition
 CC comprising a safe and effective amount of a CRF2R agonist and carrier.
 CC The methods are useful for identifying candidate compounds for regulating
 CC skeletal muscle mass or function, for increasing skeletal muscle mass or
 CC function (in a subject in which an increase is desirable), for
 CC identifying candidate compounds that are potentially useful in the
 CC treatment of skeletal muscle dystrophy and for identifying compounds that
 CC prolong or augment the agonist-induced activation of CRF2R or of a CRF2R
 CC signal transduction pathway. The compound is useful for treating skeletal
 CC muscle hypertrophy and for modulating skeletal muscle atrophy induced by
 CC e.g. surgery, bed rest, broken bones, infectious disease or AIDS
 CC cachexia. The present sequence represents a corticotropin releasing
 CC factor receptor.

XX Sequence 411 AA;

Query Match 80.7%; Score 1799; DB 8; Length 411;
 Best Local Similarity 79.8%; Pred. No. 2.7e-173;
 Matches 332; Conservative 33; Mismatches 43; Indels 8; Gaps 4;

Qy 1 MDSTIPEIIIDEFDANCSLLDAFQDSFLHSESSSSFFGFEGP--YCSATIDQIGTCWPRSL 58
 Db 1 MDAALLHSLL---EANCSL--ALAEELLGDGWPPUDPEGPSYCNTTLDDQIGTCWPRSA 55
 Qy 59 AGELVERPCPDSENGIRNTTRNVRRECENGTWASWNNYSQCVPILDNNK-RKYALHYKI 117
 Db 56 AGALVERPCPEYFGVKYNTTRNAYRECLENGTWASKINYSQCEPILDKQRKYDLHYRI 115
 Qy 118 ALIINYLGHCISILALVIAFLJFLCLRSIRCLRNIIHWNLITTFILLNIMWFLQLQMDHN 177
 Db 116 ALVVNVYLGHCVSVAALVAAFILFLAFLSIRCLRNIVHWNLITTFILRNWFLQLVDHE 175
 Qy 178 IHESNEVWCRCTTITIINYFVVTNFWMFVEGCYLHTAIIVMTYSTDKLRKWFVFLFIGWCIP 237
 Db 176 VHESNEVWCHCITTFINYFVVTNFWMFVEGCYLHTAIIVMTYSTERLRKCLFLFIGWCIP 235
 Qy 238 SPIIIVTWAICKLXPFYENEQCWIIGKEPKYIDYIYQGRVILVLLINFVFLNIVRLMTKL'R 297
 Db 236 FPIIIVAWAIGKLYENEQCWEGKEPGDVLVDIYQGPILVLLINFVFLNIVRLMTKL'R 295
 Qy 298 ASTTSETIQYRKAVAKATLVLLPLLGITYMLFFVNPGEDDVQSIVFIFYFNFSFLOSFGFFV 357
 Db 296 ASTTSETIQYRKAVAKATLVLLPLLGITYMLFFVNPGEDDLSQIMFIYFNFSFLOSFGFFV 355
 Qy 358 SVFYCFNLGEVRSAAARKRWRWQDHSLRVARAMSIPTSPTRISFHSIKOTAAV 413
 Db 356 SVFYCFNLGEVRSAAVRKRWRWQDHSLRVPMARAMSIPSTSPTRISFHSIKOTAAV 411

RESULT 13
 ID ADQ89168 standard; protein; 411 AA.
 XX ADQ89168;
 XX DT 21-OCT-2004 (first entry)
 DE Human urological disorder related protein 2543 SEQ:120.
 XX KW urological disorder; uropathic; cyostatic; urinary incontinence;
 KW benign prostatic hyperplasia; human.
 XX OS Homo sapiens.
 XX PN WO2004065576-A2.
 XX PD 05-AUG-2004.
 XX PF 14-JAN-2004; 2004WO-US000750.
 XX PR 15-JAN-2003; 2003US-0440318P.

PR 04-FEB-2003; 2003US-0444783P.
 PR 27-MAR-2003; 2003US-0457901P.
 PR 08-MAY-2003; 2003US-0468775P.
 PR 19-MAY-2003; 2003US-0471614P.
 PR 16-JUN-2003; 2003US-0478742P.
 PR 18-JUL-2003; 2003US-0488529P.
 PR 30-JUL-2003; 2003US-0491156P.
 PR 02-SEP-2003; 2003US-049594P.
 PR 26-SEP-2003; 2003US-0506332P.
 XX PA (MILL-) MILLENNIUM PHARM INC.
 XX PI Karicheti V, Silos-Santiago I, Eliasof SD;
 XX WPI; 2004-562167/54.
 XX DR N-PSDB; ADQ89167.

XX PS Sequence 411 AA;
 XX PT Use of polypeptides related to urological disorders, e.g. 44390, 54181.
 PT PT 211 or for identifying a compound capable of treating a urological
 PT disorder or identifying and treating a subject having a urological
 PT disorder.

XX PS Claim 1; SEQ ID NO 120; 542PP; English.

CC The present invention describes the use of polypeptides related to
 CC urological disorders for identifying a compound capable of treating a
 CC urological disorder, identifying a subject having a urological disorder,
 CC or treating a subject having a urological disorder. Also described: (1) a
 CC method for identifying a compound capable of treating a urological
 CC disorder; (2) a method for identifying a subject having a urological
 CC disorder; and (3) a method for treating a subject having a urological
 CC disorder. The compound has uropathic and cyostatic activities. The
 CC polypeptides related to urological disorders are useful for identifying a
 CC compound capable of treating a urological disorder, identifying a subject
 CC having a urological disorder, or treating a subject having a urological
 CC disorder. Disorders include urinary incontinence and benign prostatic
 CC hyperplasia. The present sequence represents a human urological disorder
 CC related protein, which is used in the exemplification of the present
 CC invention.

XX SQ Sequence 411 AA;

Query Match 80.7%; Score 1799; DB 8; Length 411;
 Best Local Similarity 79.8%; Pred. No. 2.7e-173;
 Matches 332; Conservative 33; Mismatches 43; Indels 8; Gaps 4;

Qy 1 MDSTIPEIIIDEFDANCSLLDAFQDSFLHSESSSSFFGFEGP--YCSATIDQIGTCWPRSL 58
 Db 1 MDAALLHSLL---EANCSL--ALAEELLGDGWPPUDPEGPSYCNTTLDDQIGTCWPRSA 55
 Qy 59 AGELVERPCPDSENGIRNTTRNVRRECENGTWASWNNYSQCVPILDNNK-RKYALHYKI 117
 Db 56 AGALVERPCPEYFGVKYNTTRNAYRECLENGTWASKINYSQCEPILDKQRKYDLHYRI 115
 Qy 118 ALIINYLGHCISILALVIAFLJFLCLRSIRCLRNIIHWNLITTFILLNIMWFLQLQMDHN 177
 Db 116 ALVVNVYLGHCVSVAALVAAFILFLAFLSIRCLRNIVHWNLITTFILRNWFLQLVDHE 175
 Qy 178 IHESNEVWCRCTTITIINYFVVTNFWMFVEGCYLHTAIIVMTYSTDKLRKWFVFLFIGWCIP 237
 Db 176 VHESNEVWCHCITTFINYFVVTNFWMFVEGCYLHTAIIVMTYSTERLRKCLFLFIGWCIP 235
 Qy 238 SPIIIVTWAICKLXPFYENEQCWIIGKEPKYIDYIYQGRVILVLLINFVFLNIVRLMTKL'R 297
 Db 236 FPIIIVAWAIGKLYENEQCWEGKEPGDVLVDIYQGPILVLLINFVFLNIVRLMTKL'R 295
 Qy 298 ASTTSETIQYRKAVAKATLVLLPLLGITYMLFFVNPGEDDVQSIVFIFYFNFSFLOSFGFFV 357
 Db 296 ASTTSETIQYRKAVAKATLVLLPLLGITYMLFFVNPGEDDLSQIMFIYFNFSFLOSFGFFV 355
 Qy 358 SVFYCFNLGEVRSAAARKRWRWQDHSLRVARAMSIPTSPTRISFHSIKOTAAV 413
 Db 356 SVFYCFNLGEVRSAAVRKRWRWQDHSLRVPMARAMSIPSTSPTRISFHSIKOTAAV 411

Qy 118 ALIINYLGHCISILALVIAFLJFLCLRSIRCLRNIIHWNLITTFILLNIMWFLQLQMDHN 177
 Db 116 ALVVNVYLGHCVSVAALVAAFILFLAFLSIRCLRNIVHWNLITTFILRNWFLQLVDHE 175
 Qy 178 IHESNEVWCRCTTITIINYFVVTNFWMFVEGCYLHTAIIVMTYSTDKLRKWFVFLFIGWCIP 237
 Db 176 VHESNEVWCHCITTFINYFVVTNFWMFVEGCYLHTAIIVMTYSTERLRKCLFLFIGWCIP 235
 Qy 238 SPIIIVTWAICKLXPFYENEQCWIIGKEPKYIDYIYQGRVILVLLINFVFLNIVRLMTKL'R 297
 Db 236 FPIIIVAWAIGKLYENEQCWEGKEPGDVLVDIYQGPILVLLINFVFLNIVRLMTKL'R 295
 Qy 298 ASTTSETIQYRKAVAKATLVLLPLLGITYMLFFVNPGEDDVQSIVFIFYFNFSFLOSFGFFV 357
 Db 296 ASTTSETIQYRKAVAKATLVLLPLLGITYMLFFVNPGEDDLSQIMFIYFNFSFLOSFGFFV 355
 Qy 358 SVFYCFNLGEVRSAAARKRWRWQDHSLRVARAMSIPTSPTRISFHSIKOTAAV 413
 Db 356 SVFYCFNLGEVRSAAVRKRWRWQDHSLRVPMARAMSIPSTSPTRISFHSIKOTAAV 411

RESULT 14	XX	SQ Sequence 411 AA;	Query Match 80.4%; Score 1793; DB 2; Length 411;
ID ABU62363 standard; protein; 411 AA.	ID	Best Local Similarity 80.0%; Pred. No. 1.1e-172;	Best Local Similarity 80.0%; Pred. No. 1.1e-172;
XX Mismatches 30; Conservative Matches 45; Indels 8; Gaps 4;	XX	Match 333; Conservative Matches 30; Mismatches 45; Indels 8; Gaps 4;	Match 333; Conservative Matches 30; Mismatches 45; Indels 8; Gaps 4;
AC ABU62363;	AC	AC ABU62363;	AC ABU62363;
XX DT 29-AUG-2003 (first entry)	XX	XX DT 29-AUG-2003 (first entry)	XX DT 29-AUG-2003 (first entry)
DE Rat corticotropin release factor receptor, rCRF-R2alpha.	DE	DE Rat corticotropin release factor receptor, rCRF-R2alpha.	DE Rat corticotropin release factor receptor, rCRF-R2alpha.
XX KW Corticotropin release factor; receptor; adrenocorticotrophic hormone; ACTH; blood flow; blood pressure; vascular bed; coronary blood flow; inflammation; vascular permeability; CRF-binding protein; parturition; Alzheimer's disease; chronic fatigue syndrome; appetite; alertness; rat; respiratory system; learning performance; depression; anxiety; memory; hypothalamic pituitary adrenal function; endocrine disorder; swelling; central nervous system disorder; CRF; rCRF-R2alpha.	XX	XX KW Corticotropin release factor; receptor; adrenocorticotrophic hormone; ACTH; blood flow; blood pressure; vascular bed; coronary blood flow; inflammation; vascular permeability; CRF-binding protein; parturition; Alzheimer's disease; chronic fatigue syndrome; appetite; alertness; rat; respiratory system; learning performance; depression; anxiety; memory; hypothalamic pituitary adrenal function; endocrine disorder; swelling; central nervous system disorder; CRF; rCRF-R2alpha.	XX KW Corticotropin release factor; receptor; adrenocorticotrophic hormone; ACTH; blood flow; blood pressure; vascular bed; coronary blood flow; inflammation; vascular permeability; CRF-binding protein; parturition; Alzheimer's disease; chronic fatigue syndrome; appetite; alertness; rat; respiratory system; learning performance; depression; anxiety; memory; hypothalamic pituitary adrenal function; endocrine disorder; swelling; central nervous system disorder; CRF; rCRF-R2alpha.
XX OS Rattus sp.	XX	XX OS Rattus sp.	XX OS Rattus sp.
PN US2003032587-A1.	PN	PN US2003032587-A1.	PN US2003032587-A1.
XX PD 13-FEB-2003.	XX	XX PD 13-FEB-2003.	XX PD 13-FEB-2003.
XX PF 26-MAR-2001; 2001US-00818009.	XX	XX PF 26-MAR-2001; 2001US-00818009.	XX PF 26-MAR-2001; 2001US-00818009.
XX PR 13-JUN-1995; 95US-0028444P.	XX	XX PR 13-JUN-1995; 95US-0028444P.	XX PR 13-JUN-1995; 95US-0028444P.
PR 11-AUG-1995; 95US-0002223P.	PR	PR 11-AUG-1995; 95US-0002223P.	PR 11-AUG-1995; 95US-0002223P.
PR 12-JUN-1996; 96WO-US010240.	PR	PR 12-JUN-1996; 96WO-US010240.	PR 12-JUN-1996; 96WO-US010240.
PR 10-DEC-1997; 97US-00981189.	PR	PR 10-DEC-1997; 97US-00981189.	PR 10-DEC-1997; 97US-00981189.
XX PA (SALK) SALK INST BIOLOGICAL STUDIES.	XX	XX PA (SALK) SALK INST BIOLOGICAL STUDIES.	XX PA (SALK) SALK INST BIOLOGICAL STUDIES.
PI Vale WW, Vaughan J, Donaldson CJ, Lewis KA, Sawchenko P;	PI	PI Vale WW, Vaughan J, Donaldson CJ, Lewis KA, Sawchenko P;	PI Vale WW, Vaughan J, Donaldson CJ, Lewis KA, Sawchenko P;
PI Rivier JEF, Perrin MH;	PI	PI Rivier JEF, Perrin MH;	PI Rivier JEF, Perrin MH;
DR WPI; 1997-077344/07.	DR	DR WPI; 1997-077344/07.	DR WPI; 1997-077344/07.
XX PT Urocortin peptide(s) related to urotensin and corticotropin-releasing factor - for increasing ACTH and beta-endorphin levels, lowering blood pressure and improving mood, memory and learning performance.	XX	XX PT Urocortin peptide(s) related to urotensin and corticotropin-releasing factor - for increasing ACTH and beta-endorphin levels, lowering blood pressure and improving mood, memory and learning performance.	XX PT Urocortin peptide(s) related to urotensin and corticotropin-releasing factor - for increasing ACTH and beta-endorphin levels, lowering blood pressure and improving mood, memory and learning performance.
XX PS Disclosure; Page 27-28; 34pp; English.	XX	XX PS Disclosure; Page 27-28; 34pp; English.	XX PS Disclosure; Page 27-28; 34pp; English.
XX CC The invention relates to a human urocortin (Ucn) peptide or an analogous sequence having only conservative substitutions to the amino acid residues in it, or an N-terminally shortened fragment of either which is biologically active to increase adrenocorticotrophic hormone (ACTH) production. Human urocortin or its N-terminally shortened antagonist peptide are useful for modifying blood flow and/or blood pressure and is further useful for modulating blood flow in a desired vascular bed. Human urocortin is also useful for increasing coronary blood flow and for decreasing swelling and/or inflammation and/or vascular permeability. A CRF-binding protein blocking compound is useful for increasing the in vivo level of CRF and/or Ucn. The amount of CRF-binding protein blocking compound is sufficient to promote parturition in a pregnant female. The amount of the compound administered is effective so as to result in an increase in free endogenous CRF and/or Ucn in the brain which causes improvement in short to medium term memory in a subject afflicted with Alzheimer's disease, relief from chronic fatigue syndrome, suppression of appetite, stimulation of the respiratory system, improvement in learning performance, improvement in memory, reduction of depression and/or lessening of anxiety. The compound is administered so that it reaches the brain. Human urocortin is useful for evaluating hypothalamic pituitary adrenal function in mammals with suspected endocrine or central nervous system pathology. Human urocortin antibodies are useful in diagnostic methods and systems for detecting the level of Ucn polypeptide, for immunoaffinity or affinity chromatography purification of Ucn, and also in human therapeutic methods. The present sequence represents the amino acid sequence of the rat corticotropin release factor receptor, rCTF-R2alpha.	CC	CC The invention relates to a human urocortin (Ucn) peptide or an analogous sequence having only conservative substitutions to the amino acid residues in it, or an N-terminally shortened fragment of either which is biologically active to increase adrenocorticotrophic hormone (ACTH) production. Human urocortin or its N-terminally shortened antagonist peptide are useful for modifying blood flow and/or blood pressure and is further useful for modulating blood flow in a desired vascular bed. Human urocortin is also useful for increasing coronary blood flow and for decreasing swelling and/or inflammation and/or vascular permeability. A CRF-binding protein blocking compound is useful for increasing the in vivo level of CRF and/or Ucn. The amount of CRF-binding protein blocking compound is sufficient to promote parturition in a pregnant female. The amount of the compound administered is effective so as to result in an increase in free endogenous CRF and/or Ucn in the brain which causes improvement in short to medium term memory in a subject afflicted with Alzheimer's disease, relief from chronic fatigue syndrome, suppression of appetite, stimulation of the respiratory system, improvement in learning performance, improvement in memory, reduction of depression and/or lessening of anxiety. The compound is administered so that it reaches the brain. Human urocortin is useful for evaluating hypothalamic pituitary adrenal function in mammals with suspected endocrine or central nervous system pathology. Human urocortin antibodies are useful in diagnostic methods and systems for detecting the level of Ucn polypeptide, for immunoaffinity or affinity chromatography purification of Ucn, and also in human therapeutic methods. The present sequence represents the amino acid sequence of the rat corticotropin release factor receptor, rCTF-R2alpha.	CC
XX PR 06-MAR-2002; 2002WO-US007476.	XX	XX PR 06-MAR-2002; 2002WO-US007476.	XX PR 06-MAR-2002; 2002WO-US007476.
XX PD 12-SEP-2002.	XX	XX PD 12-SEP-2002.	XX PD 12-SEP-2002.
XX PA (PROC) PROCTER & GAMBLE CO.	XX	XX PA (PROC) PROCTER & GAMBLE CO.	XX PA (PROC) PROCTER & GAMBLE CO.
XX PI Isfort RJ, Sheldon RJ;	XX	XX PI Isfort RJ, Sheldon RJ;	XX PI Isfort RJ, Sheldon RJ;
XX DR WPI; 2002-713413/77.	XX	XX DR WPI; 2002-713413/77.	XX DR WPI; 2002-713413/77.
XX DR N-PSDB; AAL49979.	XX	XX DR N-PSDB; AAL49979.	XX DR N-PSDB; AAL49979.
XX PT Identifying candidate compounds for regulating skeletal muscle mass or treating skeletal muscle atrophy by identifying test compounds that bind to, or activate, the corticotropin releasing factor-2 receptor.	XX	XX PT Identifying candidate compounds for regulating skeletal muscle mass or treating skeletal muscle atrophy by identifying test compounds that bind to, or activate, the corticotropin releasing factor-2 receptor.	XX PT Identifying candidate compounds for regulating skeletal muscle mass or treating skeletal muscle atrophy by identifying test compounds that bind to, or activate, the corticotropin releasing factor-2 receptor.
XX PS Claim 7; Page 112-113; 167pp; English.	XX	XX PS Claim 7; Page 112-113; 167pp; English.	XX PS Claim 7; Page 112-113; 167pp; English.

XX The present invention relates to a method of identifying candidate compounds for regulating skeletal muscle mass or function, and comprises contacting a test compound with a corticotropin releasing factor-2 receptor (CRF2R) or with a cell expressing a functional CRF2R, determining whether the test compound binds to, or activates, the CRF2R and identifying the test compounds that bind to, or activates, the CRF2R as candidate compounds for regulating skeletal muscle mass or function. The method is useful for preparing a medicament for treating skeletal muscle atrophy or for prophylactic treatment of muscular dystrophies. The present sequence is a corticotrophin releasing factor receptor

XX SQ Sequence 411 AA:

	Query Match	Score	DB	Length
Qy	MDSTIFELIDEFDANCSLLDAFQDSFLHSESSSSFFGEGP--YCSATIDQIGTCWPRLS	80.4%	5	411;
Db	MDAA--LILSLLEANCSL--ALAEELLLDGWGEPPDPEGPSYCNTTLDQIGTCWPQSA	80.0%	45;	4;
Qy	AGELVERPCPDSSNGIYRNTRNRYRECENGTWASWMYSQCVPILDNK-RKYALHYKI	59	58	
Db	PGALVERPCPEYNGIKYNTTRNAYRECLENGTWASRINYSHCEPILDKQRYKDLHYRI	56	55	
Qy	ALIINYLGHCISIALLVIAFLFLCLRSIRCLRNIIHWNLTTFILRNIMWFLQMDHN	118	117	
Db	ALIINYLGHCYSVVALVAFAFLFLVLRSIRCLRNVIHWNLTTFILRNITWFLQLIDHE	116	115	
Qy	IHESNEVWCRCITTTIINYFVVTNFFWMMFVEGCCYLHTAIIVMTYSTDKLRKWVFLFIGWCIP	178	177	
Db	VHEGNEVWCRCVTITIINYFVVTNFFWMMFVEGCCYLHTAIIVMTYSTEHLRKWVFLFIGWCIP	176	175	
Qy	SPIITVWAICKLFYENEQCWTGKEPGKYIDIYQGRVILVLLINFVFLNIVRILMTKL	238	237	
Db	CPIIVAWVGKLYENEQCWFGEKEPGDLVDIYQGPILVLLINFVFLNIVRILMTKL	236	295	
Qy	ASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGCEDDVSQLIVFVNFNSFLQSFGFFV	298	357	
Db	ASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGCEDDLSQIVFVNFNSFLQSFGFFV	296	355	
Qy	SVFYCFLNGEVRSAARKRWHRWQDHHSLRVVARAMSIPTSPTRISFHSIKOTAAY	358	413	
Db	SVFYCFLNGEVRSAARKRWHRWQDHHSLRVVARAMSIPTSPTRISFHSIKQTAAY	356	411	

Search completed: August 20, 2005, 00:25:30
Job time : 168 secs

This Page Blank (uspto)